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ABSTRACT 
 
Familial Alzheimer’s disease (FAD) is a valuable paradigm for the study of the more 
common sporadic AD (SAD). The two forms of the illness share many 
neuropathological, clinical and radiological characteristics but it is not yet possible to 
predict the onset of SAD or confirm its presence without histopathological analysis. 
Fully penetrant amyloid precursor protein (APP), presenilin 1 (PSEN1) or presenilin 2 
(PSEN2) gene mutations permit both, and therefore lend themselves to clinical research 
with results which may be applied to the study of SAD. The identification of biomarkers 
of onset and progression are vital in the selection of research participants and in the rapid 
evaluation of new therapies.  
 
This thesis further characterizes FAD with a number of studies. These address the use of 
imaging biomarkers and help clarify the nature of the relationship between FAD and 
SAD. Two reports of novel pathogenic FAD mutations are included as well as other 
studies exploring the clinical and radiological (structural and molecular) phenotypes 
associated with FAD. Key findings are as follows: the novel PSEN1 p. L166del and 
S132A mutations are both associated with FAD; the APPV717G mutation can be 
associated with pure progressive amnesia reflected in an atypical structural imaging 
profile; APP locus duplication is a significant cause of early onset dementia in the UK 
and the recognised phenotype should be expanded to include early seizures and 
 4 
apparently sporadic disease; regional cortical thickness (CTh) decline accelerates after 
diagnosis in FAD mutation carriers (MC) and differences between MC and controls are 
detectable in presymptomatic mutation carriers more than 4 years prior to clinical 
diagnosis; APP and PSEN1 mutations may produce different temporal and 
topographical patterns of cortical change; increased 11C-PiB retention in a highly 
heterogeneous pattern may be detected in presymptomatic PSEN1 mutation carriers. 
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The Problem 
 
Alzheimer’s disease (AD) represents the most common form of dementia and, as such, is 
costly both in personal and macroeconomic terms (Wimo et al. 2003).  The sporadic form 
(SAD) is thought to arise from the interaction of genetic and environmental factors, 
though the aetiology has yet to be fully elucidated. The hallmark pathological lesions of 
AD are the extracellular amyloid plaque and the intracellular neurofibrillary tangle (NFT), 
although the extracellular accumulation of oligomeric amyloid-ß (Aß) species and altered 
synaptic function are increasingly seen as important (Lesne et al. 2006). Selective regional 
vulnerability to the pathology determines the distribution of neuronal loss, which in turn 
dictates both the observable macroscopic features (atrophy) and the clinical phenotype. 
Such change characteristically begins in the hippocampus and entorhinal cortex (ERC), 
progressing to involve neocortical structures such as the posterior cingulate gyrus and 
temporo-parietal association cortices (Braak and Braak 1991). Accordingly, early cross-
sectional imaging studies using X-ray computed tomography (CT) demonstrated that 
examination of mesial temporal structures is most sensitive and specific for the detection 
of early AD changes (Masdeu 1985).  
 
Subsequently, magnetic resonance imaging (MRI) has permitted a more thorough 
exploration of structural change in the AD brain. This is most often achieved through 
analysis of atrophy, the downstream consequence of neuronal loss. However, the 
regional distribution of pathology is also reflected in measures of regional metabolism 
such as 18fluorodeoxyglucose positron-emission tomography (18FDG PET). Further, it is 
now possible to visualize plaque amyloid, associated activated microglia, and 
acetylcholinesterase (AchE) activity in vivo using radio-labelled ligands in combination 
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with PET or single photo-emission computed tomography (SPECT). The ligands 
concerned are 11C-PiB (Klunk et al. 2004), 11C-(R)-PK1115 (Edison et al. 2008; Wiley et al. 
2009; Okello et al. 2009) and 123I-5IA (O'Brien et al. 2007) respectively. Many of these 
techniques have yet to be fully evaluated. Both the ‘amyloid cascade hypothesis’ (see 1.5.) 
(Hardy and Allsop 1991) and early studies showing a positive association between ‘senile 
plaques’ and severity of dementia before death (Tomlinson et al. 1968; Tomlinson et al. 
1970) would suggest that non-invasive amyloid imaging represents a promising 
development. However, more recent work has cast doubt over the strength of the 
clinico-pathological association (Neary et al. 1986; Gomez-Isla et al. 1997), while others 
have found evidence of similar amyloid plaque loads in cognitively normal individuals 
(Davis et al. 1999a).  
 
The development of disease-modifying agents for AD is vital in the context of rapid 
demographic ageing, particularly in the developed world. As age is the most powerful of 
risk factors for SAD, a corresponding sharp increase in its prevalence is anticipated in the 
coming years. There is currently no agent that reproducibly modifies the natural history 
of AD in humans, though novel therapeutic strategies are emerging, some with 
encouraging data from murine models and early human trials (Bard et al. 2000; Gilman et 
al. 2005; Grundman and Black 2008). Ultimately, such treatment strategies must be 
judged against clinically meaningful functional and neuropsychological criteria. However, 
use of such criteria as study outcome measures necessarily requires large sample sizes 
over extended periods. Many are intrinsically reliant upon subjective impressions of 
change, have ceiling and floor effects and are unreliable in distinguishing symptomatic 
from genuine disease-modifying effects. Such considerations have galvanised the search 
for biomarkers with high predictive and diagnostic power which can reliably identify 
those at risk of developing AD (‘trait’) and those who are in the very earliest stages of the 
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disease (‘state’). Robust markers of progression are also required (‘rate’), particularly as a 
means of evaluating attempts to modify the disease process. The demand for biomarkers 
of this kind is a pervasive and topical issue in clinical research and is not unique to AD. 
 
A number of neuroimaging modalities, notably MRI and 18FDG PET, are being explored 
as surrogate markers of therapeutic efficacy using smaller sample sizes over shorter 
periods  (Alexander et al. 2002; Zamrini et al. 2004; Schott et al. 2005). Rates of neuronal 
loss are known to be reflected in regional and whole brain atrophy rates (Jack et al. 2002) 
which may be measured through both semi-automated and automated MRI techniques. 
Where serial scans are performed on an individual, each study subject acts as their own 
control, an approach which may entail digital matching (co-registration) of one image to 
another. Global atrophy rates may then be assessed via direct volume comparison, 
assessment of cerebrospinal fluid (CSF) compartment expansion or by automated 
techniques such as the Brain Boundary Shift Integral (BBSI) (Fox and Freeborough 1997; 
Freeborough and Fox 1997) or Ventricle Boundary Shift Integral (VBSI)  (Schott et al 
2005). However, the use of such techniques to assess novel therapies is a developing area 
and has sometimes provided unexpected results: In immunotherapy trials, for example, 
paradoxical changes have been observed with increased ventricular expansion and atrophy 
rates accompanying administration of experimental therapy (Fox et al. 2005). This was 
not easily reconciled with the broadly positive results of neuropsychological testing in the 
same study. 
 
In SAD it is known that AD neuropathology is already well established by the time 
symptoms occur. Accordingly, evidence from the study of autosomal dominant familial 
AD (FAD) has shown that regional and whole brain atrophy rates may differ significantly 
from controls several years before AD is clinically detectable  (Schott et al. 2003; Ridha et 
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al. 2006). Further, the accumulation of oligomeric Aß species may precede even this 
(Lesne et al 2006). There appears, therefore, to be a very real potential for early 
intervention provided agents are developed which offer disease modification and 
techniques arise to identify preclinical disease.  
 
In summary, we have entered an era in which the identification of potentially modifiable 
risk factors and early disease markers are vital to the application of new, disease-specific 
diagnostic tools and treatment modalities. The development of putative disease-
modifying therapies will demand the facility to identify this early therapeutic window 
before irreversible, pathological structural change occurs. In this way preservation of 
residual cognitive ability may be optimized and the currently inevitable 
neurodegeneration arrested or prevented. We also require the facility to evaluate swiftly 
the impact of novel therapies, particularly in light of increasing societal disease burden 
and finite resources. FAD is a valuable paradigm for the study of AD, not least because it 
is currently the only context in which truly reliable predictions about who will be affected 
can be made. It permits the use of smaller study cohorts, removes diagnostic uncertainty 
and represents a unique opportunity for characterization of the crucial presymptomatic 
phase. It may, therefore, be a key to defining robust biomarkers of risk, onset and 
progression.  
 
Work undertaken for this thesis was carried out with two main aims: to characterize FAD 
further, informing its current and future use as an AD paradigm, and to then use the 
FAD model to examine potential imaging biomarkers of onset, progression and 
intervention. Where possible, SAD cohorts were used to investigate the comparability of 
the two forms, and hence the generalizability of FAD data to SAD. By studying patients 
in both pre-symptomatic and symptomatic stages, the relationships between regional and 
 22 
whole brain volumes, cortical thickness (CTh) and clinical phenotype were examined. 
11C-PiB (11C-Pittsburgh compound B) PET has shown potential as a marker both of early 
disease and therapeutic efficacy so imaging profiles in FAD and SAD cohorts are also 
characterized.  
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1. 
 
INTRODUCTION 
 
    
The mind is its own place, and in itself 
Can make a Heav’n of Hell, a Hell of Heav’n. 
 
- John Milton, Paradise Lost 
 
1. 1. Normal ageing 
Full characterization of the anatomy and physiology of the ageing brain is essential if a 
pathological departure from the norm is to be detected early. Such characterization is 
therefore directly relevant to the central theme of this thesis. Cortical grey matter grows 
until the age of five and then inexorably declines in volume with age thereafter  
(Pfefferbaum et al. 1994). White matter growth accelerates throughout adolescence, 
plateauing in the third decade. CSF spaces expand continuously with age at the expense 
of grey matter with little volume change in the white matter volume (Resnick et al. 2003). 
However, different patterns of ageing are seen in different brain regions. There is, for 
example, selective vulnerability of the prefrontal cortex (Tang et al. 2001). Other grey 
matter structures showing age-related volume decline include the cerebellum, thalamus 
and insular cortex. Importantly, hippocampal volume seems to change little with healthy 
ageing (Sullivan et al. 2005), and this can be exploited where hippocampal volume is used 
to distinguish AD from healthy ageing (Colliot et al. 2008). 
 
Quantitative diffusion tensor imaging (DTI) (see 1. 7. 4. 5.) has repeatedly demonstrated 
a reduction in fractional anisotropy (FA) with increased diffusivity in white matter with 
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ageing (Pfefferbaum et al. 2000; O'Sullivan et al. 2001). FA decline and diffusivity increase 
may exhibit an anterior-posterior gradient (Sullivan et al. 2001). This means that frontal 
white matter, which develops relatively late (Sowell et al. 1999) and is under 
proportionately greater environmental control than more posterior regions (Pfefferbaum 
et al. 2001), is more vulnerable to age-related deterioration. 
 
The resting electroencephalographic (EEG) (see 1. 7. 2.) changes with physiological 
ageing, showing decreased " amplitude and global ‘slowing’ of background activity with 
increased theta and delta activity (Klimesch 1999). Ageing effects on parieto-occipital " 
rhythm are thought to reflect underlying default activity of the neural network in the 
resting, awake brain. This activity is modulated by thalamo-cortical and cortico-cortical 
interactions controlling the movement of sensorimotor information and the retrieval of 
semantic information from cortical stores (Brunia 1999). Regions shown by other 
modalities such as functional MRI (fMRI) to be active in the resting, default state may 
also be particularly prone to the pathological changes associated with AD  (Buckner et al. 
2005). 
 
1. 2. Dementia 
The generic term ‘dementia’ is not a diagnosis in itself, rather it describes a clinical 
syndrome of acquired, multi-domain cognitive impairment that, by definition, must 
involve episodic memory and is often accompanied by changes in personality, behaviour 
and mood. The American Psychiatric Association Diagnostic and Statistical Manual of 
Mental Disorders version 4 (DSM-IV) (Am.Psychiatr.Assoc. 1994) (DSM-V is expected 
in 2012) defines dementia as the development of cognitive dysfunction implicating 
memory and at least one of: aphasia, apraxia, agnosia or executive function. These 
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deficits must arise in the context of full consciousness and must be sufficient to impair 
normal social function and/or the ability to work. The list of aetiologies is extensive and 
includes primary degenerative diseases such as AD, dementia with Lewy bodies (DLB) 
and frontotemporal lobar degeneration (FTLD); potentially remediable processes such as 
cerebral vasculitis, hypothyroidism and vitamin B12 deficiency; and dementia secondary 
to other diseases such as human immunodeficiency virus (HIV) infection and multiple 
sclerosis (MS). Degenerative processes predominate in the elderly population and 
therefore make the most significant contribution to the societal burden of dementing 
illness.  
 
1. 3. Alzheimer’s disease 
1. 3. 1. History 
In 1906 in Tübingen, Germany the Bavarian psychiatrist and neuropathologist Aloysius 
‘Alois’ Alzheimer reported post mortem findings in a 56 year-old patient from Frankfurt 
whom he had first seen in 1901 (Alzheimer  1906). In life the patient, Auguste Deter, had 
suffered from presenile dementia with multiple cognitive deficits including reduced 
comprehension and memory, aphasia, disorientation, unpredictable behaviour, paranoia, 
auditory hallucinations, and pronounced psychosocial impairment. Neuropathological 
examination of the atrophic neocortex revealed plaques of dystrophic neurites, NFT and 
arteriosclerotic change. Emil Kraepelin (1856-1926), the head of Alzheimer’s department 
and himself a pioneer in neuropathology, later ensured that the illness gained its familiar 
eponym: ‘Alzheimersche krankheit’ (Alzheimer’s disease). 
 
For more than half a century thereafter the term ‘Alzheimer’s disease’ was used 
exclusively to describe the rare forms of presenile dementia in which the pathological 
changes of plaques and tangles were evident. However, in 1968 a study demonstrated 
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that the neuropathology of presenile and senile forms of primary degenerative dementia 
were not significantly different (Blessed et al. 1968). This seminal observation challenged 
the then accepted idea that cognitive decline was an inevitable consequence of ageing. 
Further, it was a crucial step in defining a disease entity that has come to dominate the 
study of dementia. 
 
       
        
 
 
 
 
        
 
       Alois Alzheimer (1864-1915)  Auguste Deter (1850-1906) 
 
1. 3. 2. Epidemiology 
AD accounts for around 55% of degenerative dementia. The most recent estimates of 
prevalence in the United Kingdom and United States of America are 420,000 and 
4,500,000 respectively  (Hebert et al. 2003; Knapp and Prince 2007). However, estimated 
prevalence may vary with age and definition. Meta-analyses for developed nations have 
produced broadly similar figures in the region of 1.5% at 65 years, doubling every 4 years 
to reach around 30% at 80 years (Ritchie and Lovestone 2002). Indeed, all recent 
European epidemiological studies examining dementia prevalence on the basis of 
standardized diagnostic criteria have revealed an exponential increase with female 
preponderance after the age of 75 years (Berr et al. 2005). Such figures are broadly 
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mirrored in North American studies (Alloul et al. 1998). Given the well-established 
relationship between the incidence of dementia and increasing age, the primary factor 
driving this phenomenon is likely to be increased longevity evident in developed nations. 
The anticipated, concurrent reduction in those of working age able to offer care to 
elderly, impaired individuals poses a further challenge. AD and other dementias now 
constitute a global health and social care crisis and, as this problem has become better 
publicised, the requirement for large-scale strategies has gained wider appreciation 
(Department of Health 2009). Although the burden of the dementias in the developing 
world is less well known, the problem is broadly regarded to be both under-recognised 
and growing.  
 
1. 3. 3. Risk factors 
Although no single aetiology has yet been identified for SAD, the interaction of 
environmental and genetic variables appears to be important. The same may be said of 
other forms of dementia, such as vascular dementia (VaD). However, AD arguably has a 
unique and emotive connection to the human condition, as the most powerful of its risk 
factors is also the most inevitable, namely growing old.  
 
Despite recent twin studies demonstrating heritability of up to 80% for SAD (Gatz et al. 
2006), exogenous factors are clearly important in directly conferring risk, and in the 
modification of genetic variables. One idea has been that low ‘cognitive reserve’ 
associated with reduced brain size or poor educational attainment may be an independent 
risk factor (Mayeux 2003), or that it may act as a mechanism by which other factors, such 
as head injury, exert their effect upon risk (Jellinger 2004). It remains possible, however, 
that factors such as trauma and cerebrovascular disease (with its attendant association 
with diabetes, smoking, systolic hypertension, obesity and hypercholesterolaemia – each 
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associated with a hazard ratio of about 2 (Tyas et al. 2003; Luchsinger et al. 2005; 
Kivipelto et al. 2005; Freitag et al. 2006)) may have a more intimate, causative link with 
the pathological cascade of AD rather than simply acting to reduce cognitive reserve and 
hence the threshold for the appearance of symptoms. Research in this area continues, 
typified by a recent study suggesting a link between increased cardiorespiratory fitness 
and reduced brain atrophy (Burns et al. 2008). 
 
Figure 1: Prevalence of AD as a function of age in men and women  
(Nussbaum and Ellis 2003) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data concerning the effects of dietary factors in AD are typically inconsistent and based 
on a variety of study types. Indeed, no specific dietary advice has a sound evidence base 
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in relation to AD risk and there is considerable overlap in the relevant biological 
hypotheses.  
 
Levels of homocysteine (Hcy), vitamin B12 and folate have also been extensively studied, 
with variable conclusions regarding their relationship to stroke and AD risk. Hcy is a 
precursor of methionine and cysteine and its conversion to methionine requires folate 
and vitamin B12, both co-factors for methionine synthetase. Studies have suggested a 
link between elevated Hcy and increased AD risk (Seshadri et al. 2002); that homocysteic 
acid (HA), an oxidized metabolite of Hcy, may induce intraneuronal accumulation of 
Aß1-42 (Hasegawa et al. 2005) and that Hcy may increase neuronal vulnerability to Aß-
mediated toxicity (Kruman et al. 2002). 
 
Data linking AD pathology with oxidative stress and the association of reactive oxygen 
species with neuronal damage (Markesbery 1997) have led to increased interest in 
antioxidant supplementation. However, the results of prospective studies of antioxidants 
such as tocopherol (vitamin E), vitamin C and carotene are inconsistent and do not allow 
confident assertions of their value (Luchsinger et al. 2003; Grodstein et al. 2003). 
 
In short, despite considerable research and a long list of putative associations, no 
environmental risk factor has yet been definitively linked to AD. However, many 
clinicians find it reasonable to offer general advice on lifestyle and diet in view of the 
potentially positive effect on risk for other disorders such as vascular disease. Greater 
knowledge of the risk factors leading to AD aids selection of subjects for pre-
symptomatic studies and allows earlier, more accurate diagnosis – this is amongst the 
aims of studies presented in chapters 2 and 3. 
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1. 3. 3. 1. Apolipoprotein E  
The co-ordinated expression of Apolipoprotein E (ApoE) and its receptor, the 
ApoE/ApoB (LDL) receptor, are important in cholesterol and phospholipid transport in 
the brain. Individuals may have various combinations of ApoE alleles 2, 3 and 4 on 
chromosome (Chr) 19: allele frequencies in the general population are 6.4%, 83.6% and 
10% respectively (Carmo Martins et al. 2008). Changes in the balance of lipid transport, 
synthesis and internalization via this pathway are necessary during synaptogenesis and 
neuronal remodelling and, therefore, the brain’s response to injury. During these 
reparative processes, neurones down-regulate the cholesterol-synthesising 3, 3-
hydroxymethylglutaryl-Coenzyme A (HMG-CoA) reductase enzyme, while increasing 
cholesterol internalization.  
 
Phospholipid homeostasis might also be important to the integrity of the cholinergic 
system, known to be dysfunctional in AD. The ApoE allele may modify the efficacy of 
cholinomimetic therapy in AD (Poirier 1999a), with E4 negative individuals deriving 
more benefit (interestingly the reverse appears to be true for catecholaminergic therapies 
(Poirier 1999b)). This may be explained by the reliance of the central nervous system 
(CNS) on locally available lipids for acetylcholine (Ach) synthesis and raises the 
possibility that genotyping may become a vital part of tailoring therapeutic regimens in 
future. In addition, observations arising from transgenic mouse experiments have led to a 
proposed role for ApoE in amyloid precursor protein (APP) processing and the 
clearance of extracellular Aß (Poirier 2000). 
 
The link between SAD and ApoE4 genotype was first reported in 1993 (Corder et al. 
1993; Poirier et al. 1993). Subsequent meta-analysis demonstrated an additive risk profile 
with three-fold and fifteen-fold risks in heterozygotes and homozygotes respectively  
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(Farrer et al. 1997). The ApoE4 polymorphism is now thought to account for the 
majority of genetic risk for SAD (Raber et al. 2004). Its predominant effect appears to be 
to modify age at onset (AAO) (Meyer et al. 1998), and there is evidence that it has a 
similar influence on amyloid precursor protein gene (APP), though not presenilin one 
gene (PSEN1) -related FAD (Hardy et al. 1993; Van Broeckhoven et al. 1994; Sorbi et al. 
1995). It has also been suggested that the absence of the ApoE4 polymorphism may 
direct pathology away from the MTL towards more posterior structures (Schott et al. 
2006), a hypothesis arising from the under-representation of ApoE4 amongst sufferers of 
posterior cortical atrophy (PCA). Human ApoE has since been associated with a 
redistribution of pathology (fibrillar amyloid) in a transgenic mouse model of the Dutch 
mutation (Xu et al. 2008). When compared with mice with an endogenous ApoE 
background, human ApoE 3/3 or 4/4 genotype led to a marked reduction in cerebral 
microvascular amyloid and the appearance of extensive, fibrillar, parenchymal plaque 
amyloid with strong co-localization of ApoE proteins. A corresponding shift in the 
distribution of activated microglia was observed. There was no difference between the 
groups in the total levels of Aß40, Aß1-42 or total levels of soluble and insoluble amyloid 
species. Recent data have indicated an additive effect of ApoE4 allele load upon grey 
matter volume (GMV) in medial and anterior temporal lobes bilaterally (Filippini et al. 
2008). However, the contrasting dominant effect of ApoE4 upon GMV in the left 
temporal lobe raises the possibility that ApoE exerts any influence on susceptibility, 
progression and lesion distribution via more than one mechanism. ApoE continues to 
dominate the study of genetic SAD risk, its possible epistatic influence is investigated in 
chapter 4. 
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1. 3. 3. 2. Other risk genes 
A number of other genes have been investigated as potential risk factors for SAD or 
modifiers of FAD. SORL-1, which encodes a neuronal sortilin-related receptor, directs 
trafficking of APP into endocytic recycling pathways from the cell surface and, when 
under-expressed, can result in APP being sorted into Aß-generating compartments. 
Inherited variation in this gene has recently been associated with late onset AD (Rogaeva 
et al. 2007). Polymorphisms in the promoter region of the nicastrin gene (as described 
later, nicastrin is a component of the !-secretase complex which has a fundamental role 
in amyloidogenesis) have not yet been excluded as a genetic risk factor for SAD, 
although studies have yet to demonstrate conclusively that they have a role (Orlacchio et 
al. 2004). Like nicastrin, the PEN-2 protein is a component of !-secretase. Both mis-
sense mutations and polymorphisms have been identified in the PEN-2 gene, although 
the significance of these findings remains unclear (Frigerio et al. 2005).  Genome-wide 
association studies show great promise in identifying new risk genes: 3 were very recently 
reported (see http://www.alzforum.org/new/detail.asp?id=2197): ApoJ (aka clusterin), 
CR1 (which encodes a complement receptor), and PICALM (which encodes an 
endocytic gene). Together these support key roles for innate immunity and cholesterol in 
AD. Genome-wide association studies continue to revolutionize the study of genetic risk, 
not least in AD. Related genetic screening techniques are employed in chapter 5. 
 
1. 3. 4. Mild cognitive impairment  
The gap between normal cognition and a diagnosis of AD is bridged via a heterogeneous 
clinical construct: mild cognitive impairment (MCI). Originally believed to represent part 
of a continuum of change related to normal ageing, MCI is now recognised as a 
pathological entity, albeit an aetiologically and clinically heterogeneous one. Consensus 
clinical criteria (Petersen et al. 1999; Winblad et al. 2004) require that the person is neither 
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normal nor demented; that there is evidence of cognitive deterioration shown by either 
objectively measured decline over time and/or subjective report of decline by self and/or 
informant in conjunction with objective cognitive deficits; and that activities of daily 
living are preserved and complex instrumental functions are either intact or minimally 
impaired.  
 
To develop MCI does not guarantee a progression to dementia, or that any subsequent 
dementia will be AD, but an increased AD risk is recognised relative to an age-matched 
normal population with a conversion rate of 10-15% per year (Petersen et al 1999; 
Petersen 2004). MCI is often divided into amnestic (aMCI) and non-amnestic subtypes, 
with greater prognostic variation generally seen in the latter. Characterization of MCI is, 
however, ongoing and disagreement over its nosological status and the most important 
prognostic markers remains.  
 
Atrophy of the hippocampus, ERC and temporal pole is greater in MCI subjects who 
progress to AD within 4-5 years compared to cognitively normal controls or MCI 
subjects who do not progress (Desikan et al. 2008). Microglial activation has been noted 
(Okello et al 2009) and recent evidence supports the notion that impaired episodic 
memory in non-demented people (including MCI) is strongly related to Aß deposition as 
measured by 11C-PiB-PET (Pike et al. 2007). The relationship between these factors in 
established AD is, however, far less clear with some data supporting a stable amyloid 
load even in the face of clearly deteriorating cognition  (Engler et al. 2006). The nature of 
these relationships is crucial to the timely application of anti-amyloid therapies and in 
defining the future role of 11C-PiB -PET as a potential biomarker. A clear understanding 
of the nature of very early AD is a vital component of its detection at a stage amenable to 
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modification. Hence MCI is a pertinent concept in chapters 2 and 3, which attempt to 
study patients in a period which includes this phase. 
 
1. 4. Familial Alzheimer’s disease  
Three genes have so far been implicated in autosomal dominant early-onset FAD: the 
APP, PSEN-1 and the presenilin two genes (PSEN-2), with the majority of known 
mutations found in PSEN-1.  These may cause clinically manifest AD as early as the 
fourth decade, with complete penetrance the rule. Where the presence of a mutation is 
suspected and subsequently tested, the detection rate of sequence variations in these 
three genes ranges from 57% (Finckh et al. 2005) to 68% (Janssen et al. 2003), suggesting 
a role for as yet unidentified genes. Where the strictest criteria are applied, only around 
1% of all AD is thought to fall into the autosomal dominant early onset AD (EOAD) 
group (Campion et al. 1999), although about 25% of all AD is familial in a broader sense 
(i.e., two or more persons in a family have AD) (Bird 2008). 
  
FAD has served as a useful SAD paradigm for many years (Kennedy et al. 1995a; Fox et 
al. 1998; Fox et al. 2001). Prospective studies of the early stages of sporadically occurring 
illness have proved extremely difficult due to its insidious onset and the confounding 
factors associated with co-morbidity and ageing. In contrast, FAD permits an accurate 
ante-mortem diagnosis and the opportunity to perform targeted, longitudinal studies of 
clinical, radiological and neuropsychological parameters at all stages. In addition, subjects 
can be well matched for age, socioeconomic and other genetic factors. Such knowledge 
has been incorporated into cellular models of the disease process and, more recently, has 
permitted the development of transgenic mouse models and novel therapeutic strategies 
(Schenk et al. 1999). 
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It is broadly accepted that differences exist between early and late onset forms of AD. 
Although FAD and EOAD are strictly not equivalent entities, FAD is characterized by 
early onset and previous studies have proposed a higher prevalence of impairment of 
language or other neocortical functions (Jacobs et al. 1994), a relatively more rapid 
progression (Rogaeva 2002), differences in the pattern of cortical thinning (Frisoni et al. 
2007) and more prominent myoclonus (Kennedy et al. 1995b) in early onset forms as 
compared to late-onset AD (LOAD). Further, in EOAD, there appears to be a strong 
correlation between plaque and tangle burden and severity of clinical features – a 
relationship not seen in the elderly (Prohovnik et al. 2006).  
Despite these factors, the pathological and clinical similarities are clear, and the use of 
research subjects at risk for FAD in studying the earliest stages of AD continues to yield 
valuable information (Ringman 2005). Most studies show early episodic memory and 
executive deficits in both forms (see 1. 6. 1. and 1. 6. 3.), as well as structural 
neuroimaging changes 3-4 years before symptoms (Schott et al 2003), early cerebral 
hypometabolism as demonstrated by 18FDG PET (Kennedy et al 1995a) and reduced 
CSF Aß (Andreasen et al. 1999). More recent work has shown an increase in levels of 
Aß1-42 in the plasma of presymptomatic FAD mutation carriers with a fall in these levels 
immediately prior to symptom onset (Ringman et al. 2008). Further characterization of 
the pathological, radiological and clinical hallmarks of FAD remains important, not least 
because of its potential impact on our understanding of SAD. This issue is addressed in 
chapters 4 and 5 of this thesis. 
1. 4. 1.  ß-amyloid precursor protein gene  
The path to our present understanding of the genetic basis for FAD has been punctuated 
by a number of landmarks. The first clue lay in the association of AD with trisomy 21, a 
link which had been observed for many years and was supported by the characterization 
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of Aß in 1984 in the brains of individuals with AD and Down’s syndrome (Glenner and 
Wong 1984). Some years later, the first mis-sense mutation in APP (also on Chr 21) that 
co-segregated with autosomal dominant, early onset AD was discovered (Goate et al. 
1991). This was the London mutation at position 717, significant not only for being the 
first known mutation of its kind, but also for its position near the site at which !-
secretase cleaves Aß.  
 
The APPV717I (London) mutation changes the Aß1-40: Aß1-42 ratio such that there is 
relatively more of the fibrillogenic Aß1-42 species. This is assumed to lead to an 
accumulation of neurotoxic amyloid species and the formation of plaques, thus causing 
neurodegeneration and clinical disease of far earlier onset than the more common SAD. 
With the exception of its early onset however, mutations at and around position 717 are 
most often associated with a canonical AD phenotype akin to that seen in SAD. This 
insidious, progressive impairment of episodic memory, in time leading to more 
widespread cognitive deficits, has been observed in the numerous reported, unrelated 
pedigrees with mutations around this site.  
 
The Swedish mutation at positions 670 and 671 corresponds to the site of ß-secretase 
cleavage (see Figure 3), and pedigrees have been reported with a typical AD phenotype. 
There is an increase in the absolute quantities of Aß1-40 and Aß1-42 isoforms much like that 
seen in trisomy 21 (Mehta et al. 2007). A number of mutations have been described 
which cluster around the site of " -secretase cleavage within the Aß domain itself, and 
are associated with haemorrhagic strokes and cerebral amyloid angiopathy (CAA). The 
E693Q Dutch mutation (Levy et al. 1990) is known to cause hereditary CAA associated 
with intra-cerebral haemorrhage (ICH), as is the E693K Italian mutation at the same 
site (Tagliavini et al. 1999). The D694N Iowa mutation (Grabowski et al. 2001) also leads 
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to severe CAA and the A692G Flemish mutation (Hendriks et al. 1992b) has similar 
effects, albeit in association with more typical clinical features of AD and. Any 
generalization is, however, confounded by the presence of other rare mutations such as 
the E693G Arctic mutation (Nilsberth et al. 2001) which seems to cause more typical 
clinical AD. 
 
Recent, significant discoveries have highlighted the importance of APP ‘gene dose’, 
including the role of normal variation in disomic APP expression (Wavrant-De Vrieze et 
al. 1999) in relation to SAD risk. Key observations so far have been that an increased 
quantity of !-secretase substrate skews the Aß1-42: Aß1-40 ratio in favour of the former (Yin 
et al. 2007); that mutations in the promoter region of APP may cause a neurone-specific 
increase in APP transcriptional activity in patients with AD (Theuns et al. 2006a); and 
that several independent duplications of the APP locus have been reported in French 
families (Rovelet-Lecruz et al. 2006b) (see 1. 4. 2. and 3. 1.). 
 
To date, 29 non-duplication APP mutations are known, of which 6 are not clearly 
pathogenic (see http://www.molgen.ua.ac.be/ADMutations). Most are associated with 
disease onset between 45 and 60 years and an initial amnestic syndrome progressing to 
more widespread cognitive impairment. However, patients have been described with a 
prolonged, isolated amnesia associated with the APPV717I (London) mutation (Gankam 
Kengne et al. 2007) (see 2. 3.). A similar prolonged, isolated amnestic phase, albeit with 
additional partial seizures and dysautonomia, has also been reported in association with 
the V714A Iranian mutation (Lindquist et al. 2008b) although separate reports of this 
mutation record a more typical AD clinical phenotype (Zekanowski et al. 2003). Chapter 
2 includes a report of an isolated, progressive amnesia in association with a mutation at 
the same locus as that described by Gankam Kengne et al. 
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1. 4. 2. APP  locus duplication  
Duplications of the APP locus (APPd) causing early-onset, autosomal dominant AD 
have recently been described in five French families (Rovelet-Lecrux et al 2006; Cabrejo et 
al. 2006), confirming a much earlier report of APPd in France (Delabar et al. 1987). The 
prevalence of, and phenotypic spectrum associated with APPd are yet to be fully defined, 
and the issue of copy number variations (CNV) at genetic loci is potentially of great 
interest in the study of familial dementia per se. A variable phenotype with an autosomal 
dominant mode of inheritance was seen in the APPd families, recently inviting 
comparison with the Flemish mutation (Hendriks et al 1992b; Hardy 2006). Dementia 
and CAA were universal with a quarter also suffering ICH (Cabrejo et al. 2006b). 
Clinically it would appear that this disease falls somewhere between the canonical AD 
phenotype observed in most APP mutations and the frequent, CAA-associated ICH seen 
in most intra-Aß mutations. The prevalence of, and phenotypic spectrum associated with 
APP duplications are yet to be fully defined and previous Finnish reports of suspected 
autosomal dominant, EOAD where no causative mutation was identified (Remes et al. 
2004a) may prove to be significant. Chapter 5 examines the prevalence and phenotype of 
APPd as it is a part of the FAD ‘family’ and has the potential to strengthen our 
understanding of the FAD: SAD relationship. 
 
1. 4. 3.  The presenilin 1 gene  
PSEN1 is located on Chr 14q24.3. It has 13 exons but only 3-12 code for the PS1 
integral membrane protein comprising 467 amino acids and eight transmembrane 
domains (Sherrington et al. 1995). PS1 is highly conserved in evolution and is one of four 
membrane proteins required to form an active !-secretase complex (the others are PEN-
2, nicastrin and APH-1 with a 1: 1: 1: 1 stoichiometry).  PSEN1 inactivation abolishes 
both PS1 expression and !-secretase activity (De Strooper et al. 1998). Some mutations in 
Figure X: PIB-PET Scanning 
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PSEN1 lead to a small shift in the preferred cleavage site and, therefore, the 
overproduction of the fibrillogenic form of beta amyloid peptide, Aß1-42 – an important 
component of the amyloid plaques seen in AD. However, some uncertainty remains over 
the precise mechanisms by which PSEN1 mutations exert their pathogenic effects, with 
both gain and loss of function mechanisms postulated (Bentahir et al. 2006). 
 
PSEN1 mutations tend to cluster in the regions coding for transmembrane domains and 
are the most common cause of autosomal dominant FAD with 175 reported pathogenic 
mutations (see http://www.molgen.ua.ac.be/ADMutations). Pathogenic mutations in the 
other two genes known to be associated with FAD, namely APP and PSEN2, are far less 
common. With the exception of their early onset, and despite evidence of phenotypic 
heterogeneity (Menendez 2004; Larner and Doran 2006), the majority of PSEN1 
mutations produce a clinical phenotype similar to that of SAD, with early memory 
impairment followed by progressive, multi-domain cognitive dysfunction. The most 
important exceptions are those mutations associated with early spastic paraparesis or a 
presentation resembling that of behavioural variant FTLD (bvFTLD).  
 
Mutations in exons 8 and 9 are responsible for many PSEN1-related FAD cases. 
Examples of those associated with a mixture of spastic paraparesis, spastic dysarthria and 
seizures include !9, R278T, N135S and V261L (Kwok et al. 1997; Rudzinski et al. 2008; 
Jimenez Caballero et al. 2008). Spastic paraplegia has also been reported in a patient with 
AD-like dementia and an unusual TTATAT insertion in a highly conserved 
transmembrane domain 3 interface region of PSEN1 (Rogaeva et al. 2001).  
Four deletions in exon 9 (!9 mutation) have been described (Crook et al. 1998; Houlden 
et al. 2000; Smith et al. 2001; Brooks et al. 2003) in which the phenotype comprises 
memory impairment and spastic paraparesis. These mutations destroy the splice acceptor 
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site for exon 9 resulting in deletion of exon 9 from the mutant mRNA transcript and an 
amino acid substitution (S290C). This leads to deletion of residues 291-319 of the 
protein, including the section coding for the cleavage site of PS1. The deletion 
predictably has a major effect upon PS1 metabolism, although the S290C change alone 
has just as profound an effect upon APP metabolism (Steiner et al. 1999). Cellular models 
of such deletions show increased Aß1-42 production (Borchelt et al. 1996) and 
neuropathological analysis shows unusual cortical ‘cotton wool’ plaques which are 
immunoreactive for the Aß but lack a congophilic core. In these cases spastic paraparesis 
often precedes cognitive impairment (Verkkoniemi et al. 2000). Such delay in the onset of 
cognitive features would suggest a role for as yet unidentified modifying factors at exon 
9.  
 
At least 6 PSEN1 mutations have been linked with a clinical phenotype more akin to 
bvFTLD than AD. These include a report of a behavioural presentation with relative 
preservation of posterior functions associated with a L113P mutation (Raux et al. 2000). 
Imaging in this case was consistent with bvFTLD. In addition, mutations such as P117R  
(Styczynska et al. 2004) and F280A (Duarte et al. 2004) have been linked to similar 
phenotypes. The M139V mutation has, in one African-American pedigree, been linked 
with early personality change, psychosis, rigidity, dystonia and mutism (Rippon et al. 
2003), although this mutation can present differently between kindreds, suggesting that 
other factors are important in determining the phenotype. Those reports with 
pathological confirmation include the G183V mutation (Dermaut et al. 2004) in which a 
Pick-type tauopathy was demonstrated, with no extracellular Aß deposits, in a family with 
a history of FTLD-like dementia. Interestingly, the insR352 mutation (Rogaeva et al 2001; 
Tang-Wai et al. 2002) apparently does not increase Aß1-42 but rather acts as a negative 
presenilin, leading to a partial inhibition of !-secretase (Amtul et al. 2002). This insertion 
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was not detected in more than 150 controls, 150 AD cases or 150 FTLD cases not linked 
to a tau mutation or Chr 17. 
 
An extra-pyramidal syndrome with dementia has been described in a 52 year-old man 
with a family history of a similar illness (Ishikawa et al. 2005). This case was associated 
with a three base-pair deletion in exon 12 of PSEN1 and, neuropathologically, cotton 
wool plaques, Lewy bodies and CAA. Another mutation – G217D in exon 8 of PSEN1 - 
has been described (Takao et al. 2002) with an extra-pyramidal syndrome and cotton 
wool plaques in the cortex and striatum. 
 
A particularly aggressive form of FAD is associated with the PSEN1 L166P mutation 
which, unlike the deletion at the same site, leads to cognitive impairment beginning in 
adolescence. It has been found to cause a profound over-production of Aß1-42 and also to 
impair Notch signalling (Moehlmann et al. 2002).  
 
 
1. 4. 4.  The presenilin 2 gene  
Pathogenic mutations in PSEN2 on Chr 1 causing autosomal dominant EOAD are rare, 
with only ten so far described (see http://www.molgen.ua.ac.be/ADMutations). A 
further four have been identified in which pathogenicity is either unknown or absent. 
They were first described in Volga German families in 1995 (Rogaev et al. 1995) and 
produce an AD phenotype which typically includes older AAO, though with a relatively 
wide range (44-88 years). A longer disease duration has also been noted in some cases 
(Sherrington et al. 1996). Specific examples of phenotypic heterogeneity include the 
PSEN2 A85V mutation which may produce a DLB-like clinical phenotype associated 
with synucleinopathy (widespread Lewy bodies) and AD pathology at post mortem 
 42 
(Piscopo et al. 2008). Significant language impairment has been seen (Lindquist et al. 
2008a), albeit in a mutation without conclusive evidence of pathogenicity (V393M). What 
little is known about imaging profiles suggests involvement of areas common to other 
forms of AD: 18FDG PET in PSEN2 N141I-associated FAD for example has shown left 
parietal and precuneus hypometabolism with progressive hypometabolism of both 
temporo-parietal and left frontal lobes (Nikisch et al. 2008). 
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1. 5. Neuropathology 
The hallmark pathological lesions of AD are observed in the medial temporal lobes 
(MTL) and neocortex and are the Aß (neuritic) plaque and the NFT (composed of 
hyperphosphorylated tau protein). Other pathological changes associated with AD are 
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neuronal and synaptic degeneration, reduced synaptic plasticity, CAA and inflammatory 
and oxidative stress. Changes in the neurochemistry of the AD brain are also important, 
with neurotransmitter depletion a well-established consequence of synaptic and neuronal 
loss. ACh release from fibres originating in the nucleus basalis of Meynert and projecting 
to cortical areas is particularly affected (Francis et al. 1999). The main receptor types for 
ACh in the CNS are muscarinic (subtypes M1 and M2) although
 nicotinic receptors are 
also present.  
 
Tau protein binds to microtubules, influencing their stability and the intracellular 
transport they facilitate. The six known isoforms of tau, which range from 352 to 441 
amino acids in length, are encoded by a single gene on Chr 17. Three isoforms have three 
microtubule binding domains and three have four such domains (termed ‘three repeat 
tau’ and ‘four repeat tau’ respectively) (Wischik and Harrington 2000). The 
phosphorylation and dephosphorylation of tau, and hence the relative activity of kinase 
and phosphatase enzymes, is a key means of regulating this process and is relevant in AD 
as hyperphosphorylation promotes the aggregation of tau isoforms into the paired, 
argyrophilic helical filaments of NFT and neuropil threads (NT). One important enzyme 
responsible for phosphorylation of tau isoforms is glycogen synthase kinase-3 (GSK-3). 
As an inhibitor of GSK-3, lithium has been proposed as a neuroprotective agent in both 
AD and the ‘tauopathies’ (Engel et al. 2006; Engel et al. 2008). Mutations of the 
microtubule-associated protein tau (MAPT) gene and/or accumulation of three or four 
repeat tau are the basis for a number of other neurodegenerative diseases such as 
corticobasal syndrome (CBS), progressive supranuclear palsy (PSP) and some cases of 
FTLD. 
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It is the aberrant, proteolytic processing of APP that gives rise to the core component of 
the amyloid plaque - a 40-43 amino acid peptide (Aß) which was purified and identified 
only after the problem of plaque insolubility was overcome in the mid-1980s (Masters et 
al. 1985). The pathological significance of Aß has been a central, if sometimes 
controversial theme and the basis for the amyloid cascade hypothesis (Fig. 4) (Hardy and 
Allsop 1991; Hardy and Higgins 1992). This postulates that it is the cascade from peptide 
monomer to plaque, and altered Aß equilibrium, which drive AD pathogenesis. In this 
model tau pathology is regarded as a downstream process although this view has not 
gone unchallenged. The universality of tau pathology in AD (it forms the basis of the 
Braak neuropathological criteria which describe its predictable progress in the AD brain 
(Braak and Braak 1991)) and the poor correlation between total or extracellular fibrillar 
amyloid and clinical status (Giannakopoulos et al. 2003), means it could legitimately be 
considered a form of ‘tau-opathy’. Some critics of the amyloid cascade hypothesis have 
gone further, asserting that amyloid pathology is a downstream protective response to 
oxidative and metabolic change (Lee et al. 2007) and predicting that novel anti-amyloid 
therapies will be ineffective or harmful (Smith et al. 2002). Pathological and imaging 
studies indicating that amyloid deposition may be associated with apparently healthy 
ageing (Davies et al. 1988; Davis et al 1999a; Mintun et al. 2006) further complicate the 
debate. However, perceived inconsistencies in the amyloid hypothesis are increasingly 
being addressed by new discoveries that tend to support the primacy of Aß. Recognition 
of the role of variable APP expression and the association between FAD mutations  
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and parenchymal and vascular amyloidosis have contributed in this regard, although 
another avenue of research has been particularly illuminating: Whether in vitro or in vivo, 
Aß assembles itself into an array of structures ranging from soluble oligomers to large 
insoluble fibrils and the latter, in the form of plaques, was historically considered to be 
the most important entity in neurodegeneration. However, it has become clear that 
various amyloid pools comprising different Aß species exist in dynamic equilibrium in 
the AD brain and that soluble oligomers, whether intra- or extracellular, are the main 
neurotoxic species with the more intimate link to clinical phenotype.  
 
There are several candidate mechanisms for Aß oligomer toxicity, though no suggestion 
that they are necessarily mutually exclusive. Binding to specific excitatory post-synaptic 
sites has been demonstrated, with consequent impairment of long-term potentiation (a 
measure of synaptic plasticity) in hippocampal neurones (Lambert et al. 1998; Lesne et al 
2006), providing a plausible mechanism for  impairment of memory formation. They also 
disrupt neuronal calcium homeostasis such that cytosolic calcium is increased and cell 
dysfunction/apoptotic processes ensue. This probably occurs via an increase in 
membrane permeability with initial studies indicating that the formation of aberrant 
membrane channels was responsible (Pollard et al. 1995). However, recent work has 
suggested a less specific mechanism (Demuro et al. 2005). Increased intracellular calcium 
also contributes to the formation of reactive oxygen species (ROS), mitochondrial 
dysfunction and oxidative stress (Schubert et al. 1995). Aß oligomers also potentiate the 
release of, and prevent re-uptake of the excitatory neurotransmitter glutamate in the 
synapse, producing excito-toxicity (Harris et al. 1996; Fernandez-Tome et al. 2004) from 
which memantine may offer some protection (Song et al. 2008). Amongst the most 
important observations for the amyloid cascade hypothesis are that they also readily 
induce tau hyperphosphorylation, in part via up-regulation of GSK-3  (Hoshi et al. 2003; 
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De Felice et al. 2008), and that increased levels correlate with NFT density (McLean et al. 
1999). The specific sites at which oligomerization occurs and the precise nature of the 
interactions between different Aß pools are not yet known. Also, the most important Aß 
assembly, or combination of assemblies, has not yet been established, although the time 
course of toxicity may depend upon the particular mixture of oligomers present 
(Deshpande et al. 2006). 
 
APP itself is a single transmembrane domain protein with eight possible isoforms. Of 
these the 695, 751 and 770 amino acid forms are the most common in the brain. The 
first is produced mainly in neurones whereas 751 and 770 are predominantly found in 
glial cells. All three have Aß domains and are therefore potentially amyloidogenic. APP is 
manufactured in the endoplasmic reticulum (ER) and subsequently moved through the 
Golgi network to the cell surface where it is eventually re-internalized into the 
endosomal/lysosomal system. The Aß domain is partially embedded in the plasma 
membrane but also includes 28 residues outside the membrane and 14 in the 
transmembrane domain. The function of APP in humans is not fully understood, 
although its over-expression in hippocampal neurones leads to elevated Aß production 
and consequent depression of excitatory transmission (Ting et al. 2007), suggesting a 
possible role in modulating synaptic transmission. This effect is likely to be exerted via 
Aß as mutant APP incapable of producing Aß has no such effect upon excitatory 
transmission. 
 
Initially thought to be an entirely abnormal protein, Aß was found to be a product of 
normal cellular metabolism in 1992 (Haass et al. 1992). APP may undergo proteolytic 
processing via two routes, termed amyloidogenic and non-amyloidogenic, the former 
preserving the Aß moiety intact. The route depends upon which of three enzymes act to 
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sequentially cleave the APP molecule. The non-amyloidogenic pathway involves cleavage 
by " -secretase (a member of the ADAM-10 disintegrin metalloprotease family) followed 
by !-secretase. The former cuts APP within the Aß domain and the latter acts upon the 
C-terminal fragment to produce P3 and C57/59 (Figure 3). The amyloidogenic pathway 
entails cleavage by ß-secretase (active portion is termed BACE-1) releasing the 
ectodomain of APP. The membrane-bound C-terminus, which contains the intact Aß 
section within a 99-residue fragment (C99), is then cleaved by !-secretase to produce Aß1-
40/1-42 and a C57/59 fragment. The variation in the size of these fragments and, therefore, 
the ratio of A!1-40 to A!1-42 is due to inherent small variations in the !-secretase cleavage 
site. Point mutations in PSEN-1 (Figure 2) may affect the cleavage site of !-secretase, 
changing the Aß1-40/1-42 ratio in favour of the more toxic, fibrillogenic species (Aß1-42).  
 
!-secretase is a protease complex with four components: presenilin, nicastrin, APH-1 and 
PEN-2. Presenilin (and therefore !-secretase activity) exists in both the ER/Golgi 
network and nearer the plasma membrane, meaning that !-secretase-mediated APP 
cleavage can occur at several sites in the cell. This means that two pools of Aß are 
produced. Aß generated at or close to the plasma membrane (Aßsec) is secreted and 
aggregates in the extracellular deposits (plaques) seen in AD. Aß1-42 is probably the 
initially deposited species, and indeed the predominant species in the parenchymal 
plaques of the AD brain (Miller et al. 1993; Iwatsubo et al. 1994). A proportion of the 
deposits develop from amorphous ‘diffuse’ plaques into more circumscribed ‘immature’ 
plaques and finally into ‘mature’ (cored) plaques with their well-defined amyloid core and 
halo of swollen neurites. As this ‘maturation’ proceeds they are more likely to become 
Aß1-40 positive, an observation consistent with the ‘seeding’ hypothesis (Jarrett and 
Lansbury 1993) whereby immature plaques begin with a seed of Aß1-42 and progressively 
incorporate Aß1-40 - the major soluble species in extracellular fluid and CSF. Such seeding 
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would not however explain the striking scarcity of Aß1-40 positive plaques observed in 
some cases of APPV717I mutation-associated FAD (Iwatsubo et al 1994). An alternative 
explanation for the increased proportion of Aß1-40 observed over time is that the two or 
three amino acids at the C-terminal of Aß1-42 are removed slowly in situ by 
carboxypeptidases to produce Aß1-40. Aß1-40 and Aß1-42 appear to be equally abundant 
amongst vascular amyloid deposits (Roher et al. 1993). 
 
The other pool of Aß remains intracellular, may accumulate in AD and may be important 
in its pathogenesis, possibly by facilitating neuronal death or increasing vulnerability to 
neurotoxic factors (Chui et al. 1999). Interestingly, PSEN-1 mutations seem to have a 
more profound effect upon !-secretase cleavage site specificity when it acts near the 
plasma membrane to produce Aßsec than when it acts near the ER/Golgi complex to 
produce intracellular Aß (Grimm et al. 2003).  
 
Aß is degraded by peptidases including insulin-degrading enzyme (IDE), neprilysin 
(NEP) and endothelin-converting enzyme (ECE) (Carson and Turner 2002). It may also 
be cleared from the brain across the blood brain barrier (BBB) by low density lipoprotein 
(LDL) receptor-related protein (LRP-1) (Tanzi et al. 2004). The receptor for advanced 
glycation end products (RAGE) contributes to the trafficking of amyloid from plasma 
into the CNS (Deane et al. 2004) and is now considered a potential therapeutic target 
(Sturchler et al. 2008). To date there is no evidence for an abnormality affecting these 
processes in the AD brain.  
 
Although the MTL has an established role in episodic memory, it is clear that focus 
should not fall solely upon the hippocampus and MTL when considering the earliest 
pathological changes of AD. Rather, changes affect the whole of a distributed network  
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subserving episodic memory, with close links to the limbic system. This network includes 
the MTL, mammillary bodies, dorso-medial thalamus and retrosplenial association 
cortices (particularly posterior cingulate). Amyloid deposition does not appear to occur 
especially early in the MTL and can appear early in other areas of the network (Braak and 
Braak 1991; Edison et al. 2007). Instead, extracellular accumulation of soluble, 
synaptotoxic, oligomeric Aß species (Lesne et al 2006) or abundant NFT (Bennett et al. 
2004) are more prominent pathological findings. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 4: 
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1. 6. Clinical features 
AD is a slowly progressive disorder of insidious onset. Its cardinal features are the early, 
progressive impairment of episodic memory with subsequent impairment of other 
cognitive domains leading to apraxia, aphasia, and agnosia. However, the spectrum of 
clinical features is by no means restricted to these. Dysexecutive features are common 
and the balance of the clinical and pathological burden may vary, causing atypical 
predominantly frontal or posterior (PCA) cortical syndromes. A preclinical phase of 
neurodegeneration is recognised during which the pathological lesion load increases 
before breaching a clinical threshold. This phase has been estimated to be as much as 2-3 
decades in length (Davies et al 1988).  
 
Clinical diagnostic criteria have been developed and include the National Institute of 
Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) criteria (McKhann et al 1984) (Appendix 1), 
and the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria  
(Morris et al. 1989). Such criteria are necessarily qualitative and require the clinical 
judgement of the supervising doctor in order to be successfully applied. They 
nonetheless form an important framework in the absence of a single diagnostic test. 
Revisions to the NINCDS-ADRDA criteria have recently been proposed in order to 
incorporate CSF and imaging biomarkers (Dubois et al. 2007). 
 
Evidence for the existence of atypical AD phenotypes is growing and a variety of 
progressive, focal cortical syndromes have been reported in association with proven AD 
pathology. In one recent series (Alladi et al. 2007) AD pathology was found to be 
responsible for 100% of cases of PCA, 50% of CBS, 7.1% of bvFTLD, 44.1% of PNFA, 
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71.4% of mixed aphasia and 10% of semantic dementia. Atypical presentations are also 
well established in FAD (see 1. 4.).        
 
1. 6. 1. Memory 
A decline in episodic memory function is an early feature of AD and a necessary 
condition for clinical diagnosis. This is thought to reflect the earliest pathological changes 
occurring in the MTL. However, like pathological change, memory disruption probably 
precedes the full clinical syndrome necessary for an AD diagnosis (Chen et al. 2001). 
There is increasing support for the notion that, after an initial decline, memory function 
temporarily plateaus during the preclinical period (Smith et al. 2007). This is linked to the 
concept of cognitive reserve: imaging studies indicate recruitment of pre-frontal and 
posterior cortices by early AD patients during memory tasks (Grady et al. 2003), while 
neurotransmitters and brain neurotrophic factors are maintained or up-regulated in pre-
clinical, though not established AD (Davis et al. 1999b; Mufson et al. 2003). Together 
these changes suggest that the brain may attempt to compensate for early pathological 
change and that further clinical decline corresponds with these compensatory 
mechanisms being overwhelmed. 
 
The nature of the memory deficit associated with early AD has been well characterized. 
Patients exhibit problems with delayed recall of information, even when the demands of 
retrieving that information are reduced via recognition tests (Delis et al. 1991). 
Attenuation of the primacy effect and intrusion errors are seen, and semantic encoding is 
less effective in improving memory retention than in cognitively normal subjects 
(Backman and Small 1998). As the illness progresses, a semantic memory deficit emerges, 
corresponding with a loss of general knowledge, increasing language problems (see 
below) and a degree of retrograde amnesia Patients perform poorly on tests of 
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confrontational naming and recall of over-learned facts is impaired. Performance across 
different tests of semantic memory suggest that there is a genuine loss from the semantic 
store at this stage rather than a retrieval deficit alone (Chan et al. 1998). 
 
1. 6. 2. Other cognitive domains 
Executive function is impaired early in AD, resulting in problems with mental 
manipulation of information, concept formation, problem-solving, self-monitoring, 
sequencing and cue-directed behaviours (Perry and Hodges 1999). Neuropsychological 
tools for detecting these problems include the modified Wisconsin Card Sorting Task 
(Grant and Berg 1948; Nelson 1976), the Raven Progressive Matrices Task (Raven et al. 
1976) and the Trail Making Test (Reitan 1958). A number of studies have indicated that 
executive function and attention may be the first non-memory domains to be affected in 
AD (Grady et al. 1988; Reid et al. 1996). Tasks involving the concurrent manipulation of 
information and/or the division of attention are particularly affected and disruption of 
cortico-cortical connections is probably important in producing early attentional 
difficulty. 
 
Progressive impairment of language may occur as part of a typical AD clinical 
phenotype, occasionally as one of its earliest symptoms. Linguistic deficits arise at an 
early stage in up to 10% of cases, with impairment of word fluency and semantic access 
(Emery 2000). The latter is thought to result in the word finding difficulty commonly 
manifested during discourse and in tasks of confrontational naming as the temporal lobe 
semantic store deteriorates. The resulting speech is sometimes termed ‘logopenic’. 
Articulatory and phonological impairments are relatively uncommon in these early stages 
(Bayles and Kazniak 1987) although can occur (Croot et al. 2000). Later a wider range of 
dysphasic deficits may emerge with a reduction in the grammatical complexity of 
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language, and aphasia (Kempler et al. 1998). The nature and degree of language deficit 
appears to be influenced by the extent and distribution of the pathology rather than the 
type of pathology per se. Thus, with an atypical distribution of AD neuropathology (such 
as where the hippocampus and ERC are relatively spared compared to the perisylvian 
region), phonological and articulatory disruption are, via similar mechanisms to acquired 
speech and language disorders, more common. Deficits in posterior cortical functions 
(e.g. visuospatial and visuoperceptual function) do occur in typical AD, but are usually 
less prominent until the later stages of the disease. PCA is perhaps the bet known 
exception to this. 
 
1. 6. 3. Behavioural & neuropsychiatric features 
These are an important group of symptoms and signs (Burns 2009), recognised 
increasingly as a component of many neurological disorders, including AD. In AD, 
apathy and depression are the most common and their presence is associated with 
caregiver distress and poor functional and therapeutic outcome (Benoit et al. 2007). 
Agitation is a relatively common problem and the poor side effect profile generally 
associated with pharmacological measures has led to trials of alternative treatments such 
as bright light therapy (Burns et al. 2009). Visual hallucinations are seen either as a 
primary manifestation in severe disease, or when intercurrent systemic illness and 
reduced cerebral reserve combine. They are an important cause of disability and have 
been linked with an accelerated progression of dementia and early institutionalization 
(Hauft et al. 1996). There is, therefore, substantial risk of morbidity, misdiagnosis and 
inappropriate management if behavioural and psychiatric features go unrecognised.  
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1. 6. 4. Olfaction 
A particularly large body of work relates to the potential for olfactory testing in early AD 
diagnosis i.e. as a marker of onset. Olfactory dysfunction is associated with a wide variety 
of diseases and conditions, including a number of neurological illnesses such as 
amyotrophic lateral sclerosis (ALS) (Hawkes et al. 1998), Huntington’s disease (Bylsma et 
al. 1997),  multiple system atrophy (MSA) (Wenning et al. 1995), MS (Doty et al. 1999), 
idiopathic Parkinson’s disease (IPD) (Mesholam et al. 1998), and AD (Corwin et al. 1985; 
Graves et al. 1999). Importantly, loss of olfactory function is also associated with ageing, 
increasing in frequency after age 65 years (Liu et al. 1995). Olfactory deficits are an early 
feature of AD (McCaffrey et al. 2000; Luzzi et al. 2007) with early pathological change 
occurring in the hippocampus (Hyman et al. 1984), piriform cortex (Reyes et al. 1987) and 
ERC (Kahn et al. 1987). Initial optimism surrounding the identification of AD pathology 
in olfactory neuroepithelium (Talamo et al. 1989), and its potential contribution to early 
diagnosis, was tempered by the subsequent realisation that similar changes were apparent 
in IPD and some healthy controls (Trojanowski et al. 1991). However, specificity is not 
the only issue: the relationship of AD to ageing presents further problems as 
neuroepithelium is replaced by respiratory epithelium with age, making the identification 
of olfactory neurones more difficult. Further, doubt remains over the relative 
contributions of central and peripheral damage (Mann et al. 1988) to the well established 
olfactory identification, recognition and threshold detection disturbances of AD 
(Mesholam et al 1998). The density of NFT in the ERC is inversely related to the ability 
to identify odours (Wilson et al. 2007) but pathological change occurs in the olfactory 
bulb and tract just as early i.e. there is a close temporal relationship between changes in 
peripheral and central regions (Christen-Zaech et al. 2003). 
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Olfactory testing may have potential as an early marker of AD risk (Doty 2003). Some 
tests use microencapsulated odourants that are released on scratching an impregnated 
strip (Doty et al. 1984; Doty et al. 1995), while others test detection threshold, 
discrimination or odour memory. Olfactory identification scores have been determined 
in individuals with MCI, with low scores associated with a greater risk of subsequently 
developing AD (Devanand et al. 2000). Olfactory assessment may also be superior to the 
MMSE in distinguishing AD from depression (McCaffrey et al 2000). Several studies 
seem to suggest that threshold detection is better preserved than identification (Koss et 
al. 1987; Hawkes and Shephard 1998), providing support for the view that damage to 
central olfactory pathways predominates i.e. that signals are able to reach the brain under 
the appropriate conditions but perceptual deficits prevent their correct interpretation. 
Studies of olfaction in non-demented individuals at genetic risk of dementia (as 
determined by ApoE status) suggest a higher rate of olfactory dysfunction amongst 
ApoE4 positive subjects (Salerno-Kennedy et al. 2005), while others suggest that a 
positive family history, rather than ApoE4 positivity per se, is associated with olfactory 
deficits (Schiffman et al. 2002; Handley et al. 2006). These studies did not, however, 
involve families with autosomal dominant disease and/or proven PSEN or APP 
mutations. Individuals at risk of developing PSEN1-associated FAD by virtue of a 
proven PSEN1 mutation in their family have been studied, although olfactory tests did 
not predict mutation status or AAO (Nee and Lippa 2001).   
 
1. 7. Investigations 
1. 7. 1. Neuropsychological & functional scales 
Where cognitive impairment is suspected, formal neuropsychological assessment may be 
valuable in assisting diagnosis. By adopting a standardized, systematic approach bias is 
minimised and a profile of performance across a number of cognitive domains is 
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produced. This profile may then be compared with age-specific control data or, to some 
extent, with the estimated ‘premorbid’ abilities of the individual concerned. It helps in 
confirming that a deficit genuinely exists (or that it does not), and in assessing patients 
longitudinally in order to demonstrate improvement (as with practice effects in normal 
ageing), stability or deterioration – a hallmark of neurodegenerative dementias such as 
AD. There are a large number of available tests, each designed to interrogate a particular 
cognitive domain. However, at the heart of any such assessment is the Wechsler Adult 
Intelligence Scale (Revised version) (WAIS-R) (Wechsler 1981) which provides a global 
measure of intelligence as well as two important sub-scores: the performance and verbal 
IQ.  
 
Neuropsychological assessment may have a role in detecting and defining the effects of 
any intervention, although clinically meaningful functional outcome measures remain the 
ultimate test of efficacy. The limitations of this approach in evaluating therapeutic 
strategies have been outlined earlier, including the observation that up to ten times fewer 
patients are required to detect a treatment effect where MRI or 18FDG PET are used 
rather than clinical end-points (Alexander et al 2002; Jack et al. 2003). In chapters 4 and 5, 
neuropsychometry is used to provide detailed information on the nature of clinical 
deficits in two APP mutation related forms of AD. 
 
Composite scales are widely used and may be valuable in monitoring global change. 
Perhaps the best recognised quantitative cognitive function scale is the Mini-Mental State 
Examination (MMSE) (Folstein et al. 1975). This validated 30-point assessment can be 
administered rapidly, providing information on a number of cognitive domains including 
temporal and topographical orientation, language, verbal recall, calculation and attention. 
A maximum score of 30 is to be anticipated in cognitively normal subjects and a score 
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below 26 is considered supportive of a dementing illness. A similar bedside test sensitive 
to early cognitive dysfunction is the Addenbrookes Cognitive Examination (Revised 
version) (ACE-R) (Mioshi et al. 2006; Larner 2007). This has been widely adopted as a 
screening tool and, at least in the setting of a university hospital clinic, has been reported 
to be both sensitive and specific for detecting dementia. Both the MMSE and ACE-R are 
deployed in research and clinical settings, unlike the Cognitive Subscale of the 
Alzheimer’s disease Assessment Scale (ADAS-Cog) (Rosen et al. 1984) which is used 
predominantly in research. The latter scale ranges from 0 (no impairment) to 70 (severe 
impairment) and, like the MMSE, provides information about a number of cognitive 
domains.  
 
The most accurate indicator of functional impairment is a decline in the ability to 
perform activities of daily living (ADL). A number of assessment scales focus particularly 
upon this aspect, producing scores which help to quantify disability. One such scale is the 
Disability Assessment for Dementia (DAD) (Gauthier et al. 1997) which generates a 
score between 0 and 100 via a structured informant interview. The questions relate to 
basic self-care and ADL. Other scales provide a composite score by assessing both 
cognitive and functional variables together. These include the AD Co-operative Study-
Clinical Global Impression of Change (ADCS-CGIC) (Schneider et al. 1997) and the 
Clinical Dementia Rating (CDR) (Morris 1993). These scales necessarily combine 
information from patients, informants and health professionals in generating scores. 
 
1. 7. 2. Electroencephalography  
In EEG, waveforms are described by their frequency, amplitude and location. " waves 
(8-13Hz) are seen in conscious adults and attenuate with attention (stress, eye opening, 
etc). They are normally slightly higher in amplitude on the non-dominant side and 
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present more posteriorly than anteriorly. " rhythm in the lower frequency range (8-
10.5Hz) is associated with an individual’s global attentiveness whereas, in the higher 
frequency range, it reflects the oscillating activity of neural systems elaborating 
sensorimotor and semantic information (Klimesch 1999). 
 
Beta waves (>13Hz) are variably present in adults and may be enhanced by various 
drugs. Theta (3.5-7.5Hz) and delta (<3Hz) waves are collectively termed ‘slow waves’ and 
are normally seen during sleep. Both are abnormal in the conscious adult.  
 
The hallmark changes of AD include slowing of rhythms (increased theta/delta and 
decreased " /beta) (Brenner et al. 1986) and a reduction in interaction, or ‘coherence’, 
between the neural networks of different brain regions (Hogan et al. 2003). These 
changes have been shown to correlate with severity of disease (Kowalski et al. 2001) and, 
in mixed groups of cognitively normal and affected AD subjects, EEG provides 
significant additional value in predicting future cognitive performance as compared with 
cognitive measures alone (van der Hiele et al. 2008). 
 
1. 7. 3. Cerebrospinal fluid   
The combination of decreased Aß1-42 and increased tau protein is a characteristic finding 
in the CSF of individuals with AD (Verbeek et al. 2003; Lewczuk et al. 2004). Normal 
ranges are yet to be conclusively established for these variables but an upper limit of 445 
pg/mL for total tau (ttau) and lower limit of 427 pg/mL for Aß1-42 have been proposed, 
giving a sensitivity of 86% and specificity of 88% for both as predictors of AD (Wallin et 
al. 2006). This CSF profile predicts the presence of AD pathology (Tapiola et al. 2009), 
may help distinguish AD from both normal controls (Verbeek et al 2003) and VaD (de 
Jong et al. 2006), and identifies early AD in patients with MCI (Hansson et al. 2006). CSF 
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Aß1-42, ttau and phosphorylated tau (ptau) also correlate with MTL atrophy (Herukka et al. 
2008). 
It appears that Aß equilibrium is distorted, possibly via the inhibition of soluble Aß 
transport between brain and CSF by insoluble plaques and/or increased clearance of Aß 
into plaques. Binding levels of the PiB ligand (see 1. 7. 6. 1.) to cerebral Aß have been 
reported to correlate inversely with CSF Aß1-42 levels (Fagan et al. 2006), although the 
same study found no relationship between PiB binding levels and Aß1-40, ttau or ptau, 
plasma Aß1-40 or plasma Aß1-42. F2 isoprostanes are markers of lipid peroxidation and are 
therefore also markers of inflammation. Concentrations have been shown to be elevated 
in the CSF of individuals with MCI or AD (Pratico et al. 2002) though not in FTLD  
(Yao et al. 2003).  
 
In a recent study of 21 presymptomatic carriers of PSEN1 and APP mutations a low 
CSF Aß1-40: Aß1-42 ratio and high CSF ttau, ptau and F2 isoprostanes were found compared 
with normal controls (Ringman et al 2008). In the same study concentrations of Aß1-42 in 
the plasma were raised in the presymptomatic stage, falling with disease onset and 
progression.  
 
1. 7. 4. Magnetic resonance imaging  
Structural imaging of the neuraxis is an important component of modern neurological 
diagnosis. The ability to examine the brain’s structure in vivo represented a major advance 
in the diagnosis of the dementias, beginning with the emergence of CT in the early 1970s. 
The first MRI scan of the human body followed in 1977, and structural imaging now 
constitutes an essential part of the investigation of dementia (Knopman et al. 2001). For 
some time, imaging was used primarily to exclude disease amenable to surgery, such as 
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tumours, haematomata or hydrocephalus. This remains an important role, but MRI 
sequences are now increasingly used to differentiate dementia syndromes from one 
another and from normal ageing. MRI parameters are now amongst the most promising 
biomarkers for early disease detection, tracking progression and assessing intervention. 
Its greater tissue resolution and differentiation, the facility to manipulate the sequences 
used in order to emphasise the desired pathology or structure, and the absence of 
ionizing radiation mean that MRI is now considered superior to CT in most situations. 
Challenges remain however: MRI is more expensive and hence less widely available and 
acquisition times are longer, increasing the possibility of movement artefact. 
 
1. 7. 4. 1. Volumetric MRI  
Cross-sectional MRI has been applied to the study of AD in three major ways. These 
comprise region of interest (ROI) analysis, examination of lobar structure and whole 
brain analysis. ROI studies rely upon manual delineation of the region concerned on 
consecutive slices of the scan, before a computer calculates the volume of the defined 
area by counting the voxels within it. Selection of regions a priori is a potential weakness 
of such analysis as it introduces bias, although this can be minimised through careful 
ROI selection. Ideal regions exhibit little anatomical variability between normal 
individuals, so differences between subject and control groups are more easily seen, 
changes can be reliably attributed to pathology rather than normal variation, and the 
region can be reliably delineated. Equally, it is helpful to have an idea of the magnitude of 
the expected difference between groups - usually achieved through neuropathological 
analyses. Some regions, such as the inferior temporal lobe, are particularly prone to 
artefact when imaged and can therefore be more challenging to assess. 
Neuropathological studies have indicated that MTL structures are amongst the earliest 
areas affected by AD pathology  (Braak and Braak 1991) and hence they have provided a 
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focus for cross-sectional structural study. This region is known to subserve episodic 
memory, typically the earliest function to be affected in AD, providing a rational clinico-
pathological link. 
 
Hippocampal measurements are the best-established structural biomarker in AD whether 
made using time-intensive manual segmentation or automated techniques. NFT 
accumulate early in the hippocampus, especially in the subiculum and cornu ammonis 1 
(CA1) regions (Figure 5), inducing neuronal cell death and atrophy (Convit et al. 1993). 
Hippocampal volume is reduced in MCI and AD compared with normal controls, and is 
a highly discriminating variable (Xu et al. 2000; Du et al. 2001) which can predict later 
development of AD in preclinical cases with an accuracy of approximately 80% (Wang et 
al. 2006). 
 
Figure 5: Coronal Hippocampal Anatomy 
 
 
  65 
Ante-mortem hippocampal volumes also correlate well with pathological (Jack et al 2002; 
Silbert et al. 2003), though probably not clinical (Ridha et al. 2008) severity. Frequent 
overlap in hippocampal volumes between AD subjects and controls can be problematic 
and debate over the relative merits of linear and visual rating scales compared with the 
more time-consuming volumetry clouds the issue still further (Pucci et al. 1998; Laakso et 
al. 1998; Wahlund et al. 2000; Scheltens et al. 2002). Improvements can be made by 
combining hippocampal measures with clinical data (Devanand et al. 2008) or by 
performing serial longitudinal imaging to establish rates of atrophy. The latter approach 
has been applied to both whole brain (Schott et al 2005) and hippocampal volumes 
(Barnes et al. 2008; Morra et al. 2009; Henneman et al. 2009). Regional fluid registration 
combines both automation and a longitudinal approach, and is more reliable than manual 
delineation in assessing hippocampal atrophy rates (van de Pol et al. 2007). 
 
A key advantage of the hippocampus over the nearby parahippocampal gyrus (PHG) and 
ERC is that it is less laborious to evaluate. This is due to the availability of automated 
techniques (Colliot et al 2008) and the fact that these other structures are prone to 
artefact and relatively difficult to segment due to indistinct boundaries. The ERC, which 
contains major afferent pathways into the hippocampus, is nonetheless profoundly 
affected in the earliest stages of AD (Price et al. 2001) and has been studied in similar 
detail to the hippocampus. The two structures yield comparable levels of accuracy in 
distinguishing AD from normal controls (Bobinski et al. 1999; Juottonen et al. 1999; 
Toledo-Morrell et al. 2000; Pennanen et al. 2004). Other regions studied include the 
amygdala (Scott et al. 1991) and limbic/paralimbic structures (Callen et al. 2001). 
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1. 7. 4. 2. Cortical thickness  
The ability to calculate MRI-derived cerebral CTh accurately and reproducibly is a 
relatively new development. Initial attempts to characterize cortical thinning in a number 
of disease have demonstrated that it may be complementary to existing radiological tools, 
and that it can provide meaningful statistical and clinical information in even small 
groups (Lerch and Evans 2005). Grey matter changes, often with regional specificity, are 
seen in normal ageing (Jack et al. 1997), MCI (Singh et al. 2006) and in a number of 
diseases. These include SAD (Thompson et al. 2003; Lerch et al. 2005; Frisoni et al 2007), 
FTLD (Gold et al. 2005), Huntington’s disease (Rosas et al. 2002; Rosas et al. 2005), CBS 
(Boeve et al. 1999), MS (Sailer et al. 2003), amyotrophic lateral sclerosis (ALS) (Kiernan 
and Hudson 1994), schizophrenia (Kwon et al. 1999) and congenital perisylvian 
syndrome (Kotini et al. 2004). Automated CTh analysis shares many of the advantages of 
techniques like voxel-based morphometry (VBM), in that there is no requirement for a 
priori identification of regions of interest. However, unlike voxel density, a measurement 
of CTh at a given point may in itself be meaningful. The key limitation of CTh mapping 
is that no information is provided on sub-cortical structures.  
 
Historically, the main difficulties in developing a robust, automated technique for 
measuring CTh have been the accurate delineation of the pial surface and the elaborate 
invagination of the neocortex. Dealing with these issues is technically demanding, 
particularly with current MRI resolution and the requirement for sub-millimeter accuracy 
(the human cortex varies in thickness between 1 and 4.5mm). The use of manual 
techniques with slice data has significant, inherent problems in that thickness cannot be 
reliably measured unless the cortical surface is orthogonal to the viewing plane. Further, 
partial volume effects may hinder the distinction of closely adjacent surfaces, particularly 
in deep sulci. Several techniques have been used in an attempt to address these two major 
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issues (Fischl and Dale 2000; MacDonald et al. 2000; Yezzi and Prince 2003). Fischl and 
Dale’s technique is based upon a deformable model, and first seeks to define the 
grey/white boundary with sub-voxel accuracy before deforming outwards to find the pial 
surface. This produces two surfaces, each a net of 81,920 polygons, with each white 
matter vertex related to a grey matter equivalent. CTh is then defined as the shortest 
distance between these linked vertices. Sub-voxel accuracy is achieved through 
interpolation, using information about the intensity of each voxel, the nature of 
surrounding voxels (continuity information), and the ability to assume that the radius of 
surface curvature and thickness of tissue to be measured exceed the size of the voxels 
themselves. Sufficient contrast-to-noise must also exist between the different tissue 
classes. Because, on a millimetre scale, the cortex is smooth, representations of it at this 
scale should also be smooth. Many techniques exist for constraining a surface to be 
smooth but, by their nature, these constraints work by seeking to minimize curvature. 
This means that they have problems faithfully representing highly curved regions such as 
the fundi of sulci or crowns of gyri, and will therefore inaccurately represent them. Fischl 
and Dale’s technique addresses this by first computing the curvature at patches of the 
brain surface and then altering the representation of that surface so that, on a millimetre 
scale, it also has this curvature. 
 
Studies in SAD have shown a clear reduction in both regional and mean CTh with the 
PHG most affected (Lerch et al 2005). The extent and nature of clinical deficits seem to 
correlate with CTh in defined areas (including the MTL, left anterior cingulate and left 
insula) and with a well-defined sequence of grey matter loss from temporal and limbic 
cortices to the frontal and posterior regions, sparing sensory and motor cortices. This 
sequence mirrors the spread of amyloid plaques and NFT observed in post mortem 
studies (Braak et al. 1999). To date, one study has examined the different CTh patterns 
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associated with early and late onset forms of AD (Frisoni et al 2007), with AAO the sole 
criteria for defining the groups. Chapter 2 examines how CTh measurement can assist in 
the detection of cortical changes at a very early presymptomatic stage and explores the 
nature and distribution of such changes. 
 
 
1. 7. 4. 3. 1H magnetic resonance spectroscopy  
Analysis of the biochemical and metabolic properties of brain tissue producing 
spectroscopic profiles of healthy and disease states is possible, and several metabolites 
have proved to be of interest in AD. N-acetyl aspartate (NAA) is located in neurones and 
may be a useful marker of neurone density and viability. Myoinositol (mI) is found 
predominantly in glial cells and is therefore found at increased levels in gliosis (Bitsch et 
al. 1999). Choline (Cho) is found mainly in membrane-bound phospholipids and creatine 
(Cr), being relatively stable in AD (Schuff et al. 2002), is often used as an internal 
reference.  
 
Regional reduction in the NAA/mI ratio is seen in AD patients with the most prominent 
change seen in the parietal lobe grey matter (Zhu et al. 2006). Grey and white matter loss 
in AD seems to reflect known neuropathological patterns with lower NAA/Cr ratios in 
the posterior cingulate gyri but a normal ratio in the occipital cortex (Kantarci et al. 2000). 
MRS has been used to successfully predict cognitive decline in established AD (Kantarci 
et al. 2007), to predict progression from aMCI to AD (Metastasio et al. 2006) and to 
identify changes in the brains of APP and PSEN1 mutation carriers several years before 
clinical onset (Godbolt et al. 2006). Normalization of NAA levels after treatment of AD 
with cholinesterase inhibitors has been reported (Modrego et al. 2006).   
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1. 7. 4. 4. Magnetization transfer ratio  
Magnetization transfer ratio (MTR) imaging exploits the exchange of magnetization 
between two distinct groups of protons. The first pool (approximately 80%) consists of 
protons in intracellular or extracellular water molecules. These are relatively freely 
mobile, unlike the protons of the second pool that form part of macromolecules such as 
proteins and lipids. The two groups are connected by a constant exchange of 
magnetization such that a radiofrequency pulse (MT pulse) applied to the restricted pool 
will affect the free pool (which can be seen with MRI). The nature and extent of this 
exchange depends upon the restricted: free proton ratio, the strength of the RF pulse 
and, importantly, the physical and chemical microenvironment of the protons concerned. 
Deductions regarding the microstructure of the tissue in question can therefore be made.  
 
The most widely used expression of MT characteristics is the MTR, where magnetization 
of the free pool is compared with and without the application of an MT pulse. 
Pathological processes disrupt microscopic brain architecture and hence alter (reduce) 
the MTR. Such microstructural change in remaining brain tissue, as measured by MTR 
may accompany macrostructural change (atrophy) in AD (Ridha et al. 2007) or may occur 
in the absence of atrophy in MCI (van der Flier et al. 2002). AD-related focal MTR 
changes have been noted both in the MTL (Bozzali et al. 2001) and outside the temporal 
lobes (van der Flier et al 2002).  
 
1. 7. 4. 5. Diffusion-weighted & diffusion-tensor imaging  
Diffusion-weighted imaging (DWI) and DTI allow visualization of the Brownian 
movement of water at a sub-voxel level. Physical boundaries, such as the axon sheath of 
a white matter fibre, both constrain diffusion (reducing diffusivity on DWI) and 
influence its direction such that it is greater along the axis of that boundary than across it. 
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This is known as anisotropy, measured as fractional anisotropy (FA), which ranges 
between 0 and 1 on a normalized scale, and is used in DTI to show the groups of parallel 
fibres which characterise white matter tracts. Regions with little or no boundaries, such 
as CSF have relatively unrestrained diffusion and appear isotropic on these sequences. 
DWI may be particularly useful in clinical practice where pathological processes such as 
ischaemic stroke lead to the death of tissue and the disruption of cellular boundaries to 
diffusion, providing a sensitive means of detecting such problems. 
 
1. 7. 5. Positron-emission tomography 
1. 7. 5. 1. 18Fluorodeoxyglucose PET 
18F is the most widely used positron emitter, usually conjugated to form 18FDG, which 
allows regional metabolism (expressed as cerebral metabolic rate for glucose (CMRglc) in 
"mol glucose/100 g/min units) to be assessed. It is created by proton bombardment of 
18O which produces 18F and a neutron. 18F has a radioactive T# of 110 minutes meaning 
that, unlike 11C (see 1. 7. 6. 1.), 18F-labelled tracers can be centrally manufactured and 
distributed, allowing more widespread use. Glucose is the main substrate used by the 
brain in producing energy for the maintenance of crucial ionic gradients, and hence 
neuronal function. The first step in glucose metabolism is phosphorylation by 
hexokinase, to which the 18FDG tracer is also subject, forming the basis for its use in 
assessing metabolic activity. In the normal brain CMRglc varies by region but is invariably 
higher in grey matter than in white. 
 
Symmetrical temporoparietal, posterior cingulate and precuneus hypometabolism with 
later involvement of the frontal association cortices is the characteristic pattern described 
where 18FDG PET is applied to AD (Minoshima et al. 1997; Herholz 2003) although, 
where asymmetry exists, it tends to persist. The technique is able to separate AD from 
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controls with as much as 93% accuracy (Herholz et al. 2002a) and regional posterior 
cingulate or hippocampal/entorhinal metabolism are of prognostic value in MCI  
(Minoshima et al 1997; de Leon et al. 2001). Sparing of the primary sensorimotor and 
visual cortices, basal ganglia and cerebellum is usual, reflecting the predominant clinical 
deficits associated with AD. Interestingly, metabolic deficit in the posterior association 
cortices can be difficult to assess as these areas have inherently higher resting metabolic 
rates in the normal brain meaning that, even when affected, these areas can appear much 
the same as the surrounding cortex may have decreased global CMRglc has been observed 
in individuals at risk for FAD by virtue of a family history two to three years before the 
mean AAO for their family (Kennedy et al 1995a). In these cases the pattern of 
hypometabolism was the same as that seen in established disease. 
 
1. 7. 6. Amyloid imaging 
The earliest attempts at quantitative in vivo imaging of Aß were based around radio-
labelling staining agents such as congo red (Klunk et al. 1994). A key problem was the 
inability of such bulky, ionized molecules to cross an intact BBB. Consequently, research 
became more focussed upon identifying derivatives of these substances, which 
maintained their affinity for fibrillar amyloid but could access the CNS. With time, 
progressively less ionized compounds with greater metabolic stability, brain uptake and 
clearance have been developed. Clinical trials in humans began with the use of 18F-
FDDNP (Shoghi-Jadid et al. 2002), a tracer which binds to both amyloid plaques and 
NFT. PET studies have subsequently been performed with a number of 11C and 123I-
based compounds (Verhoeff et al. 2004; Opazo et al. 2006; Newberg et al. 2006). The first 
human studies of 11C-PiB were also performed in 2002 and were reported in 2004 (Klunk 
et al 2004). 
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1. 7. 6. 1. Pittsburgh compound B  
PET using 11C-PiB represents the most successful attempt so far to visualize amyloid 
plaques in vivo. 11C-PiB is a thioflavin-based radio-ligand that shows good blood-brain 
barrier permeability and binds with high affinity to both fibrillar and vascular amyloid 
(Lockhart et al. 2005; Johnson et al. 2007; Lockhart et al. 2007), more weakly to NFT, but 
not to soluble amyloid. High affinity binding sites do exist on " -synuclein filaments 
present in Lewy bodies, although the density/availability of these sites in vivo is 
significantly less than those associated with fibrillar amyloid and so Lewy body pathology 
probably contributes very little to the retention of 11C-PiB (Ye et al. 2008).  
 
11C-PiB PET discriminates clinically probable AD patients from healthy controls, with 
AD cases showing two-fold greater retention in cingulate and neocortical association 
areas known to be targeted by amyloid deposition (Klunk et al 2004).  11C-PiB retention 
correlates with rates of cerebral atrophy in AD (Archer et al. 2006), with decreased levels 
of Aß1-42 in the CSF of demented and non-demented subjects (Fagan et al 2006), with 
post-mortem measurement of insoluble Aß levels (Ikonomovic et al. 2008) and inversely 
with rates of resting cortical glucose metabolism (Klunk et al 2004). The combination of 
11C-PiB PET and MRI seems to confer superior diagnostic accuracy to either modality 
alone (Jack et al. 2008) and retention is not influenced by anticholinesterase medication. 
Although 11C-PiB PET localises the distribution and density of Aß plaques, these 
correlate inconsistently with the degree of functional or cognitive impairment 
(Giannakopoulos et al 2003).  It seems more likely that the density and distribution of 
soluble, neurotoxic Aß oligomers are more relevant to neuronal dysfunction (Lesne et al 
2006), but these are not detected by thioflavin based radio-ligands such as 11C-PiB  
(Naslund et al. 2000).  
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11C-PiB retention is elevated in as many as 40% of cognitively normal elderly controls 
(Mintun et al 2006; Rowe et al. 2007; Gomperts et al. 2008), in keeping with the 30% of 
healthy people over 75 years of age with cerebral Aß deposition at post-mortem  (Price 
and Morris 1999). This suggests either that 11C-PiB imaging is sensitive for detection of 
preclinical AD, or that some individuals may tolerate an amyloid burden without 
developing symptoms. Longitudinal study in large cohorts will be necessary to resolve 
this question.  However, for now it seems most likely that such amyloid deposition is not 
a consequence of normal ageing, but rather that it represents preclinical AD (Villemagne 
et al. 2008). 
 
11C-PiB retention is increased in around 50% of MCI patients (Kemppainen et al. 2007) 
and these cases progress most rapidly to AD (Forsberg et al. 2008; Villemagne et al 2008) 
suggesting the potential for a prognostic/predictive role. Positive 11C-PiB scans in MCI 
resemble those of established AD and negative scans resemble normal controls 
(Kemppainen et al 2007).  
 
The 11C of 11C-PiB is produced by proton bombardment of standard nitrogen (14N). The 
unstable 11C undergoes both beta-plus decay (with positron emission) (99.77%) and 
electron capture (0.23%) to become the more stable boron isotope 11B. Half-life (T#) is 
20.38 minutes. Unfortunately 11C’s 20 minute radioactive T#, means that its use is 
restricted to sites with 11C radiochemistry expertise and cyclotron facilities. It cannot be 
centrally produced and regionally distributed like 18F ligands and so is too expensive for 
routine clinical use. 
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1. 7. 6. 2. 18F BAY94-9172 
18F-labelled amyloid tracers are an attractive prospect due to the practical benefits of 18F 
over 11C mentioned above but to date they have only demonstrated 9% greater uptake in 
AD than healthy controls (Small et al. 2006). This does not compare favourably to 11C-
PiB, which has shown up to 70% greater cortical binding in AD (Rowe et al 2007).  
Furthermore, the use of 11C-PiB-based compounds requires far less scanning time. There 
is, therefore, a well-established need for an 18F tracer with binding characteristics similar 
to those of 11C-PiB. 18F-BAY94-9172 or trans-4- (N-methyl-amino)-4’-{2-[2-(2-[18F] 
fluoro-ethoxy)- ethoxy]-ethoxy}-stilbene (also known as 18F-AV1/ZK) is structurally 
similar to PiB and competes for the same amyloid binding with similar affinity (Zhang et 
al. 2005). There is evidence to suggest that neocortical binding of 18F-BAY94-9172 is 
similar to that of 11C-PiB and that it is 57% greater than in normal controls (Rowe et al. 
2008). This compares favourably with 11C-PiB without the half-life related disadvantages 
discussed above. 
 
1. 7. 7. Single photon emission computed tomography  
SPECT has historically been the most widely available functional brain imaging modality. 
The principles are similar to those of 18FDG PET, except that a !-emitting 
radiopharmaceutical and a !-camera are employed. The most commonly used !-emitting 
tracer for functional SPECT brain imaging is 99mTc-HMPAO (hexamethylpropylene 
amine oxime) which is taken up by brain tissue in a manner proportional to cerebral 
blood flow. The close link between blood flow and regional metabolism makes 99mTc-
HMPAO a good marker for the latter, although this link may be lost in cerebrovascular 
disorders, and vessel calibre/blood flow is heavily dependent upon pCO2, making it 
more variable than regional glucose metabolism. Like 18FDG PET and spin-labelled MRI 
techniques, SPECT studies have implicated temporo-parietal regions in AD (Johnson et 
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al. 2004; Pakrasi and O'Brien 2005). The evidence suggests that, in some respects, 18FDG 
PET may be worth any extra inconvenience as it is probably superior to SPECT as a 
diagnostic test in AD (Herholz et al. 2002b). Nonetheless, accuracy of SPECT in AD 
diagnosis may be as high as 88% (Bonte et al. 2006) and meta-analysis suggests that it is 
superior to clinical criteria in its ability to differentiate AD from VaD, although inferior 
in distinguishing AD from healthy controls (Dougall et al. 2004). This is perhaps 
unsurprising if we consider that metabolic deficits are by nature more discrete in vascular 
disease than AD and hence more amenable to detection using regional metabolic 
imaging. In studies with clinico-pathological correlation, SPECT appears to be most 
useful when there is greatest clinical uncertainty, adding least where the clinical diagnosis 
is clear and most where is not  (Jagust et al. 2001).  
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Figure 6: Diagrammatic 11C-PiB PET process 
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1. 8. Alzheimer’s disease therapy 
A number of strategies exist for the treatment of AD, each addressing a distinct phase of 
the pathological process. Many are still in the very early stages of research and a truly 
disease-modifying agent remains elusive. In theory, it should be possible to intervene at 
various stages of the amyloid cascade: 
 
1. 8. 1. Decreasing Aß production  
This requires intervention at a relatively early stage of the amyloid cascade. Since the 
amyloidogenic pathway requires the action of ß-secretase (BACE-1) and !-secretase, both 
are attractive targets for novel therapies. BACE-1 inhibitors are particularly promising as 
BACE-knockout mice are apparently otherwise healthy, show no detectable ß-secretase 
activity, and produce much less Aß from APP in primary cortical cultures (Roberds et al. 
2001). Potent inhibitors have been developed which are effective in vitro and in transgenic 
mouse models (Rockenstein et al. 2001) and early data in humans are beginning to emerge 
(http://www.alzforum.org/new/detail.asp?id=1790). Just as BACE-1 may be up-
regulated by inflammation, it may be down-regulated by NSAIDs via the stimulation of 
peroxisome proliferated activated receptor-! (PPAR-!). Treatment with specific PPAR-! 
agonists (rosiglitazone) has previously been associated with significant cognitive 
improvement in AD albeit only in ApoE4 negative individuals (Risner et al. 2006). Oral 
administration of the GSK188909 BACE-1 inhibitor leads to significant reduction in 
levels of Aß in the mouse brain (Hussain et al. 2007). 
 
Inhibition of !-secretase is more problematic as the enzyme is responsible for cleaving a 
number of other important proteins, such as the notch-1 protein, which has an important 
role in normal growth. Despite this, there are currently several !-secretase inhibitors, 
some ‘notch-sparing’, in phase II trials. A related strategy is to exploit the variability of 
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the !-secretase cleavage site in an attempt to increase the Aß1-40: Aß1-42 ratio. This ensures 
that the shorter, more soluble, less toxic Aß species predominate. Agents capable of such 
modulation are termed ‘Selective ß-Amyloid Lowering Agents’ or SALAs. They include 
NSAIDs (Weggen et al. 2001) and Flurizan, a compound which reached phase III trials in 
mild AD before it failed to achieve significant benefits in primary endpoints, prompting 
recent discontinuation of its development. 
 
As the action of " -secretase precludes the production of Aß, its potentiation is a further 
theoretical option. This is achievable, for example, by stimulating muscarinic M1 
receptors. The M1 agonist talsaclidine can affect CSF Aß1-42 (Hock et al. 2003), although 
there are presently no clinical data to support the use of such agents.  
 
1. 8. 2. Facilitating Aß clearance 
Once the Aß has been allowed to form, an alternative approach is to enhance its 
clearance and thus limit its toxicity. This is most effective if it is cleared prior to 
oligomerization and may, in theory, be achieved by several means. Immunotherapy is a 
promising and popular area and can facilitate the removal of Aß via a selection of 
mechanisms. These include opsonization and Fc-dependent phagocytosis, direct 
antibody-mediated dissolution and sequestration of amyloid in the plasma such that a 
gradient is established which favours movement of amyloid out of the CNS. Chronic, 
low level activation of innate immunity has been demonstrated in AD (Akiyama et al. 
2000) , although microglia do not seem to effectively clear Aß deposits (Wisniewski et al. 
1989). One recently tested strategy is the manipulation of cytokine signalling in peripheral 
macrophages in an attempt to promote cerebral Aß clearance. Blockade of TGF-ß1, for 
example, appears to attenuate parenchymal and vascular Aß (Town et al. 2008).  
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In 1999, Schenk et al. used transgenic platelet-derived growth factor promoter-expressing 
APP (PDAPP) mice which over-expressed human mutant APP to investigate active 
immunisation. These mice exhibit, in an age and brain region-dependent fashion, amyloid 
lesions (though not tau pathology) similar to that seen in human AD (Games et al. 1995). 
In younger mice, immunization with human Aß1-42 resulted in reduced plaque formation, 
neuritic dystrophy and gliosis while in older mice there was a reduction in the 
progression of the same. Clinical improvement was later demonstrated in a similar 
experiment using a standard radial arm water maze with submerged platform (Morgan et 
al. 2000). The first trial of passive immunotherapy in mice demonstrated that peripherally 
administered immunoglobulin entered the CNS, decorated plaques and induced microglia 
to clear plaque Aß via FcR-mediated phagocytosis and peptide degradation (Bard et al 
2000). Synthetic Aß1-42 (AN1792) with an adjuvant T-helper (QS-21) was developed for 
human trials which entered phase II in October 2001 (Gilman et al 2005). Of the 372 AD 
patients randomized, 298 received AN1792. Two primary efficacy endpoints were 
identified relating to the whole brain volume as measured by longitudinal MRI and 
cognition as measured by the ADAS-cog. Only those who mounted an antibody 
response to vaccination (serum titre >1: 2200) were evaluated. Unfortunately, 18 cases of 
meningoencephalitis (Orgogozo et al. 2003) forced the trial to end prematurely. Blinding 
was maintained along with the safety and tolerability assessments for the ensuing nine 
months. Studies using peripheral blood mononuclear cells from AN1792-exposed 
patients suggest that AN1792 can induce a class II MHC restricted Th1 type response 
against itself. This, in combination with the neuropathological findings, suggests that an 
aberrant T-cell response may have been responsible for the encephalitis observed. The 
key efficacy signals from the AN1792 study were that antibodies selective for Aß cross 
the BBB, that they are specific for the N-terminus of Aß and that a number of signals are 
associated with an elevated titre. These signals included a significant reduction in brain 
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volume (Fox et al 2005), memory improvement at 12 months, less decline in executive 
function at 12 months, clearance of Aß, lower CSF tau levels and improvement in 
activities of daily living at 18 months. Post-mortem data indicated that neuropathological 
findings were similar to those of the mice with focal depletion of Aß, persistent NFT and 
immunoreactive macrophages showing aggregates of Aß. Encephalitis correlated with 
numerous T-cell infiltrates and white matter change. 
 
Passive, as opposed to active, immunotherapy has several potential advantages. It 
bypasses the need for the recipient (who is usually elderly) to mount an antibody 
response to the vaccine, has shown similar amyloid removal benefits in animal models  
(Bard et al 2000) and allows antibody levels to be controlled by changing the dose and 
frequency of administration. Also, it theoretically removes the risk of inducing the 
aberrant T-cell response thought to be responsible for encephalitis. This strategy may, 
however, have its own problems: cerebral haemorrhage has been linked with passive anti-
Aß therapy as clearance of Aß from vessels may damage their integrity (Pfeifer et al. 
2002).  A humanized monoclonal antibody has been tested in a phase II multiple 
ascending dose study in mild to moderate AD (Grundman and Black 2008), and a phase 
III trial is underway. PiB PET imaging techniques have been used to assess the success 
of this approach (see chapter 3). IVIG, IFN-" and TNF-" blockade with etanercept are 
currently in phase I trials (Dodel et al. 2004; Tobinick 2006; Yamamoto et al. 2007). 
 
There are no clinical data concerning enzymatic degradation of Aß using 
metalloproteases such as NEP, IDE and ECE, although preclinical experience is 
promising. NEP knockout mice have elevated Aß levels (Hellstrom-Lindahl et al. 2008) 
and Aß levels may be reduced in vitro by IDE, ECE and angiotensin converting enzyme 
(ACE) (Eckman et al. 2006). 
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It may be possible to regulate the passage of Aß across the BBB in either direction by 
targeting the receptors responsible for trafficking. Two main receptors are implicated: 
RAGE and LRP-1. The former principally transports Aß into the brain from the 
systemic circulation and the latter mediates its exit from the brain. The ratio of activity of 
these receptors is therefore highly relevant and is raised in the AD brain. No clinical trials 
addressing this strategy have been performed although statins (HMG-CoA reductase 
inhibitors) are known to up-regulate LRP-1 (Deane et al 2004). 
 
1. 8. 3. Preventing Aß aggregation 
Inhibition of Aß aggregation into toxic oligomeric species is a further potential strategy. 
Aß has binding sites for both zinc and copper and both have a role in its aggregation. 
Early studies of agents such as cloquinol, which chelate metal ions, have shown promise  
(Ritchie et al. 2003). However, the only aggregation inhibitor to reach phase III trials is 
the synthetic glycosaminoglycan 3-amino-1-propaneosulfonic acid (3APS, tramiprosate 
or ‘Alzhemed’) (Geerts 2004), an agent which interferes with the binding of Aß to 
glycosaminoglycans, a necessary stage in the assembly of oligomers and fibrils. These 
trials were recently discontinued due to disappointing results.  
 
1. 8. 4. Neurotransmitter manipulation 
Donepezil, galantamine and rivastigmine are currently licensed in the UK for the 
management of moderately severe AD (NICE 2007). They belong to a group of drugs 
that degrade acetylcholinesterase (AChE), the enzyme responsible for hydrolysing ACh. 
The earliest such drugs were physostigmine and tacrine, which proved impractical for use 
in AD due to poor penetration of the BBB and hepatotoxicity respectively. Amongst the 
newer agents, randomized, double-blind, placebo-controlled trials have demonstrated 
roughly equivalent efficacy in producing small but statistically significant improvements 
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in global function and cognition in mild to moderately severe AD (Birks 2006). There are 
few direct comparisons however, and no strong evidence of important differences 
between them: only one randomized, double blind study has compared two such agents 
directly (Bullock et al. 2005). This showed no differences at two years for measures of 
cognitive function and behavioural disturbance although donepezil was associated with 
fewer adverse events. Indeed donepezil remains the most widely prescribed drug for AD, 
at a maximum licensed dose of 10mg OD. Mild gastrointestinal side effects are common 
with all AChE inhibitors, though they may attenuate with time and/or careful titration. 
 
Galantamine was originally extracted from the snowdrop (Galanthus nivalis) although is 
now procured from the more abundant daffodil (Narcissus pseudonarcissus). It has a dual 
mechanism of action both enhancing the effect of ACh upon nicotinic receptors and 
reversibly inhibiting AChE.  
 
Rivastigmine is a reversible inhibitor of AChE and butyrylcholinesterase (BuChE) (unlike 
donepezil and galantamine which show no functional inhibition of the latter).  In 
addition it displays a ten-fold greater affinity for brain AChE than for peripheral AChE. 
It has been suggested that such dual inhibition may confer more sustained efficacy, or 
even modify disease (Bullock 2002). The first transdermal AD treatment has recently 
been developed in the form of a rivastigmine patch (Lefevre et al. 2008). 
 
Introduced in 2002, memantine is an antagonist at the N-methyl-D-aspartate (NMDA) 
receptor for glutamate and is thought to exert a beneficial effect in AD by ameliorating 
excitotoxicity. Benefits in functional and global outcome measures were established in 
moderate to severe AD some years ago (Reisberg et al. 2003) and it remains the only drug 
licensed for severe dementia in the UK. However, evidence for statistically significant 
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improvement in ADAS-cog and CIBIC-plus scores in mild to moderate disease also now 
exists (Bakchine and Loft 2008). Memantine may provide additional positive effects 
when combined with donepezil (Tariot et al. 2004).  
 
Dimebolin Hydrochloride (Dimebon), originally developed as a non-selective 
antihistamine, is a weak inhibitor of BuChE and AChE, and a blocker of the NMDA 
receptor (Bachurin et al. 2001). A neuroprotective capability has also been suggested 
(Lermontova et al. 2001). A recent randomised, placebo-controlled study showed a 
significant benefit as measured by ADAS-cog (Doody et al. 2008). A mean difference of 4 
points was seen at 26 weeks while differences ranging from 1.5 points to 3.9 points have 
been found in randomised clinical trials of AChE inhibitors (Kaduszkiewicz et al. 2005). 
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2. 
THE FAD PARADIGM 
I: Structural neuroimaging  
 
Chapters 2 and 3 contain studies which apply the FAD paradigm to study early disease 
features, circumventing problems inherent in the study of SAD. They help to further 
characterize radiological phenotypes associated with FAD, SAD and normal ageing, 
while assessing the potential of two relatively new imaging techniques as biomarkers of 
onset, progression and intervention. The first such biomarker is CTh, a potentially more 
reliable marker than volume as the cytoarchitectural structure of the grey matter is less 
variable (Pakkenberg and Gundersen 1997; Singh et al 2006). Changes in the cortex are a 
well established consequence of AD pathology with layer II of the ERC and layer III of 
the neocortex preferentially affected (Pearson et al. 1985; Gomez-Isla et al 1996). 
Furthermore, fully automated cortical surface reconstruction is now possible, providing 
detailed information on the thickness of the cortical ribbon. This technique is 
complementary to existing radiological tools, and may provide meaningful statistical and 
clinical information even in small groups (Lerch and Evans 2005) (see 1. 7. 4. 2.). 
Regional CTh measures in established AD, including that of the MTL, left anterior 
cingulate, frontal and parietal lobes, correlates well with the severity and nature of clinical 
deficits (Thompson et al 2003; Du et al. 2007; Dickerson et al. 2009) and its measurement 
continues to show promise as a clinical and research tool (Lerch et al. 2008). However, 
the potential of CTh as a biomarker in confirmed FAD mutation carriers has not yet 
been fully defined. The objective of this study was to examine longitudinal patterns of 
CTh in a cohort of initially pre-symptomatic FAD mutation carriers (MC) in a period 
which included symptom onset and clinical diagnosis of AD.  
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2. 1. Methods 
2. 1. 1. Subjects 
In a previously described MRI study of atrophy progression in FAD (Ridha et al 2006), 9 
carriers (four men) of autosomal dominant mutations associated with early-onset FAD 
(MC) underwent longitudinal volumetric MRI assessment (Table 1). Five had mutations 
in APP (2 V717G, 2 V717I and 1 V717L; mean 4.3 years before clinical diagnosis at 
baseline scan, range 1.2-7.6; mean AAO 52.7, range 48.0-61.1) and four in PSEN1 (2 delta 
4, 1 L250S and 1 M139V; mean 4.2 years before clinical diagnosis at baseline scan, range 
2.6-5; mean AAO 42.2, range 37.7-49.8). 25 age and sex-matched controls were recruited 
from spouses (n=7), unaffected relatives including those with negative genetic test results 
(n=4), and healthy volunteers (n=14). Between 1991 and 2005, all MC (mean 4.3 years 
before clinical diagnosis at baseline scan, range 1.2-7.6; mean AAO 48, range 37.7-61.1) 
and controls had serial volumetric MRI, which spanned the time of clinical diagnosis. 
Written, informed consent was gained from each participant.  
 
Table 1: Demographic & scan information 
 
 
 
 
 CONTROLS MC 
n 25 9 
Mean age at first scan (SD) (years) 45.8 (10.4) 43.8 (6.7) 
Mean number of scans (range) 2.2 (2-4) 4.6 (2-8) 
Mean follow-up time (range) (years) 1.5 (0.5-4.1) 4.9 (1.9-9.7) 
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2. 1. 2. Image acquisition 
Baseline scans were performed between 1991 and 2001. Imaging between 1991 and 2000 
was performed using a 1.5T GE Signa scanner (General Electric Medical Systems, 
Waukesha, WI, USA). Volumetric T1-weighted coronal MRI scans were obtained with a 
spoiled gradient echo technique (256$128 matrix, field of view 24$24 cm, 
TR/TE/NEX/FA=35 ms/5 ms/1/35°) yielding 124 contiguous 1.5 mm thick slices. 
Between 2000 and 2005 imaging was performed using a different 1.5T GE Signa scanner 
running software version 5.8 (General Electric Medical Systems, Waukesha, WI, USA). 
Volumetric T1-weighted coronal MRI scans were obtained using an inversion recovery 
prepared fast spoiled gradient-echo technique (256$256 matrix, field of view 24$18 cm, 
TR/TE/TI/NEX/FA=14 ms/5%4 ms/650 ms/1/15°) yielding 124 contiguous 1%5 mm 
thick slices. 
 
Detailed cortical surface construction and thickness estimation was achieved by applying 
Freesurfer software (http://surfer.nmr.mgh.harvard.edu/) to the resulting images, a 
technique previously described and validated  (Dale et al. 1999; Fischl et al. 1999; Fischl 
and Dale 2000). This was performed on a 64-bit Linux CentOS 4 Cluster managed by a 
Sun Grid Engine. Briefly, the process involves initially generating an automatic grey 
matter, white matter and CSF classification. The results of these segmentations were 
visually inspected, and if needed, manually edited by adding control points. Finally, an 
automatic reconstruction of the cortex was produced and CTh estimated by computing 
the average shortest distance between the white matter boundary and the pial surface. 
The standard Freesurfer processing stream was used apart from one modification: we 
used locally-generated brain masks for the skull-stripping process. This brain mask was 
produced using a semi-automated segmentation procedure that involved selection of 
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thresholds, followed by a series of erosions and dilations, yielding a brain region 
separated from surrounding CSF, skull and dura.  
 
2. 2. Cortical thinning in FAD: a cross-sectional study 
2. 2. 1. Methods 
In this study, baseline scans from PMC (mean 4.3 years before symptom onset, range 
1.2-7.6) and controls were compared. Further comparison was made between the 
baseline scans of APP (mean 4.3 years before symptom onset, range 1.2-7.6) and PSEN1 
(mean 4.2 years before symptom onset, range 2.6-5) mutation carriers using two 
approaches:  
 
- Surface maps of all groups were generated following registration of cortical 
reconstructions to a common average surface and then smoothed using a surface-based 
Gaussian kernel of 20mm full width half-maximum. A vertex-by-vertex analysis using a 
general linear model was performed to examine differences in CTh between the patient 
group and the control group.  CTh, C, was modelled as a function of group, controlling 
for age, sex and the scanner used by including them as nuisance covariates.  C=ß1 FAD 
+ ß2 controls + ß3 age + ß4 sex + ß5 scanner + " + # (where " is a constant, and # is 
error) with the contrasts of interest being the two-tailed t-test between the estimates of 
the group parameters, i.e. ß1 and ß2. Thresholding the images of t-statistics at a 0.05 
significance level generated maps of the differences between groups at this level of 
significance. We repeated these analyses after sub-stratifying for mutation.  
- Regions of interest generated during the Freesurfer processing stream were combined 
to give mean thickness values for the frontal, temporal and parietal lobes as well as the 
cingulate cortex in both hemispheres in each patient, and previously reported total 
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hippocampal volumes from the same cohort (Ridha et al 2006) retrieved for comparison. 
Differences by patient group were investigated using regression analyses adjusted for age, 
sex and scanner. Robust standard errors were used to address any differences in variance 
between the patient groups. Mean hippocampal volumes were also compared using this 
method. 
2. 2. 2. Results 
CTh maps (Figure 7) revealed distinct anatomical patterns of cortical thinning in the 
FAD group and in each mutation subgroup. Figure 7a shows the distribution of 
statistically significant (p<0.05), uncorrected differences between the FAD and control 
groups. Compared with the healthy control group, the most prominent grey matter loss 
in the FAD group as a whole was seen in the inferomedial temporal lobe, precuneus, 
posterior cingulate, posterior superior temporal sulcus, parieto-occipital junction and 
orbitofrontal cortex in both hemispheres. Figure 7b shows the distribution of statistically 
significant (p<0.05), uncorrected differences between the APP and PSEN1 mutation 
subgroups. The APP carriers had significantly thinner cortices than PSEN1 carriers in 
the middle temporal, inferior temporal and parahippocampal gyri as well as the 
precuneus. No changes survived statistical correction for multiple comparisons. 
 
Comparison of group CTh means by lobe, as well as total hippocampal volume (Table 2) 
broadly corroborated the patterns of change on CTh maps. The FAD group and APP 
subgroup had lower mean thickness than controls in frontal, temporal and parietal lobes, 
and in the cingulate gyrus, as well as lower mean total hippocampal volumes. Mean CTh 
in the APP group was lower than the PSEN1 group across all regions examined, with the 
most prominent CTh differences seen in the temporal lobes. The APP subgroup was 
largely responsible for the differences observed between FAD and control groups, 
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despite the small (0.1 years) difference in the mean time before symptom onset between 
the subgroups. Mean hippocampal volumes were lower in the FAD, APP and PSEN1 
groups than in controls, and mean total hippocampal volume was lower in the APP than 
the PSEN1 group. 
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Figure 7: Surface maps of CTh
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2. 2. 3. Discussion 
Using a fully automated method, we measured CTh across the entire brain in order to 
investigate cross-sectional differences between presymptomatic FAD mutation carriers 
and age- and sex-matched controls. The CTh profiles of carriers of the two most 
common FAD gene mutations were also examined individually.  
Cross-sectional comparison demonstrated differences between mutation carriers and 
controls occurring several years before symptom onset and, although they did not 
survive statistical correction for multiple comparisons, our findings are in keeping with 
previous volumetric data in the same groups (Ridha et al 2006) and implicate regions 
which are thought to be significant in early AD. There is much imaging and pathological 
evidence that these regions comprise the limbic and heteromodal association cortices 
(Minoshima et al 1997; Juottonen et al 1999; Xu et al 2000; Lerch et al 2005; Mosconi et al. 
2006; Dickerson et al 2009). 
In addition, VBM and CTh analyses, including a recent study of MCI patients destined to 
progress to AD (Bakkour A et al. 2008), have confirmed that very early changes occur in 
the medial temporal cortex, inferior temporal gyrus, superior parietal lobule, temporal 
pole and precuneus with lateral temporal lobe and other areas of the neocortex affected 
later  (Chetelat et al. 2002; Singh et al 2006; Bakkour A et al 2008). Many of these regions 
are highlighted as significant in Figure 7. A well-defined sequence of cortical thinning is 
recognized thereafter, progressing from temporal and limbic cortices to the frontal and 
posterior regions, sparing sensory and motor cortices. This spreading wave of grey matter 
loss mirrors the spread of amyloid and tau pathology observed in post mortem studies 
(Braak and Braak 1991; Braak and Braak 1996a). Such reports of early, significant change 
in the MTL and retrosplenial cortex are also in keeping with our findings. Further, our 
results are broadly consistent with observations made in established, late-onset SAD, in 
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which reduction of both regional and mean CTh has been documented with the PHG 
and cingulate of particular importance in discriminating SAD from healthy controls 
(Lerch et al 2005; Lerch et al 2008). Similarly, we found particular differences in the left 
cingulate gyrus when comparing the PSEN1 group with controls. As mentioned earlier, 
EOAD and FAD are not equivalent but FAD does form part of a broader group of early 
onset disease. Previous contrasting descriptions of the cortical profiles of early and late 
onset disease (Frisoni et al 2007) help to further establish historical context for our 
results. In one study, patients were stratified by age of onset (before or after 65 years) 
rather than genetic status and were symptomatic at the time of analysis. None of the 
EOAD subjects had a history suggestive of autosomal dominant disease and groups were 
matched for clinical severity. Statistically significant grey matter loss was confined to the 
temporoparietal and retrosplenial cortices in LOAD, but was more widespread in 
EOAD. The cortical signature of symptomatic LOAD therefore has similarities with the 
pattern we have described in the presymptomatic FAD group. This may reflect more 
aggressive pathological change in the early-onset sporadic forms of the disease, greater 
functional cognitive reserve amongst EOAD subjects, or genuine differences in the onset 
of ‘biological’ (i.e. pathological) change.  
Cortical thinning in the frontal lobe, albeit in the dorsolateral rather than orbitofrontal 
cortex, has been noted previously in symptomatic AD  (Du et al 2007) though not, as we 
found, in pre-symptomatic individuals destined to develop clinical disease. Also, primate 
studies have previously confirmed close links between the hippocampal formation and 
the orbitofrontal cortex (Barbas and Blatt 1995). The distribution of cortical changes we 
have identified can be understood in terms of distributed but functionally connected 
cortical networks: a limbic/para-limbic network comprising the mesial temporal 
structures and their projections, and an overlapping but distinct posterior temporo-
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parietal-prefrontal network. While this study does not address the issue of phenotypic 
correlation, preferential involvement of these cortical networks might be predicted to 
give rise to altered emotional and attentional processing, respectively, as early features in 
FAD mutation carriers. Such functions are not well captured by conventional 
neuropsychometric techniques, but do suggest a direction for future work. 
 
In this study, cross-sectional differences in CTh between FAD and control groups were 
driven largely by the APP rather than the PSEN1 carriers, as far more extensive 
differences were noted in the former group. Furthermore, the APP group had more 
cortical thinning than the PSEN1 group and hippocampal volume measurements, which 
have previously been shown to separate presymptomatic FAD from controls (Ridha et al 
2006), were smaller in the APP than in the PSEN1 group. The largest absolute CTh 
differences were seen in the temporal lobes, although statistical significance at the 0.05 
level selected was not demonstrated, possibly due to insufficient power associated with 
small group sizes. These differences between the mutation subgroups were not 
attributable to any discrepancy of interval from scanning to symptom onset between the 
groups. In light of the substantially younger mean AAO of the PSEN1 compared with 
the APP cases, it is possible that APP mutations produce earlier pathological changes 
that subsequently progress more slowly, although larger groups would be required to 
confirm that the groups genuinely have different imaging profiles at equivalent stages. 
There are currently no data directly comparing the imaging characteristics of APP and 
PSEN1 carriers at equivalent biological disease stage.  
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Table 2:  Differences in Group CTh Means by Lobe (mm)  
                                           GROUPSCOMPARED                                        
LOBE 
(FAD) – (CONTROLS)       
(95% CI) 
(APP)  – (CONTROLS)  
(95% CI)  
(PSEN1)   – (CONTROLS)       
(95% CI)  
(APP)  – (PSEN1)                   
(95% CI) 
LEFT -0.02(-0.143, 0.11) p=0.8 -0.04(-0.23, 0.15) p=0.7 0.02(-0.13, 0.18)  p=0.8 -0.06(-0.28, 0.17) p=0.6 
FRONTAL  
RIGHT -0.04(-0.16, 0.08) p=0.5 -0.06(-0.25, 0.14) p=0.5 -0.01(-0.12, 0.10) p=0.8 -0.04(-0.26, 0.17) p=0.7 
LEFT -0.07(-0.19, 0.06) p=0.3 -0.13(-0.31, 0.05) p=0.1 0.02(-0.10, 0.14) p=0.7 -0.15(-0.36, 0.06) p=0.1 
TEMPORAL  
RIGHT -0.08(-0.22, 0.06) p=0.2 -0.13(-0.35, 0.08) p=0.2 -0.01(-0.11, 0.09) p=0.8 -0.12(-0.35, 0.11) p=0.3 
LEFT -0.08(-0.20, 0.04) p=0.2 -0.10(-0.28, 0.07) p=0.2 -0.05(-0.20, 0.11) p=0.5 -0.06(-0.28, 0.17) p=0.6 
PARIETAL  
RIGHT -0.07(-0.21, 0.07) p=0.3 -0.09(-0.29, 0.11) p=0.4 -0.05(-0.21, 0.12) p=0.6 -0.04(-0.30, 0.21) p=0.7 
LEFT -0.02(-0.14, 0.10) p=0.7 -0.11(-0.25, 0.03) p=0.1 0.10(-0.003, 0.21) p=0.06 -0.21(-0.37, -0.08) p=0.008 
CINGULATE  
RIGHT -0.03(-0.16, 0.09) p=0.6 -0.06(-0.75, 0.13) p=0.5 0.004(-0.14, 0.15) p=1.0 -0.07(-0.30, 0.17) p=0.6 
TOTAL HIPPOCAMPAL VOLUME (mm3) -609(-1125, -94) p=0.02 -709(-1386, -31) p=0.04 -478(-1291, 335) p=0.2 -231(-1281, 820) p=0.7 
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2. 3. Cortical thinning in FAD: a longitudinal study 
2. 3. 1. Methods 
This longitudinal study made use of all the scans in order to examine CTh changes over a 
period which included symptom onset. I identified four ROI in which there is existing 
evidence for early structural and/or functional cortical change (see Discussion): ERC, 
posterior cingulate, PHG and precuneus. I selected two control regions for their relative 
preservation in typical AD: pericalcarine and paracentral. 
 
For each region, a linear mixed model (developed with expert statistical support – see 
acknowledgements) was used to describe the association between CTh and age in the 
control group, adjusting for scanner. Denoting CTh and age (in years) at the jth scan for 
the ith patient by CThij and aij respectively and with sij taking the values 0 and 1 according 
to scanner:  
 
          
 (1) 
with  and independently . 
 
A similar model was used to describe the relationship between CTh and years since 
clinical diagnosis in the MC group. A fixed quadratic term describing acceleration in the 
rate of decline over time was added. Denoting years since clinical diagnosis at the jth scan 
for the ith patient by dij: 
 
     
   (2) 
with  and independently  
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For each region, a combined model for both MC and controls was fitted to describe the 
way in which MC deviated from normal ageing in controls. With dij taking the value zero 
in controls, and with gi taking the values 0 and 1 in controls and MC respectively:  
 
 
   (3) 
with and independently . 
 
The b2i and b3i random effects for age and years since clinical diagnosis respectively were 
only included in regions showing evidence of the need for such effects in the group-
specific analysis. If the covariance between b0i and b5i could not be estimated, then this 
was set to zero. For individuals d years after diagnosis, the estimated difference in mean 
CTh between MC and controls is given by . The statistical 
significance of a Wald test of this linear combination of parameter estimates was 
determined for a range of values of d. The value of d corresponding to a one-sided p-
value of 0.05 identified the earliest point at which there was a significant difference 
between cases and controls, allowing for normal ageing.  
 
2. 3. 2. Results 
The nature of the decline in CTh with age was characterized using a mixed model (1) in 
the control group. There was no evidence that the decline varied between individuals in 
any region and so the random effects (b2i) were omitted from the models. Table 3 shows 
the estimated age-related decline in CTh in controls. For example, in the posterior 
cingulate, the mean CTh for a 50-year old is 4.46-(0.014x(50-45)) = 4.39mm, where the 
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age-related decline is estimated to be 0.014mm/year. There was strong evidence for a 
decline in CTh with age in the posterior cingulate (change of -0.014mm/yr (95% CI -
0.023 to -0.004)), and borderline evidence for a decline in the precuneus (change of -
0.009mm/yr (95% CI -0.020 to 0.002)) and the paracentral region (change of -
0.011mm/yr (95% CI -0.024 to 0.001)). However, there was also borderline evidence of 
an increase in the CTh of the ERC (change of 0.017mm/yr (95% CI -0.003 to 0.038)). 
There was no evidence for a change in CTh in the PHG or pericalcarine regions with 
age.  
 
A similar analysis was carried out in the MC group to investigate changes in CTh with 
respect to time since clinical diagnosis of AD. There was no strong evidence that the rate 
of decline varied between individuals in any region and so the random effects (b3i) were 
omitted from the models. There was evidence of accelerated decline in all four regions of 
interest, but no evidence of acceleration in either of the control regions and so quadratic 
acceleration terms were retained in each model. The estimated mean CTh in each region 
according to years since diagnosis is displayed in Figure 8. Table 4 shows the estimated 
change in CTh in MC in relation to years since diagnosis. For example, in the precuneus, 
the estimated mean CTh at diagnosis is 3.11mm. The estimated reduction in mean CTh 
in the final year before diagnosis is 0.10 mm, whilst that in the first year after diagnosis is 
0.11mm, corresponding to acceleration in the rate of loss of 0.01mm/year2. From these 
values the rate of loss in the penultimate year prior to diagnosis can be inferred to be 
0.09mm/year and that in the second year post diagnosis to be 0.12mm/year etc. The 
mean levels of CTh at two years prior to diagnosis, one year prior to diagnosis, at 
diagnosis, one-year post-diagnosis and two years post-diagnosis are therefore 3.30mm, 
3.21mm, 3.11, 3.00 and 2.88mm respectively. 
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The final analysis combined data from both MC and controls in order to adjust the 
results in Table 4 for normal ageing. Table 5 shows departures from normal ageing 
according to years since diagnosis in MC and also gives estimates of the number of years 
before/after clinical diagnosis of AD at which MC had significantly different CTh than 
controls. Since there was no strong evidence in the control/MC-specific models for 
random effects with either age or years since clinical diagnosis, these terms were not 
included in the combined model. The table reports estimated changes in mean CTh in 
MC over and above those seen in controls of the same age according to the number of 
years from diagnosis in the MC. For example, in the precuneus, the mean CTh at 
diagnosis is 0.50mm below that of a control of the same age. The estimated reduction in 
mean CTh in the final year before diagnosis is 0.09 mm greater than that in a control of 
the same age, whilst that in the first year after diagnosis is 0.10mm greater, corresponding 
to an acceleration in the rate of loss (relative to that in controls) of 0.01mm/year2. From 
these values the rate of loss in the penultimate year prior to diagnosis can be inferred to 
be 0.08mm/year greater than that in a control of the same age and that in the second 
year post diagnosis to be 0.11mm/year greater etc. The mean levels of CTh at two years 
prior to diagnosis, one year prior to diagnosis, at diagnosis, one-year post-diagnosis and 
two years post-diagnosis are therefore respectively 0.33mm, 0.41mm, 0.50mm, 0.60mm 
and 0.71mm lower than that in a control of the same age. In both the ERC and PHG, 
the analysis suggested that CTh did not identify MC as significantly different from 
controls until after clinical diagnosis. However, in the posterior cingulate and precuneus, 
CTh measurements identified a significant difference between MC and controls 1.8 years 
and 4.1 years before clinical diagnosis respectively. Figure 8a illustrates the difference in 
mean CTh between cases and controls with respect to time since clinical diagnosis in the 
cases. The point at which the upper bound of the 90% CI indicates this difference is zero 
therefore corresponds to the years since diagnosis at which there is a significant 
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difference using a one-sided test. In contrast, in both the control regions, CTh did not 
differ significantly between the two groups at any point in the study period. Surface maps 
of regions differing early between MC and control groups are shown in Figure 9. 
 
Table 3: Mean regional CTh in controls according to age (adjusted for scanner) 
REGION Mean CTh at age 45 
(mm) (95% CI)$ 
Change in mean CTh per year of 
age (mm) (95% CI)* p-value 
ROI   
ERC** 5.82 (5.15, 6.50) 
 
 
0.017 (-0.003, 0.038), 
p=0.1 
 
PHG 5.32 (4.78, 5.87) 
 
 
-0.008 (-0.025, 0.009), 
p=0.4 
 
Posterior cingulate 4.46 (4.16, 4.75)  
 
-0.014 (-0.023, -0.004), 
p=0.005 
 
Precuneus 3.74 (3.40, 4.08) 
 
-0.009 (-0.020, 0.002), 
p=0.1 
 
CONTROL REGION   
Paracentral 3.49 (3.11, 3.87) 
 
-0.011 (-0.024, 0.001), 
p=0.08 
 
Pericalcarine 2.59 (2.38, 2.80) 
 
-0.003 (-0.010, 0.004), 
p=0.4 
 
$ For scanner 1 
* Positive values indicate gain with age 
** One individual was removed from the analysis due to probable Freesurfer error in 
calculating cortical thickness 
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Table 4: Mean regional CTh in mutation carriers according to time since clinical diagnosis of AD (adjusted for scanner) 
REGION Mean CTh at 
diagnosis$ (mm) 
(95% CI) 
Change in mean CTh in 1st 
year pre-diagnosis (mm) 
(95% CI), p-value* 
Change in mean CTh in 1st 
year post-diagnosis (mm)  
(95% CI), p-value* 
Acceleration in change in 
mean CTh (mm/ year2)  
(95% CI), p-value* 
ROI     
ERC** 5.93 (5.08, 6.79) 
 
-0.11 (-0.16, -0.07) 
p<0.0005 
-0.15 (-0.21, -0.09) 
p<0.0005 
 
-0.04 (-0.06, -0.01) 
p=0.001 
PHG 5.28 (4.71, 5.84) 
 
-0.11 (-0.14, -0.08) 
p<0.0005 
-0.14 (-0.19, -0.10) 
p<0.0005 
 
-0.03 (-0.05, -0.02) 
p<0.0005 
Posterior cingulate 4.05 (3.73, 4.38) 
 
-0.08 (-0.11, -0.06) 
p<0.0005 
-0.10 (-0.13, -0.07) 
p<0.0005 
 
-0.01 (-0.02, -0.005) 
p=0.004 
Precuneus 3.11 (2.72, 3.50) 
 
-0.10 (-0.13, -0.07) 
p<0.0005 
-0.11 (-0.15, -0.08) 
p<0.0005 
 
-0.01 (-0.02, 0.001) 
p=0.07 
CONTROL REGION     
Paracentral 3.20 (2.65, 3.75) 
 
-0.05 (-0.12, 0.008) 
p=0.09 
-0.08 (-0.16, 0.01) 
p=0.08 
 
-0.02 (-0.05, 0.009) 
p=0.2 
Pericalcarine 2.99 (2.65, 3.33) 
 
0.02 (-0.002, 0.05) 
p=0.07 
0.02 (-0.01, 0.05) 
p=0.3 
 
-0.004 (-0.02, 0.008) 
p=0.5 
$ For scanner 1 
* Change in each additional year post-diagnosis = change in 1st year post-diagnosis + [acceleration x (number of years post-diagnosis – 1)]. Similarly, change in each 
additional year pre-diagnosis = change in 1st year pre-diagnosis - [acceleration x (number of years pre-diagnosis – 1)] ** One individual was removed from analysis 
due to probable Freesurfer error in calculating cortical thickness 
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Table 5: Mean levels of and changes in regional CTh in mutation carriers relative to those in controls of the same age, according to time 
     since clinical diagnosis of AD (adjusted for scanner) 
 Mean change in CTh (mm) in MC relative to that  
in controls of the same age(95% CI), p-value 
 
 
Mean CTh in MC 
at diagnosis (mm) 
relative to controls 
of the same age 
(95% CI), p-value 
In 1st year pre-   
diagnosis (A) 
In 1st year post-
diagnosis (B) 
Acceleration (mm/year2) 
(B-A) 
ROI     
Earliest time relative to 
clinical diagnosis where 
the difference between 
MC and controls is 
statistically significant** 
ERC* 
 
-0.46 (-1.05, 0.12) 
p=0.1 
 
-0.14 (-0.22, -0.07) 
p<0.0005 
-0.17 (-0.27, -0.07) 
p=0.001 
-0.03 (-0.06, 0.004) 
p=0.09 
0.1 
PHG 
 
-0.17 (-0.57, 0.24) 
p=0.4 
-0.10 (-0.14, -0.06) 
p<0.0005 
-0.13 (-0.18, -0.08) 
p<0.0005 
 
-0.03 (-0.05, -0.02) 
p<0.0005 
1.3 
Posterior cingulate 
 
-0.28 (-0.47, -0.08) 
p=0.006 
-0.07 (-0.10, -0.04) 
p<0.0005 
-0.09 (-0.12, -0.05) 
p<0.0005 
 
-0.01 (-0.03, -0.002) 
p=0.02 
-1.8 
Precuneus 
 
-0.50 (-0.73, -0.27) 
p<0.0005 
 
-0.09 (-0.13, -0.06) 
p<0.0005 
-0.10 (-0.15, -0.06) 
p<0.0005 
 
-0.01 (-0.03, 0.003) 
p=0.1 
-4.1 
Control regions      
Paracentral 
 
-0.07 (-0.30, 0.17) 
p=0.6 
-0.04 (-0.10, 0.02) 
p=0.2 
-0.06 (-0.15, 0.03) 
p=0.2 
 
-0.02 (-0.05, 0.007) 
p=0.1 
N/A*** 
Pericalcarine 
 
-0.02 (-0.15, 0.12) 
p=0.8 
0.01 (-0.02, 0.05) 
p=0.5 
0.02 (-0.03, 0.06) 
p=0.5  
 
0.003 (-0.01, 0.02) 
p=0.7 
N/A*** 
One individual was removed from the analysis due to probable Freesurfer error in calculating cortical thickness. ** Negative values indicate that the earliest point at 
which differences are statistically significant (5%, 1-sided test) is prior to clinical diagnosis. *** MC do not significantly differ from controls at any point up to 30 
years post-diagnosis 
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Figure 8: Estimated mean CTh in MC, by years since clinical diagnosis 
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Figure 8a: Difference in mean cortical thickness between cases and controls, by years since clinical diagnosis (with 90% CI) 
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Figure 9: Earliest Time (yrs), relative to clinical diagnosis, at which regional differences emerge between MC and controls. 
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2. 3. 3. Discussion    
Using a fully automated method, we have measured CTh in the brains of FAD mutation 
carriers and age/sex-matched controls. CTh change was investigated via longitudinal 
analysis of six regions in relation to age and time of clinical diagnosis of AD. ROI were 
selected on the basis of existing evidence that they are significant in early AD and may 
provide an early signal of disease. Histopathological and structural imaging studies 
indicate that limbic and heteromodal association areas fall into this group, including the 
MTL (particularly the PHG) and precuneus  (Juottonen et al 1999; Xu et al 2000; Lerch et 
al 2005; Dickerson et al 2009). Functional imaging modalities have also demonstrated 
early change in the retrosplenial and posterior cingulate cortices  (Minoshima et al 1997; 
Mosconi et al 2006), which have a role in episodic memory function and some 
visuospatial processing  (Maguire 2001; Burgess et al. 2001). CTh measurement of sub-
regions of the hippocampal formation has been previously performed  (Burggren et al. 
2008) although assessing CTh in this region is less well-established than other regions 
and is technically highly demanding due to the elaborate invagination of the cortex. This, 
the presence of other candidate MTL regions, and our desire to avoid duplication 
(previous hippocampal volumetric data in the same group has been reported  (Ridha et al 
2006)) led us not to select this as an ROI. Motor, sensory and primary visual cortices are 
relatively spared in the early stages of AD  (Braak and Braak 1996b; Rizzo et al. 2000; 
Prvulovic et al. 2002) and were therefore selected as control regions. 
 
Age-related grey matter loss has been well documented in all major lobes of the brain  
(Allen et al. 1991; Van Petten et al. 2004; Salat et al. 2004). There is an historically 
prominent view that such decline occurs with an anterior-posterior gradient although this 
is not universally accepted and, frequently, widespread patchy thinning implicating both 
primary and association cortices is found to accompany ageing  (Raz and Rodrigue 2006). 
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In our healthy control group we demonstrated a very small degree of age-related CTh 
decline across all regions except the ERC, the wide distribution of which was 
commensurate with previously observed changes in normal ageing  (Salat et al 2004). In 
particular, the relative sparing of the PHG was familiar, although the prominence of 
change in the posterior cingulate was unexpected. An implausible increase in ERC 
thickness was also unforeseen, although this should be interpreted with caution in view 
of well documented difficulties with surface reconstruction of this region using 
Freesurfer (Han et al. 2006). The magnitude of this increase and of the age-related decline 
in other regions in healthy controls was, in biological terms, exceptionally small. 
However, it was fully consistent with previous high-resolution MRI studies, which have 
demonstrated rates of global atrophy in healthy people of 0.2% per year at age 30-50 and 
0.3-0.5% per year at age 70-80 (Fox and Schott Lancet 2004). 
 
Analysis of the MC group provided insight into CTh change with respect to time since 
clinical diagnosis of AD. It showed strong evidence of non-linear CTh decline in all four 
ROI with acceleration over time. MTL structures showed the highest rates of thinning 
and there was no evidence for thinning or acceleration in the control regions. These 
findings support our initial hypothesis and choice of ROIs. They also echo previous 
findings of prominent early cortical thinning in the MTL and precuneus in amnestic mild 
cognitive impairment (aMCI) patients destined to progress to AD  (Bakkour A et al 
2008). Despite broad acceptance of an early role for the precuneus in particular, and 
previous observations that it may be more affected in early onset forms of AD  (Karas et 
al. 2007), not all studies support a special role for the region relative to other areas of the 
neocortex  (Nelson et al. 2009). The limitations of the measurement technique again 
demand the cautious interpretation of the effect shown in the ERC. Rates of whole brain 
atrophy in aMCI patients have been shown to be non-linear, accelerating as individuals 
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progress to typical, late-onset AD  (Jack et al 2008), while other studies of rates of 
atrophy in AD also seem suggest acceleration  (Chan et al. 2003). Our observation that 
CTh in FAD similarly accelerates beyond diagnosis supports the notion that FAD is a 
credible paradigm for sporadic, late-onset AD and that automated measurement of 
cortical change can reproduce the patterns described where more established 
neuroimaging techniques are deployed.  
 
A combined analysis provided some evidence that CTh in the posterior cingulate and 
precuneus differed between the MC and control groups prior to clinical diagnosis. In the 
precuneus, a significant difference was apparent more than four years before diagnosis, a 
comparable duration to that found in a previous volumetric study of the whole brain and 
hippocampi in the same group  (Ridha et al 2006). It was interesting that the PHG should 
not be useful in this regard in view of previous observations about its significance  
(Juottonen et al 1999; Xu et al 2000; Lerch et al 2005). Although the rate and acceleration 
of loss in this region were similar to those observed in the posterior cingulate and 
precuneus regions, the difference between the controls and cases at diagnosis was 
smaller. As members of the MC cohort develop established AD, any variability in the rate 
and acceleration of thinning between regions will lead to a change in the regions which 
best distinguish them from controls. Further, it is important to emphasise that failure to 
detect significant effects in certain regions does not necessarily imply the genuine 
absence of an effect in those regions. MRI-derived measurements have limitations 
inherent in their acquisition, and may have a lower sensitivity to detect change in certain 
regions because different brain structures are variably affected by artefacts such as 
susceptibility or inhomogeneity. The key advantage of CTh measurement over 
volumetric studies is that it is automated, and hence more rapid and less operator-
dependent. However, as discussed above, there are important caveats to consider when 
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interpreting our findings, which relate to limitations of the technique and of the analysis. 
These include the cross-scanner analysis, which relates to the extended nature of the 
study. This does present a continuity problem, which we have attempted to mitigate 
statistically.  Further, the statistical analysis of our measurements was designed to answer 
questions, which we felt the data were equipped to address. We cannot, for example, 
conclude that CTh decline in the posterior cingulate and precuneus precedes such 
changes in the ERC and PHG as this was not the hypothesis, and the analyses performed 
were not designed to establish this relationship. Caveats surrounding the differential 
sensitivity of MRI depending upon the size and location of brain region concerned are 
again relevant, as this may have obscured an effect in one or more of the ROI. The use 
of larger groups would certainly be helpful in further defining the utility of CTh analyses 
although, in this study, the small groups reflect the rarity of this form of the illness and 
the still greater rarity of cases whose genetic status has been established. The use of 
subjects at risk for autosomal dominant AD here was advantageous in at least one 
important sense: that we could study subjects who were certain to develop clinical AD 
while they were still asymptomatic. Despite the many similarities between FAD and 
SAD, the extent to which our findings are generalizable to the more common sporadic 
disease remains unknown. However, our data do contribute to a growing body of 
evidence that imaging biomarkers may be highly sensitive for detecting presymptomatic 
AD  (Dickerson et al 2009), perhaps years before the illness declares itself clinically. While 
functional and structural neuroimaging techniques may be sensitive to change in different 
brain regions, CTh analysis in AD would appear to implicate regions previously 
highlighted by both. Perhaps CTh has the potential to reveal something interesting about 
the functionally related network of MTL and retrosplenial structures, which is so crucial 
in AD pathology. It certainly continues to show promise as a relatively practical, rapid 
and sensitive technique, although further work is needed to evaluate its role in stratifying 
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different molecular pathologies, and to define the phenotypic correlates of the cortical 
changes identified. 
 
3. 
THE FAD PARADIGM  
II: Molecular neuroimaging 
 
3. 1. A longitudinal 11C-PiB PET study in FAD and SAD 
Previous studies have suggested prominent, early striatal 11C-PiB retention in FAD 
(Klunk et al. 2007; Remes et al. 2008), a pattern not yet observed in SAD. In this study, 
the aim was to further characterize the 11C-PiB PET profiles of PSEN1 mutation carriers 
in the preclinical and early stages of their illness, and to compare these with profiles of 
healthy controls and individuals with SAD. To achieve this early cross-sectional data 
from a larger prospective, longitudinal 11C-PiB PET cohort study were used. 
 
3. 1. 1. Methods 
Table 6 details subject demographics. Seven presymptomatic and mildly affected 
(MMSE!20) PSEN1 mutation carriers, 10 patients with SAD and 10 healthy controls 
(including four members of autosomal dominant FAD families with negative predictive 
tests for the causative mutation) had PET. PSEN1 mutations studied were Y115C (Cruts 
et al. 1998), M139V (Clark et al. 1995), M146I (Jorgensen et al. 1996), L171P (Ramirez-
Duenas et al. 1998), E184D (Yasuda et al. 1997), R278I (Godbolt et al. 2004) and intron 4 
(Tysoe et al. 1998; Janssen et al. 2003). Exclusion criteria comprised a current or recent 
history of drug or alcohol abuse/dependence, pregnancy, inability to undergo PET 
scanning (the most common reason envisaged was an inability to tolerate the process of 
   
 110 
reclining supine for 90 minutes) and a history of cancer within the last 5 years (except 
non-melanoma skin and prostate cancer).  
 
Presymptomatic mutation carriers (PMC) were, on average, 7.2 years younger than the 
documented mean AAO for their family. Mean MMSE (Folstein et al 1975) score for the 
mutation carrier group was 27.2 (range 21-30). Whole brain and regional uptake from a 
single, baseline 11C-PiB PET scan were examined. The study received approval from the 
ethics committee of the National Hospital for Neurology and Neurosurgery and Institute 
of Neurology and the Hammersmith Hospitals Trust.  Permission to administer radiation 
was granted by the Administration of Radioactive Substances advisory Committee 
(ARSAC) UK. 
 
Patients were approached by the investigators and oral and written information provided 
prior to consent. All subjects and controls underwent 11C-PiB PET imaging at the 
Hammersmith Hospital. PET scanning was performed using a Siemens ECAT EXACT 
HR+ scanner in 3 dimensional mode as described previously (Edison et al 2007). Each 
scan participant received a bolus administration of up to 370 MBq 11C-PiB intravenously 
followed by a 90-minute dynamic PET scan.11C-PiB was manufactured by Hammersmith 
Imanet, GE Healthcare and a 10-minute transmission scan was performed prior to the 
injection of 11C-PiB.  
 
All mutation carriers and controls had anatomical T1-weighted, volumetric MRI to allow 
co-alignment of parametric PET images of 11C-PiB binding, permitting anatomical 
localization of regions-of-interest (ROI). Where possible, MRI was performed on the 
same day as the PET scanning, although an interval between the two scans of up to three 
months was deemed acceptable. 
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3. 1. 1. 1. Image analysis 
Amyloid plaques have been reported to be present in the cerebellar cortex in FAD cases 
(Verkkoniemi et al 2001). Parametric ratio images of 11C-PiB retention were therefore 
created using the pons as a reference region. The late (60 to 90-minute) summation 
images of tracer uptake were co-registered to each subject’s MRI using SPM2 (Statistical 
Parametric Mapping; Wellcome department of Imaging Neuroscience, University College 
London, UK) software. Each late summation image was then normalized into Montreal 
Neurological Institute (MNI) space using individual MRIs as a template. Activity in the 
pons was sampled using an ROI placed manually on the corresponding normalized MRI 
image, allowing the calculation of a pontine uptake value and subsequent creation of the 
target region: pons ratio image. Using an individualized anatomical atlas, created using 
analyze software and an in-house probabilistic brain atlas (Hammers et al. 2003), we 
sampled 11C-PiB uptake for each subject in the anterior and posterior cingulate, the 
thalamus, striatum and the frontal, temporal, parietal, occipital and cerebellar cortices. In 
order to allow comparison with studies that have used the cerebellum as a reference 
region we also calculated regional ratios relative to the cerebellum – these are given in 
Table 8. 
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Table 6: Subject Demographics 
 
SEX 
 
 
 
GROUP 
 
 F M 
MEAN AGE (RANGE) 
MEAN 
MMSE 
(RANGE) 
CONTROLS 
 
7 3 47.7 (25-66) n/a 
SAD 
 
4 6 61.9 (51-69) 21.7(12-26) 
PSEN1 
- AFFECTED 
2 0 51.5 (40-63) 22(21-23) 
PSEN1 
- PMC 
4 1 34.6 (31-40) 28.7(27-30) 
PSEN1 
- TOTAL 
6 1 38.8 (31-63) 27.2(21-30) 
 
3. 1. 1. 2. Statistical analyses 
Statistical interrogation was performed using SPSS (release 17.0, SPSS Inc.). Mean 
regional 11C-PiB region: pons ratios were analysed to detect significant differences. 
Groups were compared using the Mann-Whitney test. P values were corrected for the 
total number of comparisons using the Hochberg Correction combined with the p-plot 
estimation of the number of Null-Hypotheses in the set (Turkheimer et al. 2001).  
 
 
3. 1. 2. Results 
Across all regions sampled, mean region: pons ratios demonstrated statistically significant 
differences when the SAD group was compared with controls with the exception of 
cerebellum. When PSEN1 and control groups were compared, all regions except the 
cerebellum (p=0.133) showed significant differences that survived correction for multiple 
comparisons. When the same comparison was made using the cerebellum as the 
reference region, the temporal region was no longer significant, after correction for 
multiple comparisons, but all other regions remained significantly different to controls.  
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When PSEN1 and SAD groups were compared, thalamus (PSEN1>SAD), frontal and 
temporal regions (SAD>PSEN1) demonstrated significant differences that survived 
multiple comparison corrections. When the same comparison was made using the 
cerebellum as the reference region (Table 8) the sporadic group had significantly greater 
PiB retention ratios in parietal and occipital as well as frontal and temporal regions.   
 
Two mutation carriers (E184D and intron 4 mutations) had higher striatal 11C-PiB 
retention ratios than the mean for the SAD group (1.71 and 1.54 respectively). Figures 10 
and 11 demonstrate regional variation in11C-PiB retention for PSEN1 and SAD groups 
when compared with controls. Figure 12 shows 3 transaxial 11C-PiB scans with different 
binding patterns in three separate PSEN1 mutation carriers. 
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Figure 10: Univariate scatter plot showing region: pontine 11C-PiB retention ratios 
for PSEN1  subjects (f1-f7) vs. Controls  
 
 
 
f2 and f4 = affected/symptomatic PSEN1 mutations carriers 
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Figure 11: Univariate scatter plot showing pontine 11C-PiB retention ratios for SAD 
subjects (s1-s10) vs. Controls 
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Table 7: Mean regional 11C-PiB uptake by group (Pontine reference region) 
 
 
11C-PiB UPTAKE RATIO, ROI: PONS (SD) 
 
 
ROI 
PSEN1 SAD 
 
CONTROLS 
 
ANTERIOR CINGULATE 1.24 (0.22)
†
 1.44 (0.18)
†
 
 
0.69 (0.08) 
 
POSTERIOR CINGULATE 1.24 (0.24)
†
 1.42 (0.18)
†
 
 
0.72 (0.05) 
 
THALAMUS 1.09 (0.14)
†
* 0.88 (0.11)
†
 
 
0.68 (0.07) 
 
STRIATUM 1.20 (0.35)
†
 1.25 (0.11)
†
 
 
0.71 (0.06) 
 
FRONTAL 1.08 (0.17)
†
* 1.30 (0.13)
†
 
 
0.67 (0.08) 
 
TEMPORAL 0.99 (0.14)
†
* 1.18 (0.14)
†
 
 
0.68 (0.07) 
 
PARIETAL 1.09 (0.17)
†
 1.27 (0.15)
†
 
 
0.67 (0.07) 
 
OCCIPITAL 1.04 (0.14)
†
 1.12 (0.18)
†
 
 
0.70 (0.08) 
 
CEREBELLUM 0.75 (0.17) 0.63 (0.07) 
 
0.62 (0.07) 
 
 † p<0.05 vs. controls * p<0.05 vs. SAD 
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Table 8: Mean regional 11C-PiB uptake by group (Cerebellar reference region) 
 
 
 
11C-PiB UPTAKE RATIO, ROI: CEREB (SD) 
 
 
ROI 
PSEN1 SAD 
 
CONTROLS 
 
ANTERIOR CINGULATE 
 
1.78 (0.56)
†
 2.29(0.32)
†
 
1.09(0.07) 
 
POSTERIOR CINGULATE 
 
1.76 (0.50)
†
 2.25(0.29)
†
 
1.17(0.08) 
 
THALAMUS 
 
1.55 (0.40)
†
 1.41(0.25)
†
 
1.09(0.11) 
 
STRIATUM 
 
1.74 (0.73)
†
 1.98(0.26)
†
 
1.15(0.07) 
 
FRONTAL 
 
1.53 (0.37)
†
* 2.07(0.26)
†
 
1.07(0.05) 
 
TEMPORAL 
 
1.39 (0.30)* 1.87(0.28)
†
 
1.10(0.03) 
 
PARIETAL 
 
1.53 (0.35)
†
* 2.02(0.28)
†
 
1.08(0.05) 
 
OCCIPITAL 
 
1.46 (0.27)
†
* 1.78(0.27)
†
 
1.13(0.05) 
 
† p<0.05 vs. controls * p<0.05 vs. SAD 
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Figure 12: Transaxial 11C-PiB images (pontine reference region) in PSEN1 mutation carriers showing heterogeneity of 11C-PiB binding 
pattern. 
(a) Increased cerebellar binding in PSEN1 M146I PMC.  
(b) Increased striatal binding in an affected PSEN1 E184D mutation carrier (f2 in figure 10).  
(c) Typical AD-like pattern in an affected PSEN1 R278I mutation carrier (f4 in figure 10).
3. 1. 3. Discussion 
At a group level, we observed significantly higher global 11C-PiB uptake in established 
SAD cases compared with the PSEN1 group, in which the majority were 
presymptomatic and around seven years before the anticipated onset of symptoms. 
However, we have confirmed previous findings (Klunk et al. 2007; Remes et al. 2008) that 
it is possible to detect significantly elevated 11C-PiB retention in the brains of individuals 
destined to develop clinical AD before symptoms arise. Structural and metabolic changes 
are already known to occur early in FAD patients (Matsushita et al. 2002; Ridha et al. 
2006) as they are in SAD (Minoshima et al. 1997; Desikan et al. 2008) and MCI 
(Kemppainen et al. 2007).  In SAD, the earliest 11C-PiB retention may occur in the 
retrosplenial cortices, particularly the precuneus (Mintun et al. 2006) although early 
retention has been noted in the striatum as well as the frontal, parietal, temporal, and 
occipital cortices (Klunk et al. 2004).  
 
The rarity of FAD mutations means that rather less is known about their associated 11C-
PiB PET profiles. One study of the PSEN1 C410Y and PSEN1 A426P mutations 
showed elevated 11C-PiB retention beginning in the striatum of presymptomatic and 
affected mutation carriers, with neocortical areas involved later (Klunk et al. 2007). A 
similar pattern has been observed in those with early-onset disease associated with 
atypical clinical (spastic paraparesis) and neuropathological (cotton wool plaques) features 
(Koivunen et al. 2008) and in amyloid precursor protein (APP) gene duplication cases 
(Remes et al. 2008). Such studies raise important issues about the neuropathological 
profile of early-onset forms of AD, although the extent to which they are representative 
remains unknown, particularly as other investigators have found a more typical, SAD-like 
11C-PiB profile in symptomatic APP mutation-carriers (Theuns et al. 2006). Our study 
included two individuals (E184D and intron 4 mutations) with higher striatal 11C-PiB 
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retention ratios than the mean for the SAD group (1.71 and 1.54 respectively) although, 
at a group level, the clear striatal prominence seen in previous reports was not evident. 
This finding serves to underline the value of studying a number of different mutations: it 
permits the observations that striatal prominence is not universal and that amyloid 
imaging profiles, even amongst the mutations of a single gene, may be varied. The two 
PSEN1 mutations studied by Klunk and colleagues in 2007 were in exons 11 and 12, 
unlike our mutations, none of which was situated beyond exon 8. This may have 
contributed to the different profiles observed, just as clinical phenotypic heterogeneity is 
known to be associated with varied mutation position (Larner and Doran 2006).  
 
In APP duplication cases, abundant intravascular amyloid, particularly in the 
leptomeningeal vessels, may contribute to increased 11C-PiB signal (Remes et al. 2008) 
and it is possible that retention in our subjects was similarly influenced. Without 
neuropathological examination, the amount of cerebrovascular amyloid in our subjects, 
along with any possible influence on 11C-PiB signal, cannot be precisely known. 
However, we can say that our study did not include any APP duplications and that, for 
PSEN1 mutations, significant cerebral amyloid angiopathy (CAA) is more frequently 
associated with those beyond codon 200 (Mann et al. 2001), for example L282V 
(Dermaut et al. 2001), E280G (O'Riordan et al. 2002) and G217D (Takao et al. 2002). As 
5 out of 6 coding region mutations in our study affected regions between codons 100 
and 200, we suggest that cerebrovascular amyloid alone is unlikely to account for our 
findings. 
 
We observed marked 11C-PiB retention in the thalamus, a pattern peculiar to the PSEN1 
group.  The thalamus is not a structure traditionally associated with a heavy amyloid 
burden, although thalamic Aß deposition has previously been described in a post-
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mortem study of PSEN1 mutation carriers (Lippa et al. 1996). Specific mutations, such as 
M146I, have since been associated with unusually high levels of Aß pathology in the 
thalamus and mesencephalon (Gustafson et al. 1998) raising the possibility that such a 
pattern is codon- or mutation-specific. Post-mortem histopathological analyses have 
previously demonstrated immunopositive, diffuse Aß plaques in the thalamus of a 
PSEN1 M139V carrier (Larner and du Plessis 2003) and small increases in thalamic 11C-
PiB have been noted  (Kemppainen et al. 2006).  
 
The cerebellum has long been used as a reference region for non-specific tracer binding 
in 11C-PiB PET imaging as, in the SAD brain, it does not classically accumulate amyloid 
or retain 11C-PiB (Svedberg et al. 2009). In accord with this we found that the sporadic 
AD subjects did not have raised PiB retention – with almost identical cerebellum/pons 
ratios when compared with the controls. However 11C –PiB retention does occur in the 
cerebellum in FAD although there is considerable variability between subjects; this 
suggests, in line with previous studies (Klunk et al. 2007), that the cerebellum may not be 
an appropriate reference region in FAD and that the pons (as used here) is a suitable 
alternative. In order to allow comparison with other studies in AD we subsequently also 
calculated ratios with the cerebellum as the reference region. The respective pontine and 
cerebellar ratios highlight slightly different regions, though with considerable overlap. 
Full interpretation of these differences would require pathological correlation beyond the 
current scope of this study. Our results also suggest that the distribution of tissue 
pathology (at least in terms of plaque amyloid) associated with PSEN1 mutations may be 
more varied than previously thought. This may have implications for the usefulness of 
PiB imaging in evaluating new therapies (see 1. 8. 2.). Finally these findings raise 
intriguing questions about why these different patterns of amyloid binding occur and 
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what their clinical and pathological implications may be – directions perhaps for future 
research. 
 
4. 
CHARACTERIZING FAD 
I: Epistasis & single case studies  
    
 
Know your enemy…and you will not 
be imperilled in a hundred battles. 
 
- Sun Tzu, The Art of War. 
 
Contemporary treatment strategies are increasingly reliant upon genetic models and 
robust biomarkers for their development. Studies using transgenic mouse models and 
human FAD pedigrees continue to inform our approach to AD although, for the FAD 
paradigm to remain credible, clarification of the FAD/SAD relationship through an 
understanding of FAD’s phenotypic spectrum is vital. Much progress has already been 
made in this regard (see 1. 4.), helping to highlight both the promise and limitations of 
this approach. Chapters 2 and 3, address this issue, examining the phenotypes associated 
with several genetic defects as well as a potential epistatic influence on the clinical 
phenotypes of known APP and PSEN mutations. 
 
4. 1. Methods 
An ongoing, longitudinal FAD cohort study of more than 20 years duration, has been 
subject to various amendments, existing in its current form since 2002. Clinical, 
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neuroimaging and neuropsychology data from this ongoing study have been a vital 
resource for a number of other studies, including those in this thesis.  
 
This study currently involves 4 key cohorts, recruited primarily from a 
tertiary/quarternary dementia service and stratified according to clinical/genetic status:  
 
• Individuals at risk of AD by virtue of an autosomal dominant family history.  
• Presymptomatic, FAD mutation carriers (PMC) in whom predictive genetic 
testing has demonstrated a mutation (or duplication) in APP, PSEN1 or PSEN2.  
• Symptomatic, confirmed FAD mutation carriers.  
• Controls (spouses or siblings of individuals from all groups in whom predictive 
genetic testing has shown no mutation). 
 
Each participant is assessed annually. Subjects in the ‘at risk’ category were recruited 
when they were 5 years below the 95% confidence interval for mean AAO in their 
family. AAO was established through clinical assessment i.e. it corresponds to reported 
age at onset of symptoms as recorded on Dementia Research Centre database. With 
predictive genetic testing more widely available, and a greater number of pathogenic 
mutations discovered, an amendment was made to the study in 2002 such that it was 
possible to recruit presymptomatic individuals who had positive genetic tests from the 
time of referral (by which time they had already have received their positive test result 
from a geneticist). This was often at a much younger age than that stated in the original 
study protocol and, where they remained unaffected, they participate until they are five 
years older than the oldest known AAO in their family. Affected individuals participate 
until it is no longer possible for them to tolerate the assessments, usually by virtue of the 
severity of their illness. Each participant is given an information sheet and adequate time 
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to read and discuss it before signing a consent form. Both documents have been 
approved by the National Hospital for Neurology and Neurosurgery and UCL Institute 
of Neurology Joint Ethics Committee. Annual assessments comprise: 
• Volumetric brain MRI: Imaging between 1991 and 1998 was performed on a 
1.5T GE Signa scanner (General Electric Medical Systems, Waukesha, WI, USA). 
Volumetric T1-weighted coronal MRI scans were obtained with a spoiled 
gradient echo technique (256!128 matrix, field of view 24!24 cm, 
TR/TE/NEX/FA=35 ms/5 ms/1/35°) yielding 124 contiguous 1"5 mm thick 
slices. Between 2000 and 2006 imaging was undertaken on a different 1.5T GE 
Signa scanner running software version 5.8 (General Electric Medical Systems, 
Waukesha, WI, USA). Volumetric T1-weighted coronal MRI scans were obtained 
using an inversion recovery prepared fast spoiled gradient-echo technique 
(256!256 matrix, field of view 24!18 cm, TR/TE/TI/NEX/FA=14 ms/5"4 
ms/650 ms/1/15°) yielding 124 contiguous 1"5 mm thick slices. An MRI Safety 
questionnaire was completed prior to each scan.  
• Magnetic resonance spectroscopy (PMCs and controls only). 1.5 T Signa 5X 
system PROBE/SV, PRESS (TR=2000 msec, TE=30 msec, 192 avg).  
• A T1-weighted spin echo sagittal scout is followed by six 5mm fast IR images 
obtained in the axial plane. A 15mm thick VOI is placed within 3 adjacent slices 
maximizing grey matter cingulate content, and minimizing partial volume effects 
• Neuropsychological assessment.  
• Clinical assessment (history, examination, MMSE). 
 
4. 2. FAD and the ApoE4 polymorphism  
Previous studies have demonstrated a modifying effect of the ApoE4 polymorphism on 
age at symptom onset in APP-associated FAD (Hardy et al 1993; Sorbi et al 1995), though 
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not PSEN1-associated FAD (Van Broeckhoven et al 1994). The collation of data for our 
FAD cohort allowed analysis of AAO, where known, in relation to ApoE genotype. The 
aim was to establish whether these data supported existing evidence of the effect of 
ApoE on AAO. Table 9 characterises available data on individuals with a known FAD 
mutation and ApoE genotype.  Table 10 shows ApoE genotype and allele frequencies for 
these subjects and the corresponding data when an additional 64 subjects, in whom FAD 
is clinically suspected but no mutation has been demonstrated, are added. Population 
data from the literature are presented for comparison.  
 
4. 2. 1. Methods 
Subjects for this analysis (n=60) were selected purely on the basis that their ApoE 
genotype, AAO and mean family AAO (AAOf) were known. f-tests were applied and 
variance in the datasets found to be unequal throughout. Subsequent two-tailed, unpaired 
heteroscedastic t-tests were used to test two hypotheses: That ApoE4 positive FAD 
mutation carriers (5 APP, 17 PSEN1) had a different mean AAO to ApoE4 negative 
FAD mutation carriers (11 APP, 27 PSEN1), and that the differences between mean 
AAO and mean family AAO were greater in the ApoE4 positive group i.e. that ApoE4 
carrier status modified AAO, hastening symptom onset. 
Table 9: Autosomal dominant AD cases, mutation known (n=73) 
Family No Gene Mutation AAO AAOf ApoE Genotype Pathology (where available) 
 
19 
 
APP 
 
V717G 
 
46 
 
51.5 
 
33 
 
19 APP V717G 48 51.5 33 AD with CAA 
19 APP V717G 47 51.5 33  
19 APP V717G 50 51.5 33  
19 APP V717G 47 51.5 34  
19 APP V717G 45 51.5 34  
23 APP V717I  53.7 33  
23 APP V717I 51 53.7 33 AD with diffuse Lewy body disease 
23 APP V717I 52 53.7 33  
23 APP V717I 58 53.7 33 Diffuse Lewy body disease, AD, CAA 
171 APP V717L 51 45.8 33 AD 
171 APP V717L 48 45.8 33  
172 APP V717I 56 52.5 33  
172 APP V717I 47 52.5 33 AD with CAA 
172 APP V717I 50 52.5 34  
172 APP V717I 56 52.5 34  
172 APP V717I 49 52.5 34 AD with vascular malformation of the thalamus 
408 APP A692G   33  
175 PSEN1 delta4 35 37.7 33 AD 
175 PSEN1 delta4  37.7 33  
177* PSEN1 L153V 36 35 34 AD 
183 PSEN1 E280G 42 43.5 33  
184 PSEN1 L250S 56 53.3 34  
184 PSEN1 L250S 47 53.25 34  
196 PSEN1 P267S 37 35.75 34  
196 PSEN1 P267S 38 35.75 34  
206‡ PSEN1 M139V 35 39 33  
  127 
206‡ PSEN1 M139V 39 39 33  
206‡ PSEN1 M139V 38 39 33  
206‡ PSEN1 M139V 37 39 34  
226* PSEN1 R269H 51 52.3 44 AD 
267* PSEN1 L235V 44  33 AD 
278 PSEN1 F283L 47 48 33  
278 PSEN1 F283L 46 48 33  
278 PSEN1 F283L 48 48 34  
283* PSEN1 R377M 38 38 33 AD and cerebrovascular disease 
342* PSEN1 delta4   33  
346 PSEN1 R278I   23  
353 PSEN1 A260V   33  
364 PSEN1 E184D 41 40.5 33  
364 PSEN1 E184D 40 40.5 33  
37* PSEN1 F237L 47  34  
53* PSEN1 delta167 43 52 44 AD 
74 PSEN1 S290Cd9 39 42.8 23 AD and CAA 
74 PSEN1 S290Cd9 44 42.8 33 AD and CAA 
74 PSEN1 S290Cd9 42 42.8 33  
102 PSEN1 E280G 40 41.8 33  
102 PSEN1 E280G 40 41.8 33  
102 PSEN1 E280G 41 41.8 34  
102 PSEN1 E280G 41 41.8 34  
105 PSEN1 delta4 36 37.4 33 AD 
105 PSEN1 delta4 39 37.4 33 AD and CAA 
105 PSEN1 delta4 39 37.4 33 AD and CAA 
105 PSEN1 delta4 38 37.4 34 AD 
105 PSEN1 delta4 33 37.4 44 AD and severe CAA 
121 PSEN1 E120K 35 36.3 33 AD and CAA 
134* PSEN1 G378V 43 44.71 33  
134* PSEN1 G378V 47 44.71 33 AD 
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148‡ PSEN1 M139V 36 42.1 33  
148‡ PSEN1 M139V 43 42.1 33  
148‡ PSEN1 M139V 43 42.1 34  
148‡ PSEN1 M139V 45 42.1 34  
156 PSEN1 I143F 53 55.5 33 AD 
156 PSEN1 I143F 59 55.5 33  
156 PSEN1 I143F 55 55.5 33  
168 PSEN1 E280G 43 42.2 33  
168 PSEN1 E280G 47 42.2 34 AD, Lewy body pathology, pontine infarct 
168 PSEN1 E280G 39 42.2 34  
427 PSEN1 delta166   34  
382 PSEN1 PS1   33 AD and CAA 
428 PSEN1 Q222P   34  
267* PSEN1 L235V   33  
438 PSEN1 M139V   33  
*also see Janssen et al, 2003 ‡also see  Fox et al. 1997 
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Table 10: ApoE genotype and allele frequencies 
Mutation Known 
 
All FAD Subjects 
 
 
n % n % 
Expected SAD %  
(Poirier e t  a l  1993; 
Ashford and 
Mortimer 2002) 
Expected population %        
 (Ashford and Mortimer 2002; Carmo 
Martins e t  a l  2008)  
22 0 0 1 0.7 0.1 1 
23 2 2.7 4 2.9 4 12 
24 0 0.0 3 2.2 3 2 
33 46 63.0 61 44.5 35 61 
34 22 30.1 59 43.1 42 22 
44 3 4.1 9 6.6 16 2 
Genotype 
Total 73 100 137 100 100 100 
 
2 2 1.4 9 3.3 3 6.4 
3 116 79.5 185 67.5 59 83.6 
4 28 19.2 80 29.2 38 10 
Allele 
Frequencies 
Total 146 100 274 100 100 100 
4. 2. 2. Results  
Table 11: t-test results for ApoE4 hypotheses  
 
 
4. 2. 3. Discussion 
There were no significant differences between the ApoE4 positive and negative groups 
in terms of their mean AAO or AAOf. E4 positive subjects, on average, developed 
symptoms 1.13 years earlier than their family mean AAO compared to 0.83 years earlier 
for ApoE4 negative subjects, although this difference was not significant. The same 
analyses were performed after stratifying by FAD mutation and revealed no significant 
differences.  
 
These data do not, therefore, match previous findings of an epistatic effect of ApoE on 
AAO in APP-associated FAD. This may have been due to the genuine absence of an 
effect in this cohort. However, the groups have several characteristics that would hinder 
 
 
Mean AAO 
 
(SD) 
 
Mean family AAO (SD) 
Mean                           
(AAO)-(AAOf) (SD) 
 
ApoE4+ve 
(n=22) 
43.95 (6.34) 45.08 (6.82) -1.13 (3.58) 
 
ApoE4-ve 
(n=38) 
44.42 (6.67) 45.26 (2.71) -0.83 (2.71) 
 
p 
 
0.79 
 
0.92 
 
0.74 
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detection of such an effect if present, making a type 2 error more likely. Although 
previous reports have described ApoE’s influence on the clinical phenotype of APP 
mutations (Hardy et al 1993; Sorbi et al 1995), no such effect has been shown in PSEN1 
mutations. The large contribution of PSEN1 carriers to the groups may, therefore, have 
masked any differences, especially as the ApoE4 positive group contained a smaller 
proportion of APP carriers. The exclusion of PSEN1 cases or further stratification by 
mutation may have rendered significant differences undetectable due to insufficient 
power related to small group size. A further limitation of the analysis is related to an 
inconsistency inherent in the source longitudinal study, namely that ascertainment of 
AAO could not have been performed by the same individual across such an extended 
period. Further study of the genetic basis for AD is a key requirement, not least on the 
subject of potential epistatic influence. Our ever-expanding ability to analyse large 
quantities of genetic data, using for example genome-wide association studies, will be 
invaluable in this regard. 
 
4. 3. Pure progressive amnesia and the APPV717G mutation. 
An isolated, progressive amnestic clinical phenotype has previously been associated with 
the APPV717I (London) mutation (Gankam Kengne et al 2007). The following describes 
a similar pure progressive amnesia in association with a mutation at the same locus. 
Additional longitudinal, volumetric MRI and neuropsychological data are presented. 
4. 3. 1. Case description 
Our patient (Designated VG in Figure 13) belongs to a family with an average AAO of 
51.5 years (range 40-67) with pathologically proven AD in one affected member and an 
APPV717G mutation demonstrated in the proband. The extended family tree (Figure 13) 
is consistent with autosomal dominant inheritance:  
Figure 13: Pedigree 
 
 
 
 
 
 
 
 
VG A B 
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The patient first developed memory problems at 44 years-of-age, with repetitious speech 
and reliance upon written reminders. Over the ensuing 15 years a progressive, global 
impairment of memory function occurred with striking preservation of his intellectual 
capacity. This profile was demonstrated via longitudinal neuropsychological testing 
(Figures 14a and 14b): He was tested approximately annually on the verbal and 
performance subscales of the WAIS-R (Wechsler 1981) together with the Recognition 
Memory Tests for words and faces (Warrington 1984; Warrington 1996). By 46 years, his 
memory was globally impaired whereas his abilities on both the verbal and performance 
subscales of the WAIS-R remained fairly static and close to the level achieved at his first 
assessment.  
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Figure 14: Neuropsychological data 
14a 
 
14b 
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14c 
 
14d 
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14e 
 
 
14f 
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ApoE genotype was E3/3. Annual volumetric brain MRI (Figure 9) between 1991 and 
1998 was performed using a 1.5T GE Signa scanner (General Electric Medical Systems, 
Waukesha, WI, USA). Volumetric T1-weighted coronal MRI scans were obtained with a 
spoiled gradient echo technique (256!128 matrix, field of view 24!24 cm, 
TR/TE/NEX/FA=35 ms/5 ms/1/35°) yielding 124 contiguous 1"5 mm thick slices. 
Between 2000 and 2006 imaging was undertaken on a different 1.5T GE Signa scanner 
running software version 5.8 (General Electric Medical Systems, Waukesha, WI, USA). 
Volumetric T1-weighted coronal MRI scans were obtained using an inversion recovery 
prepared fast spoiled gradient-echo technique (256!256 matrix, field of view 24!18 cm, 
TR/TE/TI/NEX/FA=14 ms/5"4 ms/650 ms/1/15°) yielding 124 contiguous 1"5 mm 
thick slices. The software package MIDAS was used for all manual hippocampal and 
whole brain segmentations (Freeborough et al. 1997). Fluid registration (Scahill et al. 
2002) of volumetric images between 1992 and 1997 showed expansion of CSF spaces 
with generalised cerebral volume loss, but clear predominance of hippocampal atrophy 
(Figure 16).  
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Figure 15: Longitudinal hippocampal & whole brain volumes 
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Figure 16: Fluid registration 1992-1997.  
 
 
VG’s father had been affected from the age of 59 years, and also had a relatively lengthy, 
predominantly amnestic illness, dying at 74 years. Unfortunately, no more detailed 
information on the nature of his illness is available. Longitudinal neuropsychological data 
are available for two affected members of the same generation (designated A and B in 
Figure 13). These both show a contrasting pattern characterized by deterioration in both 
memory and non-memory domains (Figure 14). 
Comparator A developed memory impairment at the age of 47 years. The initial 
manifestation was difficulty in learning new tasks at work and he stopped work within a 
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year of symptom onset. He quickly developed global cognitive decline (Figures 14c and 
14d) and died aged 56 years. ApoE genotype was E3/4. 
Comparator B also first experienced an insidious onset of memory problems aged 47 
years. She progressed to global cognitive decline and was unable to attend for clinical or 
research assessments beyond the age of 52 years (Figures 14e and 14f). At our last 
contact she was 54 years old and dependent upon her husband for most activities of daily 
living. ApoE genotype was E3/4. 
The mother of comparator A, whose age at symptom onset was 53 years and age at death 
61 years, had pathological confirmation of AD with diffuse deposits of amyloid 
throughout the cortex. Neuritic plaques and NFT were abundant in all cortical regions 
including the hippocampus and amygdala. No other inclusion bodies were seen, but 
severe congophilic angiopathy was noted.  
4. 3. 2. Discussion 
The majority of FAD cases are associated with a predominantly amnestic clinical 
phenotype similar to that seen in most SAD cases. However, phenotypic heterogeneity 
does exist: Prominent examples include the spastic paraparesis (Kwok et al 1997; Crook et 
al 1998; Houlden et al 2000; Smith et al 2001; Brooks et al 2003) or frontal presentations 
(Styczynska et al 2004; Duarte et al 2004) associated with some PSEN1 mutations. The 
spectrum of clinical presentations associated with the APP mutations is expanding. It 
includes CAA with ICH (Dutch mutation) (Levy et al 1990) and the ‘intermediate’ 
phenotypes of the Flemish mutation (Hendriks et al 1992b) and APPd (Rovelet-Lecrux et 
al 2006b) which produce CAA in association with memory-led cognitive decline.  
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The term pure progressive amnesia, as used by Barbeau et al. (2006), describes a rare 
amnestic syndrome of insidious onset, with memory performance that can remain stable 
or decline slowly over many years. Crucially, other cognitive domains and functional 
independence are typically preserved throughout this period. It is generally held to be a 
rare presentation of AD which results from MTL damage (Butters et al. 1996) and has 
been reported in association with EOAD (Stokholm et al. 2005), SAD (Caselli et al. 1998), 
the APPV717I (London) mutation (Gankam Kengne et al 2007) and in the context of 
preserved semantic processing (Fossard et al. 2006). To date, all cases followed up have 
progressed to dementia and several have had neuropathological AD confirmed (Caselli et 
al 1998).  
 
Although EOAD and autosomal dominant early onset FAD are not equivalent, FAD 
forms part of a broader group of early onset disease, and it is interesting to note previous 
descriptions of the clinical profile of EOAD which contrast with that of our patient. In 
particular, previous studies have reported a higher prevalence of language impairment or 
other neocortical functions (Jacobs et al 1994) as well as a relatively more rapid 
progression (Rogaeva 2002) in EOAD as compared with LOAD. This contrasts starkly 
with VG, in whom the isolated amnesia was stable over an extended period of at least 13 
years. VG also differs from two comparators in the same generation of the same family, 
both of whom show a decline in both memory and non-memory domains. This suggests 
that the unusual phenotype seen in VG is not a function of the APPV717G mutation per 
se.  
 
ApoE genotype differs between VG (E3/3) and the comparators (both E3/4). ApoE 
status has been reported to modify AAO in APPV717I-associated FAD via an epistatic 
effect between the APP and ApoE genes (St George-Hyslop et al. 1994; Sorbi et al 1995). 
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This would suggest that the presence of the E4 allele predisposes to an earlier AAO, 
although this is not what we observed (subject AAO 47 years, comparator’s AAO 47 and 
45 years, mean AAO for family 51.5 years). 
Neuroimaging in this case is consistent with the clinical features in that slow, progressive 
cortical atrophy was demonstrated, though with disproportionate involvement of each 
hippocampus. Medial temporal and posterior cingulate hypometabolism on SPECT and 
focal hippocampal and ERC atrophy on MRI have been previously demonstrated in pure 
progressive amnesia (Barbeau et al. 2006). However, little is known about the specific 
radiological profile of FAD-associated pure progressive amnesia, although MRI has 
previously been reported as normal (Gankam Kengne et al 2007). The rate and focality of 
brain atrophy in VG differs from previous studies of early-onset, though non-autosomal 
dominant, cases. For example, Frisoni et al. (2007) demonstrated more severe grey matter 
atrophy in EOAD than LOAD with neocortical areas more profoundly affected in 
EOAD and the hippocampus more profoundly affected in LOAD. Patients were 
classified according to age only (<65 years), with no information on the presence of 
FAD gene mutations or autosomal dominant family histories. The clinical and 
radiological phenotypes are congruous in this case: the symptomatic decline, while 
pathological, is not as rapid as one would expect in canonical AD. Similarly, the mean 
rate of hippocampal volume loss over a period of more than 14 years is intermediate 
(2.54%/year) between the values reported in cognitively normal subjects and those with 
AD. Previous studies have found rates of 0.80% (Du et al. 2004) and 0.41% (Fox et al. 
2000) for normal controls and 5-6% (Du et al 2004; Hashimoto et al. 2005) and 2.37% 
(Fox et al 2000) for AD patients.  
Our case provides further evidence for the existence of a protracted, purely amnestic 
phenotype related to APP717 mutations, this time over at least 13 years. It also provides 
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new information regarding the nature of the regional brain volume changes associated 
with this clinical syndrome.  
4. 4. A novel presenilin 1 deletion (p.L166del)  
4. 4. 1. Case description 
The proband (II-4 Figure 17) is a member of a pedigree in which there is a history 
consistent with autosomal dominantly inherited dementia. Her mother (I-2 Figure 17) 
had died at the age of 46 years after suffering from progressive memory impairment 
leading to dementia. The proband is a 40 year-old woman who presented with a two-year 
history of insidious, progressive impairment of episodic memory first noticed by her 
family. This would manifest chiefly as repeated questioning, forgetting names and the 
mislaying of objects. Other early features included topographical memory impairment 
and dyscalculia. Latterly, further problems had emerged such as emotional lability and an 
inability to plan or order tasks.  
 
Neurological examination was normal with no myoclonus, extrapyramidal or upper 
motor neurone signs and a MMSE score of 16/30. At presentation she had clear, 
widespread cognitive impairment, most notably of verbal and visual recall, working 
memory and visuospatial abilities. Formal neuropsychometric testing was undertaken 
showing variable performance across the subtests of the WAIS but low-average and 
extremely low scores on verbal and performance IQ respectively. In addition she 
performed very poorly on tests of information processing speed, visual reasoning 
abilities, the Wechsler Memory Scale and Hopkins Verbal Learning Task. She achieved 
average performances on tests of general knowledge and abstract verbal reasoning but 
had substantial difficulty with mental arithmetic tasks. 
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MRI (Figure 18) revealed generalized, symmetrical cerebral atrophy most marked in the 
MTL with a few foci of high signal within the peripheral white matter. EEG revealed 
diffuse, poorly responsive theta activity at 4-6 Hz and frequent, intermittent runs of 3Hz, 
raised amplitude, notched delta activity which was generalised but with a clear bilateral, 
anterior emphasis. Small sharp waves were noted on occasion in the anterior regions. 
CSF was normal.  
 
4. 4. 2. Genetic analysis 
Analysis of PSEN1 was conducted as described previously (Palmer et al. 1999). A novel 
3bp CTT deletion at codon 166 was detected in the proband in both forward and reverse 
sequencing of exon 6. This was not detected in any of 100 normal controls. 
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Figure 17: Pedigree 
 
 
 
 
Figure 18: MRI brain, coronal T1 & axial T2 
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Figure 19: Sequencing electropherogram for part of the reverse compliment of 
PSEN1  exon 6 showing a deletion of AAG (CTT in forward compliment, codon 
166). 
 
 
 
 
 
4. 4. 3. Discussion 
Located in the third transmembrane domain of exon 6, amino acid position 166 of 
PSEN1 shows significant phylogenetic conservation and in homologous proteins such as 
PS2 and Sell2, suggesting that the position is of functional significance. Further, this 
novel deletion was not detected in 100 healthy controls – suggesting that it is unlikely to 
represent a common, non-pathogenic polymorphism. Mutations at this site co-
segregating with clinical disease have previously been reported (Ezquerra et al. 2000; 
Moehlmann et al 2002; Pantieri et al. 2005) as has a deletion at codon 167 (Janssen et al 
2003). In two of the former cases, a clinical phenotype similar to our proband is 
described (Ezquerra et al 2000; Pantieri et al 2005). In the third (L166P), an aggressive 
onset in adolescence occurs with later spastic paraparesis (Moehlmann et al 2002). Other 
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mutations, namely PSEN1 delta 290-319 and R278T, have been linked with spastic 
paraparesis in some of the affected family members (Kwok et al 1997). 
 
In contrast to deletions reported at other sites on PSEN1, our case was associated with 
the ‘typical’ presentation of EOAD seen in most exon 6 mutations, and in most PSEN1 
mutations per se. The presence or absence of cotton wool plaques that accompany some 
other deletions remains unknown and, despite the evidence presented above, it remains 
difficult to comment definitively upon the pathogenicity of this novel deletion. To do so 
will require extending our knowledge of the family and revisiting the case in the light of 
any future neuropathological or genetic evidence. 
 
4. 5. A novel presenilin 1 substitution (S132A)  
4. 5. 1. Case description 
The proband was seen clinically at the National Hospital for Neurology and 
Neurosurgery, London, presenting at the age of 64 years with a five-year history of 
neuropsychiatric and cognitive symptoms. Visuoperceptual and agnostic problems, 
reduplicative (Capgras) phenomena with persecutory delusions of imprisonment and 
complex visual hallucinations of animals, workmates and deceased relatives were all 
evident at this stage. Additional features included urinary incontinence, speech 
production and comprehension problems. He was noted to have myoclonic jerks of his 
arms and shoulders, bradykinesia, limb hypertonia and bilateral grasp and palmomental 
reflexes. 
 
His family history was consistent with an autosomal dominant pattern of inheritance 
(Figure 20). A condition similar to that observed in the proband was noted in his mother 
(who died age 61 years after an ICH), a maternal aunt, a maternal uncle (who died at 65 
   
 148 
years) and his maternal grandmother who died at 76 years in an institution after a 10-year 
illness associated with ‘cortical atrophy of (the) brain’.  
 
EEG showed dominant slow wave activity and only occasional, poorly reactive ! 
rhythm. MRI was too poorly tolerated to be informative. Brain CT performed at age 64 
years showed mild to moderate cerebral and cerebellar atrophy. 
 
4. 5. 2. Genetic analysis 
Analysis of PSEN1 was conducted as previously described (Palmer et al 1999). A novel 
substitution at codon 132 was detected in the proband in both forward and reverse 
sequencing of exon 5. The complete open reading frame of the prion protein gene was 
also sequenced and no mutations were detected. The codon 129 genotype was 
methionine valine heterozygous. It was not possible to confirm cosegregation through 
testing other members of the family, although the mutation was not identified in 100 
normal controls. 
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Figure 20: Pedigree 
 
 
 
4. 5. 3. Discussion 
Codon 132 lies in exon 5 of PSEN1 and has not previously been associated with AD-
related mutation. Nearby mutations are, however, well documented and cluster in the 
adjacent second transmembrane domain (TMII) where 21 examples are so far recognised 
(see http://www.molgen.ua.ac.be/ADMutations). Examples closest to 132 include 
N135D (Crook et al. 1997), N135S  (Rudzinski et al 2008), A136G (Fang and Jia 2007) 
and several substitutions at codon 139  (Boteva et al. 1996; Fox et al. 1997; Dumanchin et 
al. 1998; Campion et al 1999). There is considerable clinical, neuropsychological and 
neuropathological heterogeneity amongst TMII mutations, just as there is in the PSEN1 
mutation group as a whole, and such variety may even be seen within single mutations 
such as M139V. Nonetheless, mutations at codon 135 seem to have a particularly early 
age of onset in common, with symptoms typically developing in the fourth decade of life. 
Spastic dysarthria, spastic paraparesis, memory-led multi-domain cognitive decline and a 
generalized seizure disorder have been observed (Rudzinski et al 2008), as has a more 
typical AD-like decline with a neuropsychiatric prodrome (Crook et al 1997).  
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There are very few similarities, therefore, between the reported features of nearby 
mutations and the clinical phenotype observed in our proband. Although limb 
hypertonia was observed, he displayed a relatively late AAO with prominent behavioural 
and neuropsychiatric features, including visual hallucinosis. The psychiatric prodrome 
described by Crook et al. was observed in only one member of the pedigree and was not 
characterized by psychotic features, but rather by mood disturbance alone. The history of 
ICH in the mother does raise the possibility of an associated CAA, although there was no 
way to confirm this in the proband or mother and histopathology did not reveal 
significant CAA in either of the codon 135 mutations discussed above. The poorly-
defined cerebellar atrophy apparent on the CT scan is consistent with previous reports of 
cerebellar amyloid plaques in PSEN1 mutations (Verkkoniemi et al. 2001). 
 
The possibility remains that the novel substitution observed here represents a non-
pathogenic polymorphism and, in the absence of confirmed cosegregation, this is 
difficult to address. The strongly suggestive family history and failure to identify such a 
change in a sample of normal controls does, however, lend some weight to the case for 
its pathogenicity.  
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5. 
CHARACTERIZING FAD 
II: APP  locus duplication 
 
5. 1. Duplications of APP  are a significant cause of early onset dementia in a large     
UK referral series. 
Patients presenting before old age with AD-like features and evidence of a familial 
disease should be screened for FAD mutations. However, conventional sequencing will 
not detect gene deletions or duplications. Over recent years it has become recognised 
that copy number variation (CNV), caused by duplication or deletion of parts of 
chromosomes, are relatively common and occur with a non-random distribution across 
the genome (McCarroll and Altshuler 2007). The altered regions may include genes that 
encode for proteins known to be implicated in disease.  
 
The association between AD and Down’s syndrome has long been known, providing 
evidence that a higher gene dosage of APP is sufficient to produce an AD phenotype. 
Recently a number of small chromosomal duplications which include the APP locus have 
been reported (see 1. 4. 2.) with an estimated frequency of 8% (Rovelet-Lecrux et al 
2006b), about half the contribution of missense APP mutations to early onset, autosomal 
dominant AD (Raux et al. 2005). Whilst these studies uncovered an important mutational 
mechanism at APP, questions remain about the frequency of these mutations in larger, 
less selected APP patient cohorts in different countries and the associated phenotypic 
spectrum. The following study investigated the presence and frequency of CNV at APP 
loci in a large referral cohort of UK patients, and presents an optimized methodology for 
cost-effective high-throughput screening of patients for such structural variation. It also 
examined the phenotype associated with APPd in this group. 
   
 152 
5. 1. 1. Methods 
5. 1. 2. Subjects 
The AD cohort comprised two subgroups. One group was formed from a referral series 
of 381 patients for a diagnostic test of AD gene mutation, average age was 53 +/- SD 10, 
47% were male. This series were screened for mutations in APP, PSEN1, and PSEN2 
although not all patients were screened for all genes as, for example, some patients were 
referred prior to the identification of the presenilins as causal genes. This cohort largely 
comprises probands with familial dementia followed-up at the Dementia Research 
Centre, UCL Institute of Neurology. A further 492 patients comprise a collection of 
patients thought to have AD but with insufficient clinical evidence to justify screening of 
causal genes. All patients gave informed consent for genetic analysis. The University 
College London Hospitals NHS Trust Local Ethics Committee gave ethical approval for 
the study. 
 
5. 1. 3. Samples 
Genomic DNA (gDNA) was extracted from peripheral whole blood or post mortem 
brain material using standard techniques. gDNA quality was assessed using agarose gel 
electrophoresis. Only those gDNA samples of average molecular weight >10Kb were 
included in the study. Concentration was assessed using a NanoDrop spectrophotometer 
(ThermoScientific, NanoDrop Products, Wilmington, DE) and samples were diluted to 
20ng/!l in 1X tris-EDTA buffer prior to use.  
 
5. 1. 4. Real-Time Quantitative PCR (exon-qPCR) 
APP alleles were quantified on an ABI 7000 Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA) using the 5’ nuclease assay and duplexed minor 
groove binding (MGB) probes designed to detect APP (exon 5) and GRN (Chr 17, 
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exon1). Relative quantification of APP using GRN as the internal reference was 
determined using the !Ct method. Twenty nanograms of gDNA were amplified in a 25"l 
reaction volume containing 1X Expression Mix (Applied Biosystems), and the respective 
primer (900nM) and probe (200nM) sets for both the gene of interest and the internal 
reference using the universal protocol. Each sample was quantified in triplicate with each 
replicate having a different plate reference to minimise the affect of inter-well variation. 
One sample with trisomy 21 was included as a positive control on all plates. All samples 
with a dosage quotient (expressed as a !CT) two standard deviations from the mean 
were considered as potential CNVs.  
 
5. 1. 5. Fluorescent Microsatellite Quantitative PCR (fm-qPCR) 
APP alleles were quantified by the genotyping of two microsatellites located within 
intron 1 of APP (196999; Chr21: 26,460,990 – 26,461,175) and 330kb centromeric from 
APP (188463; Chr21: 25,841,358 – 25,841,530). Twenty nanograms of gDNA were 
amplified by denaturation at 95˚C for 1 minute followed by 24 cycles of 95˚C for 30 
seconds, 53˚C for 30 seconds and 72˚C for 1 minute. Amplicons were analysed using an 
ABI 3130xl automated sequencer and GeneMapper software v.4.0 (ABI). In all 
individuals heterozygous for a given marker the allelic ratio was assessed by relative peak 
area. Cases were deemed CNV positive by fm-qPCR if allelic ratios were two standard 
deviations from the mean and if i) both of a microsatellite pair had altered allelic ratio or 
ii) one of a microsatellite pair had an altered peak ratio with the other genotyped as 
homozygous or iii) only one of a microsatellite pair had an altered peak ratio but it was 
the one nearest to the gene of interest.  
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5. 1. 6. Illumina 610 Bead Array 
Samples identified as “potential CNV” by exon-qPCR and/or fm-qPCR were assayed 
using the Illumina bead array system according to the manufacturers protocol. All 
samples were assayed using the Illumina Human 610-Quad BeadChips (Illumina Inc, San 
Diego, CA, USA) as per manufacturer’s instructions, using 200 ng of genomic DNA. 
These BeadChips assay more than 610,000 tag single nucleotide polymorphisms (SNP) 
and markers, including 60,000 CNV markers, based on the International Human 
HapMap project release 23 (www.hapmap.org). All the samples genotyped had a 
genotype success rate of more than 99%. 
 
Individual chromosomes were examined using a method previously demonstrated to be 
reliable for detecting genomic copy number mutations (van de Leemput et al. 2007; 
Simon-Sanchez et al. 2008; Knight et al. 2008). We looked at the whole genome in each 
sample, with particular interest in the region containing APP, in order to be able to 
confirm the results previously obtained. 
 
5. 1. 7. Results  
5. 1. 7. 1. Laboratory findings 
Using Exon-qPCR comparison was made between the amplification of APP and an 
internal reference marker (APP-GRN). 21 samples from the AD cohort were considered 
as potential CNVs based on the selection criteria of samples with a !Ct value greater than 
2 standard deviations from the mean (see Table 12).  
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Table 12: APP  CNV Screen 
 
 
Total Sample 
Number 
 
 
Double 
homozygotes 
 
 
Number 
Screened 
 
Positives 
 
False Positive 
Rate 
 
Exon-qPCR 
873 N/A 873 21 16 
fm-qPCR 
873 54 819 42 37 
Both 
873 N/A 873 5 0 
Illumina Array 
5 N/A 5 5 N/A 
 
 
Using fm-qPCR two polymorphic microsatellites within intron 1 and 330kB centromeric 
to APP were amplified using a standard PCR protocol for analysis using fm-qPCR. A 
comparison of peak area was made in all heterozygous individuals for either one or both 
of the microsatellite pair. The samples screened were assessed for CNVs in this way with 
only 6.1% of individuals being double homozygotes (see Table 12). 42 samples were 
considered as potential CNVs. Three allelic peaks appeared on the electropherogram of 
Proband 3 (microsatellite 196999). This was consistent with an unbalanced translocation 
that does not appear to include Down’s syndrome critical regions.  
 
Five samples from the APP cohort were deemed positive by both exon-qPCR and fm-
qPCR. All these samples were confirmed as heterozygote duplicates by the Illumina 
array. The complementary use of these two techniques therefore represents a highly 
accurate screening process for heterozygous duplications, using the Illumina array as the 
gold standard assay. 
 
The Illumina 610 Bead array was used for the verification of duplication in samples that 
were identified as potential CNVs from exon-qPCR and fm-qPCR. These data showed 
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duplicated regions of Chr21q, which included the APP gene locus in all 5 probands 
identified as CNVs by both exon- and fm-qPCR. There was considerable heterogeneity 
in duplication size (2.77, 6.35, 4.96, 6.49Mb, see Figure 23), showing that these patients 
represented separate duplication events. Although Proband 3 had been identified by fm-
qPCR as having three microsatellite alleles, the array revealed this patient to have an 
extended discontinuous duplication of Chr21q. There are no available SNP for the p arm 
of Chr21 so this could not be assessed. The large duplicated region is interrupted by a 
region of unduplicated SNP (see Figure 16). In conjunction with the microsatellite 
haplotyping, these data are consistent with an unbalanced translocation of Chr 21. Of the 
five positive individuals of the AD cohort, 4 (1%), (Probands 1, 2, 3 and 5) originated 
from the referral series of 381 patients for a diagnostic test of AD gene mutation and 
screened for APP, PSEN1, PSEN2 and 1 (0.2%), (Proband 4) originated from 492 
patients comprising a collection of patients thought to have AD but with insufficient 
clinical evidence to justify screening of causal genes. 
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Figure 21: APPd detection using alteration in the ratio of area under the curve of 
microsatellite alleles on electropherogram traces.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The histograms in Figure 21 illustrate the distribution of allelic peak area ratios. Variation 
occurring among the ratios of microsatellite allelic areas appeared to be polymodal. This 
observation was caused by ‘stutter’ peaks immediately preceding each microsatellite allele. 
Microsatellite stutter peaks accentuate the peak of the shorter allele to a degree that is 
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based upon the size differential of the two alleles. Thus, the degree of difference in base 
pairs between two alleles accounts for part of the variation in allelic ratios. When the two 
microsatellite alleles are widely separated in length, the ratio is not affected by stutter 
peaks, whereas when alleles are adjacent the ratio is affected most. This phenomenon 
accounts for most of the false positives using this method alone. 
 
Differences in base number between allelic pairs are illustrated by different colour. 
Shaded areas highlight samples 2 standard deviations from the mean.  
 
A) Microsatellite marker 188463: Proband 5 had a normal allelic peak ratio. Array 
analysis confirmed that this marker lay outside the duplication boundary for this 
individual. 
B) Microsatellite marker 196999: Proband 3 had three microsatellite peaks. And 
Proband 1 was uninformative due to homozygosity. 
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Figure 22: Confirmation of APPd using Illumina array technology 
Heterozygous duplications in 5 probands. Regions of duplication are highlighted in red 
boxes. In order to examine individual chromosomes for structural mutations the 
visualization tool Genome Viewer version 3.2.9 within Beadstudio version 3.1.3.0 
(Illumina Inc, San Diego, CA, USA) was used. An ideogram of Chr 21 and the B allele 
frequency is illustrated. 1 pixel=56 KB. 
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Figure 23: Chr 21 diagram showing APPd regions with respect to genes 
APPd in 5 probands. Black horizontal bars indicate the extent of heterozygous duplications. Minimal sizes (in parentheses) of previously reported 
duplications are indicated by grey horizontal bars and the intervals of the duplication boundaries by dotted lines. Start of gene is indicated by a vertical 
bar. Note: Proband 1 has a partial duplication of NCAM2 and Proband 2 has a full duplication. 
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5. 1. 7. 2. Clinical and investigation findings 
5. 1. 7. 2. 1. Proband 1   
This 54y-old man had a progressive impairment of episodic memory, beginning 
insidiously at the age of 48y. Impairment of verbal memory was clearly impaired at 
presentation, although general intellectual functions were preserved. He went on to 
develop an apperceptive agnosia, limb apraxia and dysexecutive features. He was a 
former smoker. At 52y he had a generalized tonic-clonic seizure and elected not to 
commence anti-convulsant treatment, although donepezil 10mg was prescribed around 
this time. There was an autosomal dominant family history of EOAD: his father died at 
62y after onset of disease in his late 40s, a paternal uncle died at 63y and a paternal aunt 
died at 49y, both after an undefined dementing illness (Figure 26a).  
 
Initial MRI brain scanning showed widespread T2 FLAIR white matter hyperintensities 
consistent with subcortical vascular disease; multiple small, deep cerebral and cerebellar 
haemorrhages on T2* imaging and an old left-sided amygdala haemorrhage (see Figure 
24). EEG was unremarkable. There was no history of sustained hypertension and 
cholesterol was 3.5mmmol/L. Tests for Notch 3 (CADASIL), ITM2B (Familial British 
Dementia), APP, PSEN1, PSEN2, PRNP and MAPT mutations were all negative. CSF 
analysis was unremarkable except for ttau of 555pg/mL and Aß1-42 of 128pg/mL.  
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Table 13: Proband 1: Longitudinal Neuropsychometry 
 
 
 
 
 
                 DATE(AGE) 
 
TEST 
2006(52) 2007 
 
Jan 2008 Nov2008 
VIQ 
 
90 87 
 
88 Unknown 
PIQ 
 
76 80 
 
78 Unknown 
RMTwords (%ile) 
 
CHANCE <5 
 
<5 <5 
GNT (%ile) 
 
25 5-10 
 
10-25 10 
MMSE 
 
25 23 
 
Unknown                            26
 
 
 
 
Figure 24: MRI scans from proband 1 showing extensive white matter 
abnormalities and an amygdala haemorrhage (arrow). 
 
 
 
 
 
 
 
 
 
DONEPEZIL 
COMMENCED 
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5. 1. 7. 2. 2. Proband and family 2   
This man belongs to a family with a strong history of both early onset seizures and mid-
life cognitive impairment (Figure 26b). He developed a variety of seizure types from the 
age of 11y with brief absences occurring up to five times per day and generalized tonic-
clonic seizures on average once per year. A flurry of seizures at the age of 40y heralded 
increasing social withdrawal, apathy and an inability to follow simple commands. His 
cognition progressively deteriorated, including problems with memory, mood and 
wandering, as well as prominent myoclonus. From the age of 49y he had word-finding 
difficulties, which progressed to the extent that he would barely speak. He became 
increasingly immobile and incontinent of urine. He had no other past medical history, 
though he had previously been a heavy smoker. On examination at the age of 50y he had 
an MMSE score of 10/30, a paucity of speech, perseveration, poor concentration, 
moderate limb dyspraxia and visuoperceptual difficulties.  
 
Figure 25: MRI scans from proband 2 (aged 47y) showing white matter 
abnormalities and hippocampal atrophy. 
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General neurological examination revealed a supranuclear gaze palsy affecting vertical 
movements, a brisk jaw jerk and brisk limb reflexes. His final MRI brain scan at age 50y 
revealed severe, generalized cerebral volume loss and bilateral hippocampal atrophy. 
There was extensive periventricular white matter signal change, more so on the right than 
the left. EEG showed an excess of slow wave activity with absent !-rhythm, while 
telemetry revealed bifrontal spike activity. CSF was acellular with normal total protein, 
negative oligoclonal bands and negative Whipple’s PCR. Genetic screening for APP, 
PSEN1, PSEN2, ITM2B, DRPLA, HD and common mitochondrial mutations were 
negative. White cell enzymes were normal. He also underwent skeletal muscle and skin 
biopsies. The former showed no evidence of mitochondrial myopathy and the latter 
showed no Lafora bodies. Longitudinal neuropsychological testing was undertaken 
(Table 14) which demonstrated a relentless, slow, global cognitive decline. His sister also 
developed both generalized and absence seizures at the age of 11y. From the age of 50y 
she had a gradual, progressive impairment of episodic memory, with mild word-finding 
difficulties, low mood and emotional lability. Her MRI brain scan showed scattered, 
bilateral, peri-ventricular areas of high signal in the deep white matter, basal ganglia and 
pons. There was also a high signal area in the right frontal lobe consistent with an old 
infarct. CSF examination was unremarkable. Early onset seizures also affected his 
mother, a maternal aunt, one of his sisters, the daughter and granddaughter of one of his 
unaffected sisters as well as the grandson of another of his unaffected sisters although 
samples are not available for testing of segregation in these individuals. His mother died 
aged 64y with a long history of psychiatric problems. Lifelong generalized epilepsy was 
complicated by post-ictal paranoid psychosis and, although little information is available 
on her early life, problems with activities of daily living, self-care and an inability to 
remember her medication were present at least from the age of 62y.  
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Table 14: Proband 2: Longitudinal Neuropsychometry with corresponding EEG and imaging profile. 
               YEAR(AGE) 
 
TEST 
1998(44) 2000 2001 2002 2003 2004(50) 
VIQ 
 
71 78 76 75 62 63 
PIQ 
 
73 67 63 64 62 57 
RMTwords 
 
29/50 34/50 27/50 16/25* CHANCE CHANCE 
RMTfaces 
 
28/50 27/50 25/50 14/25* CHANCE CHANCE 
GNT (%ile) 
 
10-25 10-25 10-25 10 5-10 5 
MMSE 
 
 22  15 10 10 
MRI 
 
 
FRONTAL WHITE MATTER 
LESIONS. 
NO REGIONAL ATROPHY 
 
WHITE MATTER 
LESIONS BOTH 
HEMISPHERES NO 
REGIONAL 
ATROPHY 
 
WHITE MATTER 
LESIONS BOTH 
HEMISPHERES 
BILATERAL 
HIPPOCAMPAL 
ATROPHY 
 
 
WHITE MATTER LESIONS 
BOTH HEMISPHERES.  
GENERALIZED ATROPHIC 
CHANGE, GREATER 
ANTERIORLY. BILATERAL 
HIPPOCAMPAL ATROPHY 
RIGHT SMALLER THAN 
LEFT 
 
 
GENERALIZED, SEVERE 
CEREBRAL VOLUME LOSS. 
EXTENSIVE WHITE MATTER 
CHANGE MORE 
PROMINENT IN RIGHT 
HEMISPHERE. BILATERAL 
HIPPOCAMPAL ATROPHY 
 
EEG 
 
FRONTOTEMPORAL 
SLOWING 
 
TRACES OF !  
RHYTHM, LARGE 
AMOUNTS OF 
THETA IN BOTH 
HEMISPHERES 
 
 
 
WIDESPREAD SLOWING. 
NO NORMAL RHYTHMS. NO 
POSTERIOR !  RHYTHM  
 
VIQ/PIQ = VERBAL AND PERFORMANCE SUBSCALES OF WAIS-R (WECHSLER 1981)  
RMTw/RMTf = RECOGNITION MEMORY TEST FOR WORDS AND FACES (*SHORT VERSION) (WARRINGTON EK 1984 & 1996) 
GNT = GRADED NAMING TEST (MCKENNA & WARRINGTON 1980) 
MMSE = MINI-MENTAL STATE EXAMINATION (FOLSTEIN 1975)  
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Information about histological post-mortem brain examination was limited, and hence 
inconclusive. A cavity consistent with previous haemorrhage or infarct was noted in the 
white matter, with abundant haemosiderin and surrounding gliosis. Several of the cortical 
and leptomeningeal vessels had evidence of hyaline degeneration and scanty diffuse 
amyloid plaques were present in the striatum. 
 
5. 1. 7. 2. 3. Proband 3  
This Greek man presented at 42 years old with a three-year history of mislaying items 
and forgetting events. Later problems with route finding were noted with increasing 
social withdrawal. Episodes of uncontrollable weeping occurred with associated malaise, 
rolling of the eyes and post-ictal confusion. These episodes were responsive to anti-
convulsant therapy. He was an only child of two healthy parents and had no known 
extended family history of dementia (Figure 26e). MRI brain scans revealed generalized 
atrophy and EEG revealed an absence of ! rhythm with disorganised activity and delta 
discharges. CSF analysis was unremarkable. Screening of APP, PSEN1 and PRNP was 
negative. Neuropsychometry revealed a relatively preserved social façade, marked 
difficulty with non-verbal reasoning, dysexecutive features and impaired episodic 
memory. Comprehension was intact, word-retrieval problems and speech production 
errors (in the form of substitutions, deletions and transpositions) were evident as well as 
apperceptive agnosia. Reading, writing, calculation, visuoperceptual and visuospatial skills 
were impaired and limb apraxia was present.  
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5. 1. 7. 2. 4. Proband and family 4  
Little clinical information about this proband is available, although it is known that she 
suffered from a progressive temporoparietal dementia. Later she developed 
extrapyramidal features, although the sporadic use of dopamine antagonists may have 
contributed. AAO is unknown but by 57y she was resident in a nursing home and had a 
severe dementia with dysphasia, dyspraxia, motor perseveration, utilization behaviour 
and wandering. We lost contact at this point, after obtaining the blood sample used for 
this analysis and determining her ApoE genotype as E3E3. Nothing is known about her 
only sibling but her mother is known to have died aged 49y from pathologically 
confirmed ‘cerebral haemorrhage’ and ‘cystic degeneration of the brain’ after a presenile 
dementing illness (Figure 26c shows pedigree). 
 
5. 1. 7. 2. 5. Proband and family 5  
This 55 year-old woman had progressive memory problems since the age of 48y when 
she fell out of bed having had a focal seizure. Seizures consisted of an olfactory aura 
followed by a focal seizure affecting her right arm. Complex partial and atonic seizures 
progressed and were refractory to therapy. She developed progressive cognitive 
symptoms. Aged 53y her MMSE was 16/30 and ACE 50/100. Aged 54y MMSE was 
12/30 and a year later, MMSE was 4/30. Her cognitive profile was typical of AD. Apart 
from generally brisk reflexes, neurological examination was normal.  
 
MRI imaging showed atrophy of the left temporal lobe compared to the right. HMPAO 
SPECT scan which showed some irregular diminution of perfusion of the left parieto-
occipital region compared to the right. These appearances were felt to represent 
ischaemic change or AD. 
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The patient’s mother died aged 66y of cancer but had progressive cognitive problems for 
5 years including word finding difficulties and neologisms (see Figure 26d for pedigree). 
 
Figure 26: Pedigrees 
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Table 15: Clinical features of 16 individuals with definite or probable APPd. 
Pedigree Proband APPd AAO Age of Death Clinical features Seizures ICH 
AIII.1 1 (14660) Yes 48 - 
Memory loss, apraxia, 
dysexecutive 
Late onset tonic-clonic 
Yes 
AI.1  - - - - - - 
AI.2  - - - - - - 
AII.1  - - 63 Dementia No - 
AII.2  - Late 40s 62 Dementia No - 
AII.3  - - 49 Dementia No - 
BIII.2 2 (8183) Yes 40 - 
Memory loss, myoclonus Early onset tonic-clonic 
from age 11 
No 
BI.1  -  - No Early onset - 
BI.2  -  - No Early onset - 
BII.1  -  - No Early onset - 
BII.2  -  - No Early onset - 
BIII.1  - 50 - 
Memory loss, word finding 
difficulty, altered mood 
Generalized and 
complex partial seizures 
No 
CII.1 3 (7015) Yes 39 - 
Memory loss, social 
withdrawal 
Probably complex 
partial seizures 
No 
DII.1 4 (19505) Yes - - - - No 
DII.2  - - 49 Dementia - Yes 
EII.1 5 (17320) Yes 48 - 
Memory loss Late onset generalized 
and complex partial 
No 
EI.1  - 61 66 
Memory loss, word finding 
difficulty 
No 
No 
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5. 1. 8. Discussion 
We describe the screening of a large and heterogeneous referral series to identify CNVs 
causing early onset dementia. Five probands with APPd were identified in the screen, 
four with evidence of familial dementia and one with a sporadic disease. The overall 
frequency of mutation in our series was 0.57% (95% CI 0.19-1.33). Although we confirm 
APPd to be relatively rare, the frequency in this series was comparable to that of 
missense mutations (5 different APP missense mutations in the series). The previously 
reported mutation frequency in FAD was 8% (95% CI 2.6-17.1) in a French series  
(Rovelet-Lecrux et al. 2006a), 2.7% (95% CI 0.32-9.3) in a Dutch series of FAD  (Sleegers 
et al. 2006) and 0% in a Swedish and Finnish cohort of EOAD (95% CI 0-2.58)  (Blom et 
al. 2008). Our data are not directly comparable with more selected studies as two from 
the five probands were not identified as having a familial disease until after mutations 
were identified and this aspect of the history was reconsidered. Only one from the five 
probands was considered likely to have CAA because of a scan finding of a small ICH.  
 
In one proband (3) we detected a complex discontinuous APPd mutation associated with 
sporadic EOAD. This individual had three microsatellite alleles at one locus and a double 
allele dose at the second locus tested. The APPd patchily involved almost the entire 
Chr21q, but critically did not include the Down’s Syndrome Critical Region around 
21q22. The largest continuous region of duplication was 15.5Mb. These data are 
consistent with a different mutational mechanism from other APPd, an unbalanced 
translocation. In four probands, continuous duplications of 1.6-6.5 Mb including APP 
were detected; one mutation was slightly larger than any previously reported.  
 
Although the clinical phenotype of APPd may vary within families, it does not appear to 
be influenced by the size of the duplication itself  (Rovelet-Lecrux et al. 2007), a finding 
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supported by our results. Documented ages at onset range from 40-59y which is broadly 
in keeping with our data (range 39-61y)  (Remes et al. 2004b; Cabrejo et al. 2006a). No 
clinical features of Down’s syndrome have yet been observed although dementia and 
CAA seem universal, with a quarter also suffering ICH. There was also a high incidence 
of seizures (57%) in published series. Our data corroborate these reports with a high 
proportion of patients having seizures in the clinical course. One family (B) has an 
autosomal dominant family history of partial seizures, with partial seizures from 
adolescence in both patients subsequently affected by a cognitive disorder. Whether 
these early seizures are coincidental, are caused by a linked gene abnormality, or 
a very early manifestation of CAA is unknown. Clinically, APPd-related AD is 
intermediate between the canonical AD phenotype observed in most APP mutations and 
the frequent, CAA-associated ICH seen in the Dutch mutation. This intermediate 
phenotype has already prompted comparison with the Flemish APPA692G mutation 
(Hendriks et al. 1992a), which has similar characteristics. It seems likely that CAA does 
indeed underlie ICH and white matter lesions in these patients given the clear evidence 
of CAA-associated ICH in other APP mutations mentioned above. The anticipated 
association with microhaemorrhage is confirmed only in Proband 1 through the use of 
gradient echo/T2* MRI sequences (Figure 24). These sequences had not been 
performed in other cases or were not available. 
 
The methods used, successfully identified 5 patients where duplication had occurred. 5 
further samples that showed borderline abnormalities on exon-qPCR were all normal 
using the Illumina array. Each detection method has its own merits and neither can be 
used exclusively for the detection of CNV. Although not fully accurate, exon-qPCR 
cannot be confounded by genomic admixture due to accidental contamination. In 
contrast the accuracy of fm-qPCR supercedes that of exon-qPCR but is susceptible to 
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admixture as well as requiring heterozygosity of the marker, although this is largely 
resolved by typing two markers rather than one. In tandem the techniques are highly 
complementary and extremely effective at detecting duplications. Screening large 
numbers of samples as described here is a relatively powerful way of detecting and 
characterizing rare genetic phenomena. However, it presents ethical as well as practical 
challenges because the findings may have real clinical implications for the families 
concerned. Many samples had been held for a number of years and contact had long 
since been lost with individuals, meaning that the potential for communicating a positive 
finding was minimal. Despite this, every effort was made to give the relevant individuals 
the opportunity to discuss positive findings and to offer them the appropriate clinical 
support. The issue of sample age is a key limitation of this study as the most modern 
supportive investigations (such as the latest MRI sequences and CSF biomarkers) could 
not be incorporated into the characterizations. This factor may also have influenced 
diagnostic accuracy and therefore frequency estimation. The potential influence of CNVs 
at other loci and in other genes/diseases is an intriguing prospect and a possible focus 
for future research. 
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6. 
CONCLUSIONS 
 
Chapter 2 confirmed that structural measurement of the cerebral cortex is now both 
feasible, and practical, with the potential to be a useful biomarker of onset, progression 
and intervention. In this respect it could be considered to have achieved its aims. It 
demonstrated that CTh analysis may detect the pathological onset of AD some years 
before symptoms are apparent – the very period in which any new disease-modifying 
therapy would ideally be introduced. It therefore constitutes further evidence of a 
preclinical ‘window of opportunity’. Further, by showing that diagnosis accompanies an 
acceleration of grey matter loss, it also highlights the consequences of failing to recognise 
this window and intervene appropriately. Accelerated cortical thinning might be the 
radiological correlate of accelerated clinical decline observed after a preclinical plateau 
(see 1. 6. 1.). This plateau may represent the temporary success of compensatory 
mechanisms and is possibly related to cognitive reserve. Particular regions in the MTL 
and heteromodal association cortices are identified as significant in early disease, helping 
to focus subsequent clinical and research imaging.  
 
The precise nature of the relationship between cerebral Aß, macroscopic disease and 
clinical state remains controversial and interpretation of the 11C-PiB PET data presented 
herein (see chapter 3) is correspondingly challenging.  However, several important issues 
are raised by this study. It offers support for the notion of heterogeneity amongst 
PSEN1 mutations both in terms of their molecular imaging profiles and, by inference, 
their regional pathological profiles. Some individuals displayed widespread 11C-PiB 
retention, some showed striatal prominence, while others had more retention in the 
cerebellum than other areas of the brain. It is possible that, in future, 11C-PiB PET could 
   
 174 
help to sub-classify FAD more precisely and that clinico-pathological studies may be able 
to identify the clinical correlates of the various imaging profiles identified. Chapter 3 also 
demonstrates that, just as presymptomatic disease may be detected with structural and 
functional imaging techniques, so abnormal levels of fibrillar Aß can be detected in 
clinically unaffected individuals destined to develop manifest AD. 11C-PiB PET is, 
therefore, another technique with the potential to facilitate earlier diagnosis and monitor 
the success of disease-modifying therapies. FAD and SAD subjects both demonstrated 
elevated levels of brain Aß which distinguished them from controls. However, 
differences were highlighted in the imaging profiles of these groups indicating that the 
relationship of one to another is not simple and raising issues about the limitations of the 
familial paradigm. As amyloid imaging becomes more widespread, confirmation that the 
cerebellum may not be a universally appropriate reference region is an important 
additional finding. So far such labour intensive, expensive structural and molecular 
markers have provided only incremental advances in diagnostic sensitivity and specificity. 
They are some way from being suitable or practical for use in the routine care of typical 
AD, but this situation is likely to change in light of future research and improved 
availability. 
A viable familial paradigm demands as full a characterization of FAD as possible, and 
variations in clinical phenotype within FAD families provide an ideal opportunity to 
explore environmental and genetic factors which may underlie disease expression. 
Chapters 4 and 5 contribute to this. Their component studies have identified two novel 
pathogenic PSEN1 mutations (p. L166del and S132A), explored their clinical, 
neuroimaging and neuropsychological features, and added to existing evidence of 
heterogeneity in this group. Similarly, through the novel association of pure progressive 
amnesia with the V717G substitution, they have expanded our understanding of the 
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varied APP mutation-associated syndromes. Single case studies of this kind, while useful 
in generating hypotheses and alerting us to unusual phenomena, have important 
limitations: In particular, they are descriptive rather than explanatory by nature and do 
not allow conclusions to be drawn about populations. Such qualitative studies have no a 
priori hypothesis and merely provide a modest, incremental contribution to an existing 
body of knowledge on the FAD group. They also highlight the sometimes unreliable 
phenotypic links between FAD and SAD and could be considered superficially damaging 
to the FAD paradigm in this regard. However, the continuing discovery of mutations in 
genes implicated in APP processing, which produce AD pathology and, in the vast 
majority of cases, a typical AD clinical phenotype is in itself supportive of an intimate 
link between FAD and SAD. In this respect these case descriptions strengthen the 
FAD/SAD bond. It is important that such work continues into the future, with 
heterogeneity a crucial area for study if we are to more precisely define said relationship. 
At a group level, non-canonical FAD phenotypes emphatically remain the exception and, 
while this situation persists, the paradigm at the heart of this thesis survives.  
In chapter 5, APPd, to date a less well-defined phenomenon, was shown to be an 
important, if rare cause of familial dementia in one of the largest groups so far examined, 
and was found to have characteristic clinical and neuroimaging features. These include 
dementia, CAA, ICH and generalized seizures. The descriptive portion of the study 
contributes to the concept of a familial ‘model’ in the manner discussed above. Beyond 
this, my initial hypotheses were two-fold: first that large-scale screening of samples for 
these rare mutations was feasible and second that the prevalence of APPd was higher 
than was widely appreciated, making such screening a desirable facility. The first was 
proven while the second was, in a strict sense, inconclusive. However, if the unselected 
nature of my cohort is taken into account, the mutation frequency is relatively high i.e. it 
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is not dissimilar to figures found in highly selected cohorts. That APPd may be more 
common than first thought has real implications for the clinical care of families with 
autosomal dominant dementia, especially in cases where no missense mutation or 
deletion has yet been found. This study helps to highlight the ethical issues inherent in 
translational research where patient autonomy and informed consent must be reconciled 
responsibly with new discoveries, especially where they relate to long-held biological 
samples. The prospect that CNVs may be important in other degenerative diseases is also 
raised - a potential avenue for further research.  
 
The known similarities and differences between FAD and SAD are summarized in 
section 1.4. although, as discussed above, the former remain more numerous and hence 
more compelling. The pros and cons of using this model are clear: there are persuasive, 
enduring similarities between FAD and SAD, which currently provide the only realistic 
opportunity to predict and make diagnoses with certainty. However, the apparently 
strong relationship between the two is inexact and incompletely defined. Proof of the 
validity of the FAD paradigm was not amongst the aims of this thesis and, therefore, no 
component study was designed to specifically address this. Rather, reference to the 
familial paradigm in the title was intended to reflect a methodological imperative – the 
need to utilise FAD to explore the potential of imaging biomarkers in identifying, 
monitoring and modifying AD per se. The validity of FAD as a model for SAD is not 
refuted by any findings herein although the aims did include a better understanding of 
relevant limitations of the paradigm through examination of comparatively rare 
phenotypic variations attributable to equally rare specific mutations. These more 
qualitative objectives were largely met through the descriptive studies presented. I can 
make no more assertive a statement than to say that there are, in my opinion, more 
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reasons to suppose features of FAD are broadly generalizable to SAD than there are to 
suppose they are not. 
 
I believe this work offers grounds for optimism where the successful application of these 
imaging biomarkers is concerned. It also supports the view that a small number of 
families may hold the key to helping the many people living with AD, both now and in 
the future. Each story is unique, most are humbling, but those who so kindly participated 
in this research were united in their hope of sparing future generations their own burden. 
To hear their stories and to join them in this aim has been a privilege. 
  
 
     
Ich hab mich verloren (I have lost myself) 
 
- Auguste Deter 1850-1906 
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7. 
APPENDICES 
 
7. 1. NINCDS-ADRDA criteria for the diagnosis of Alzheimer’s disease 
(McKhann e t  a l  1984).  
 
Criteria for the clinical diagnosis of PROBABLE Alzheimer’s disease include: 
Dementia established by clinical examination and documented by the MMSE or some 
similar examination and confirmed by neuropsychological tests; 
• deficits in at least two areas of cognition 
• progressive deterioration of memory and other cognitive functions 
• no disturbance of consciousness 
• onset between ages 40 and 90 
• absence of systemic disorders that in and of themselves could account for the 
progressive deficits. 
 
Diagnosis of PROBABLE Alzheimer's disease supported by: 
Progressive deterioration of specific cognitive functions such as language (aphasia), motor 
skills (apraxia) and perception (agnosia) 
• impaired activities of daily living 
• family history of similar disorders, particularly if confirmed neuropathologically 
• normal CSF and EEG 
• evidence of cerebral atrophy on CT with progression documented by serial observation 
Features consistent with the diagnosis: 
• plateaus in the course of the disease 
• associated psychiatric symptoms 
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• neurological abnormalities with more advanced disease including increased tone, 
myoclonus or gait disorder 
• seizures in advanced disease 
• CT normal for age 
 
Diagnosis of PROBABLE Alzheimer’s disease unlikely if: 
• sudden onset 
• focal neurological signs 
• seizures or gait disturbance early in the disease  
 
       DEFINITE Alzheimer’s disease if: 
• clinical criteria for probable Alzheimer’s disease 
• histopathological evidence obtained from biopsy or autopsy 
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7. 2. Neuropathological stageing of AD-related changes (Braak and Braak 1991) 
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7. 3. Publications related to this thesis 
Duplications of APP – but not PRNP – are a significant cause of early onset dementia in 
a large UK referral series *McNaughton D., *Knight W. D. et al 
In press Brain August 2010 (Joint first authorship) 
 
Knight W. D., Kim L.G., Douiri A., Frost C., Rossor M. N., Fox N. C 
Acceleration of cortical thinning in familial Alzheimer’s disease  
Neurobiology of Aging 2009: In press (doi: 10.1016/j.neurobiolaging.2009.11.013) 
 
W. D. Knight MRCP(UK), R. Laila. Ahsan MSc, Jessica Jackson BSc, Lisa Cipolotti 
PhD, Elizabeth K. Warrington DSc, Nick C. Fox FRCP, Martin N. Rossor FRCP.   
Pure Progressive Amnesia & the APPV717G Mutation.  
Alzheimer Disease and Associated Disorders 2009; 23: 410–414. 
 
W. D. Knight, N. C. Fox, M. N. Rossor and J. D. Warren. 
The Cultural Context of Visual Hallucinations.  
Postgraduate Medical Journal 2008; 84: 103-105. 
 
Rohrer JD, Knight WD, Warren JE, Fox NC, Rossor MN, Warren JD 
Word-finding difficulty: a clinical analysis of the progressive aphasias. 
Brain 2008; 131(Pt 1): 8-38. 
 
W. D. Knight, J. Kennedy, S. Mead, M. N. Rossor, J. Beck, J. Collinge, C. Mummery.  
A Novel Presenilin 1 Deletion (p.L166del) Associated with Early Onset Familial 
Alzheimer’s Disease. European Journal of Neurology 2007; 14: 829-831. 
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the IMP (bapineuzumab) is about to commence. 
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